data_5lcb_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5lcb _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.163 0 CA-C-O 124.188 1.947 . . . . 0.0 109.349 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.3 m -74.79 133.41 41.94 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 120.352 -1.468 . . . . 0.0 110.972 -177.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.71 179.32 8.71 Favored Glycine 0 CA--C 1.533 1.169 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.36 13.69 82.62 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 111.705 -0.558 . . . . 0.0 111.705 178.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.57 54.19 3.44 Favored Glycine 0 N--CA 1.47 0.93 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 30.0 m -88.02 -10.83 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 113.999 1.111 . . . . 0.0 113.999 -179.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -71.54 -56.58 5.62 Favored 'General case' 0 CA--C 1.552 1.052 0 N-CA-C 115.51 1.671 . . . . 0.0 115.51 -175.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.8 m -51.98 -42.41 62.91 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.752 -174.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -62.05 -25.04 67.45 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.446 HG22 HD13 ' A' ' 10' ' ' ILE . 63.5 mt -62.92 -43.05 98.72 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.093 0 C-N-CA 118.428 -1.309 . . . . 0.0 110.16 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 32.1 tp -58.02 -42.92 86.32 Favored 'General case' 0 CA--C 1.49 -1.353 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.743 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -58.99 -35.42 73.19 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -74.61 -49.03 23.15 Favored 'General case' 0 C--O 1.196 -1.738 0 CA-C-N 114.415 -1.266 . . . . 0.0 113.827 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.08 -40.25 76.57 Favored 'General case' 0 C--N 1.318 -0.768 0 O-C-N 121.366 -0.834 . . . . 0.0 110.218 -178.167 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.83 -48.58 33.37 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.578 -0.82 . . . . 0.0 111.257 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 70.4 ttt-85 -68.45 -42.67 78.46 Favored 'General case' 0 CA--C 1.554 1.116 0 CA-C-N 115.006 -0.597 . . . . 0.0 112.119 -177.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.427 HG21 HD13 ' A' ' 17' ' ' ILE . 93.3 mt -67.06 -44.45 88.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 O-C-N 120.893 -1.13 . . . . 0.0 110.339 -177.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 22.8 t80 -57.43 -18.82 19.99 Favored 'General case' 0 N--CA 1.442 -0.869 0 C-N-CA 118.793 -1.163 . . . . 0.0 109.359 -176.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -62.41 -30.49 71.25 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 124.71 1.256 . . . . 0.0 108.186 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 66.8 t -74.59 -49.23 31.52 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 98.1 mmm -63.83 -43.5 96.0 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-O 121.659 0.742 . . . . 0.0 111.833 -176.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.2 p -67.15 -39.48 83.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 114.418 -1.265 . . . . 0.0 113.002 -178.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -64.12 -45.89 86.57 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -177.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.78 -28.7 70.36 Favored Glycine 0 CA--C 1.546 2.026 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.839 179.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -61.48 -38.25 86.61 Favored 'General case' 0 CA--C 1.571 1.783 0 N-CA-C 115.869 1.803 . . . . 0.0 115.869 -174.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.569 ' CE3' ' OD1' ' E' ' 46' ' ' ASN . 99.3 m95 -74.18 -32.53 63.12 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 117.716 2.487 . . . . 0.0 117.716 -177.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -49.47 -33.42 14.25 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 114.334 1.235 . . . . 0.0 114.334 -174.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 m -55.07 -40.43 70.34 Favored 'General case' 0 CA--C 1.564 1.484 0 N-CA-C 114.448 1.277 . . . . 0.0 114.448 -176.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.2 t -60.88 -41.88 90.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 117.841 2.534 . . . . 0.0 117.841 -174.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -50.15 -45.35 43.17 Favored Glycine 0 CA--C 1.541 1.677 0 C-N-CA 120.549 -0.834 . . . . 0.0 115.128 -171.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 64.3 mmm -68.35 -33.11 73.68 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 119.13 1.465 . . . . 0.0 113.127 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 11.2 tp -51.35 -59.18 4.51 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 117.994 2.59 . . . . 0.0 117.994 -171.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 30.5 t80 -72.71 -43.05 63.5 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 120.478 1.49 . . . . 0.0 112.635 -179.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -59.68 -50.34 74.23 Favored 'General case' 0 CA--C 1.556 1.208 0 N-CA-C 118.375 2.731 . . . . 0.0 118.375 -173.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.433 ' OG ' ' CB ' ' M' ' 12' ' ' ALA . 4.8 t -53.1 -26.55 16.81 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -173.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 42.0 tp -63.5 -31.4 72.55 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 117.111 2.263 . . . . 0.0 117.111 -176.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -51.24 -29.22 21.63 Favored Glycine 0 CA--C 1.544 1.851 0 C-N-CA 118.161 -1.971 . . . . 0.0 114.246 -170.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 16.4 mttt -67.0 -38.48 86.09 Favored 'General case' 0 CA--C 1.555 1.17 0 N-CA-C 116.596 2.073 . . . . 0.0 116.596 -178.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -62.67 -33.65 87.34 Favored Glycine 0 CA--C 1.545 1.908 0 N-CA-C 116.125 1.21 . . . . 0.0 116.125 -174.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.1 p -71.47 -23.42 61.82 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 113.715 1.005 . . . . 0.0 113.715 -176.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' MET . . . . . . . . . . . . . 91.4 mmm -60.99 -41.57 96.73 Favored 'General case' 0 CA--C 1.553 1.079 0 N-CA-C 118.615 2.82 . . . . 0.0 118.615 -174.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 88.4 mmt-85 -63.88 -41.78 97.66 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-N 120.09 1.313 . . . . 0.0 114.119 -174.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 33.0 mm -63.86 -42.2 95.05 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.569 0 N-CA-C 108.193 -1.039 . . . . 0.0 108.193 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 -58.41 -39.62 80.21 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.53 178.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.8 ttp180 -63.33 -44.49 94.78 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 115.675 1.731 . . . . 0.0 115.675 -177.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.584 ' OD1' ' CE3' ' M' ' 26' ' ' TRP . 0.7 OUTLIER -73.47 -64.1 1.06 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 117.119 2.266 . . . . 0.0 117.119 -175.831 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -57.23 -34.63 68.77 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -174.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -99.08 34.37 2.14 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 118.695 2.85 . . . . 0.0 118.695 -174.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -69.85 -12.08 67.23 Favored Glycine 0 CA--C 1.564 3.124 0 N-CA-C 117.915 1.926 . . . . 0.0 117.915 -175.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 53.5 m -106.34 116.61 32.23 Favored 'General case' 0 N--CA 1.501 2.09 0 CA-C-N 120.916 2.358 . . . . 0.0 111.809 -178.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 68.2 mtm -86.75 -33.39 19.98 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.387 0.613 . . . . 0.0 110.417 178.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -55.06 107.22 0.68 Allowed Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.47 -34.56 90.27 Favored Glycine 0 N--CA 1.448 -0.545 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.57 -170.59 46.47 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.5 p -74.51 161.11 30.08 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-O 121.12 0.486 . . . . 0.0 111.244 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 59.0 tp -88.53 128.31 35.55 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.688 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 45.2 ttt85 -60.42 135.28 57.7 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.581 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.63 15.53 77.7 Favored Glycine 0 CA--C 1.526 0.749 0 C-N-CA 121.059 -0.591 . . . . 0.0 111.635 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 88.7 p . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.863 -1.065 . . . . 0.0 111.018 179.78 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.49 ' CE ' ' H1 ' ' B' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.159 0 CA-C-O 123.649 1.69 . . . . 0.0 109.181 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 10.2 m -68.32 135.11 51.36 Favored 'General case' 0 C--N 1.326 -0.435 0 O-C-N 119.805 -1.809 . . . . 0.0 109.869 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . 70.19 172.12 10.36 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.44 16.68 80.48 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 121.444 -0.408 . . . . 0.0 113.017 178.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.11 53.49 3.57 Favored Glycine 0 N--CA 1.469 0.894 0 N-CA-C 110.546 -1.022 . . . . 0.0 110.546 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' B' ' 7' ' ' PHE . 30.9 m -84.76 -14.53 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 113.168 0.803 . . . . 0.0 113.168 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' PHE . . . . . 0.634 ' O ' ' N ' ' B' ' 9' ' ' ASP . 0.3 OUTLIER -66.67 -140.01 0.0 OUTLIER 'General case' 0 C--O 1.188 -2.183 0 N-CA-C 105.258 -2.127 . . . . 0.0 105.258 175.843 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' THR . . . . . . . . . . . . . 15.2 m 41.43 -66.16 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 176.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' ASP . . . . . 0.634 ' N ' ' O ' ' B' ' 7' ' ' PHE . 11.9 t70 -56.08 -26.6 50.12 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 123.944 0.897 . . . . 0.0 111.247 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' ILE . . . . . 0.435 HG22 HD13 ' B' ' 10' ' ' ILE . 46.2 mt -63.66 -42.87 97.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 C-N-CA 117.885 -1.526 . . . . 0.0 108.873 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' LEU . . . . . . . . . . . . . 25.5 tp -58.78 -42.88 90.05 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.031 -0.668 . . . . 0.0 109.277 178.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' ALA . . . . . 0.451 ' CB ' ' OG ' ' H' ' 35' ' ' SER . . . -58.5 -35.21 71.88 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 178.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' ALA . . . . . 0.536 ' O ' ' N ' ' B' ' 16' ' ' ARG . . . -73.91 -75.95 0.14 Allowed 'General case' 0 C--O 1.209 -1.051 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.973 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' ALA . . . . . . . . . . . . . . . -30.95 -32.53 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 113.396 0.888 . . . . 0.0 113.396 -179.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' B' ' 13' ' ' ALA . . . -81.17 -49.02 5.74 Favored Glycine 0 CA--C 1.52 0.351 0 N-CA-C 109.176 -1.569 . . . . 0.0 109.176 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' ARG . . . . . 0.536 ' N ' ' O ' ' B' ' 13' ' ' ALA . 74.5 ttt-85 -67.99 -43.31 79.2 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 113.98 -1.11 . . . . 0.0 111.042 -179.003 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.41 HG21 HD13 ' B' ' 17' ' ' ILE . 88.4 mt -63.72 -43.49 98.04 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.899 0 C-N-CA 120.337 -0.545 . . . . 0.0 110.014 -177.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -57.5 -20.14 29.24 Favored 'General case' 0 CA--C 1.484 -1.559 0 C-N-CA 118.789 -1.164 . . . . 0.0 110.826 -177.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -61.4 -33.96 74.57 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 119.009 -1.076 . . . . 0.0 110.203 178.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.38 -48.49 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.22 0 C-N-CA 119.808 -0.757 . . . . 0.0 112.892 -178.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' MET . . . . . . . . . . . . . 97.6 mmm -64.63 -44.27 91.03 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-O 121.42 0.629 . . . . 0.0 112.384 -176.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' VAL . . . . . . . . . . . . . 14.3 p -67.35 -38.77 81.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 CA-C-N 115.434 -0.803 . . . . 0.0 112.915 -178.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -64.35 -42.53 96.19 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -176.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' GLY . . . . . . . . . . . . . . . -91.03 13.83 65.13 Favored Glycine 0 N--CA 1.472 1.074 0 N-CA-C 112.605 -0.198 . . . . 0.0 112.605 -178.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 2.6 t-80 -100.36 -15.87 17.83 Favored 'General case' 0 CA--C 1.564 1.495 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -176.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' TRP . . . . . 0.594 ' CZ3' ' OD1' ' H' ' 46' ' ' ASN . 97.0 m95 -94.42 -33.65 13.05 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 -178.055 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -50.16 -24.25 2.67 Favored 'General case' 0 N--CA 1.482 1.16 0 N-CA-C 115.773 1.768 . . . . 0.0 115.773 -176.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' THR . . . . . . . . . . . . . 81.3 m -61.82 -41.51 97.87 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -178.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' VAL . . . . . . . . . . . . . 68.7 t -61.27 -45.58 98.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 116.215 1.932 . . . . 0.0 116.215 -174.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' GLY . . . . . . . . . . . . . . . -27.73 -61.42 0.11 Allowed Glycine 0 CA--C 1.549 2.162 0 N-CA-C 115.255 0.862 . . . . 0.0 115.255 -176.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' MET . . . . . . . . . . . . . 4.2 mtp -67.73 -33.25 74.5 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 115.558 1.688 . . . . 0.0 115.558 -176.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 2.0 tp -41.78 -75.14 0.03 OUTLIER 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 114.862 1.43 . . . . 0.0 114.862 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -62.84 -44.96 94.73 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 119.346 -0.942 . . . . 0.0 113.519 -176.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -52.26 -70.73 0.08 Allowed 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -176.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' SER . . . . . . . . . . . . . 1.5 t -32.0 -33.23 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 117.059 2.244 . . . . 0.0 117.059 -174.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 47.4 tp -62.15 -44.34 96.83 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 116.434 2.013 . . . . 0.0 116.434 -175.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -29.49 -38.51 0.02 OUTLIER Glycine 0 CA--C 1.549 2.187 0 N-CA-C 115.857 1.103 . . . . 0.0 115.857 -173.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -66.1 -39.36 89.92 Favored 'General case' 0 CA--C 1.548 0.868 0 N-CA-C 115.607 1.706 . . . . 0.0 115.607 -174.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . -62.29 -32.64 83.47 Favored Glycine 0 N--CA 1.481 1.683 0 N-CA-C 117.047 1.579 . . . . 0.0 117.047 -174.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' THR . . . . . . . . . . . . . 7.2 p -76.0 -14.01 60.23 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 118.628 1.214 . . . . 0.0 112.941 -177.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' MET . . . . . . . . . . . . . 91.9 mmm -64.92 -41.13 95.81 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' ARG . . . . . 0.509 ' NH1' ' OE2' ' C' ' 23' ' ' GLU . 89.3 mmt-85 -64.83 -42.08 95.23 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 118.989 -1.085 . . . . 0.0 113.634 -174.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 26.3 mm -63.38 -42.66 97.13 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.913 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -60.52 -36.24 77.92 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.207 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' ARG . . . . . . . . . . . . . 2.0 ttp180 -62.58 -45.78 91.35 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' ASN . . . . . 0.575 ' OD1' ' CD2' ' J' ' 26' ' ' TRP . 0.4 OUTLIER -76.32 -69.84 0.48 Allowed 'General case' 0 N--CA 1.484 1.247 0 N-CA-C 116.658 2.096 . . . . 0.0 116.658 -175.336 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.09 -40.34 31.62 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 120.401 -0.519 . . . . 0.0 111.591 -174.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -104.68 114.97 29.53 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.08 -22.01 0.53 Allowed Glycine 0 N--CA 1.482 1.76 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' SER . . . . . . . . . . . . . 36.1 m -99.95 107.21 19.13 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 117.195 0.498 . . . . 0.0 111.314 -179.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' MET . . . . . . . . . . . . . 64.8 mtm -75.2 -34.49 61.5 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.838 177.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -52.39 107.06 0.44 Allowed Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 -178.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.02 -33.45 87.29 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.43 -171.07 47.32 Favored Glycine 0 N--CA 1.46 0.281 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' SER . . . . . . . . . . . . . 87.9 p -75.33 163.24 27.67 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.079 0.466 . . . . 0.0 111.631 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' LEU . . . . . . . . . . . . . 54.1 tp -88.03 130.55 34.95 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.626 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 39.3 ttt180 -63.61 132.4 51.05 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.13 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.89 16.05 76.0 Favored Glycine 0 CA--C 1.536 1.387 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 78.4 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.424 179.789 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.148 0 CA-C-O 124.162 1.934 . . . . 0.0 109.191 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 2' ' ' SER . . . . . . . . . . . . . 7.2 m -52.12 136.22 30.15 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 114.403 -1.272 . . . . 0.0 109.915 179.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.36 164.2 13.49 Favored Glycine 0 N--CA 1.438 -1.221 0 CA-C-N 115.098 -0.956 . . . . 0.0 110.894 -179.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.07 16.35 80.8 Favored Glycine 0 CA--C 1.532 1.107 0 C-N-CA 121.445 -0.407 . . . . 0.0 113.595 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.69 69.33 2.24 Favored Glycine 0 N--CA 1.473 1.162 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 6' ' ' VAL . . . . . . . . . . . . . 18.6 m -103.12 -6.16 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 7' ' ' PHE . . . . . 0.567 ' O ' ' N ' ' C' ' 9' ' ' ASP . 0.8 OUTLIER -71.63 -98.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 CA-C-O 117.058 -1.448 . . . . 0.0 109.278 -179.899 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 8' ' ' THR . . . . . . . . . . . . . 31.8 m -7.15 -49.63 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 116.067 1.877 . . . . 0.0 116.067 -179.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 9' ' ' ASP . . . . . 0.567 ' N ' ' O ' ' C' ' 7' ' ' PHE . 14.7 t70 -61.69 -27.05 68.42 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 117.872 0.305 . . . . 0.0 111.611 -179.238 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 10' ' ' ILE . . . . . 0.417 HG22 HD13 ' C' ' 10' ' ' ILE . 21.4 mt -65.12 -43.66 95.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 O-C-N 120.663 -1.273 . . . . 0.0 108.457 179.151 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 11' ' ' LEU . . . . . 0.437 ' O ' ' O ' ' C' ' 13' ' ' ALA . 41.3 tp -61.01 -40.03 92.0 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.4 -39.86 88.86 Favored 'General case' 0 C--O 1.234 0.238 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 177.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 13' ' ' ALA . . . . . 0.508 ' O ' ' N ' ' C' ' 15' ' ' GLY . . . -79.71 -158.78 0.18 Allowed 'General case' 0 C--O 1.175 -2.862 0 N-CA-C 101.643 -3.466 . . . . 0.0 101.643 174.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 14' ' ' ALA . . . . . . . . . . . . . . . 60.2 -38.85 0.09 Allowed 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 122.067 2.212 . . . . 0.0 113.135 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 15' ' ' GLY . . . . . 0.508 ' N ' ' O ' ' C' ' 13' ' ' ALA . . . -95.6 -48.01 2.42 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 106.314 -2.714 . . . . 0.0 106.314 178.202 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 16' ' ' ARG . . . . . . . . . . . . . 76.6 ttt-85 -65.35 -43.57 90.45 Favored 'General case' 0 C--N 1.353 0.752 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 76.6 mt -63.77 -42.95 97.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.657 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 18' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -56.79 -19.0 14.79 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.911 -0.715 . . . . 0.0 111.721 -177.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 19' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -65.66 -36.9 85.0 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-O 121.479 0.657 . . . . 0.0 110.655 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 20' ' ' VAL . . . . . . . . . . . . . 91.2 t -66.41 -47.78 82.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 C-N-CA 119.918 -0.713 . . . . 0.0 110.891 -178.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 21' ' ' MET . . . . . . . . . . . . . 97.0 mmm -66.64 -45.63 78.4 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 -177.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 22' ' ' VAL . . . . . . . . . . . . . 14.7 p -67.08 -37.56 79.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.886 -178.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 23' ' ' GLU . . . . . 0.509 ' OE2' ' NH1' ' B' ' 42' ' ' ARG . 88.8 tt0 -61.78 -44.7 96.35 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 -178.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 24' ' ' GLY . . . . . . . . . . . . . . . -92.67 22.97 30.6 Favored Glycine 0 CA--C 1.547 2.048 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 25' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -107.92 -9.86 15.63 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 112.635 0.606 . . . . 0.0 112.635 -178.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -99.99 -36.21 9.45 Favored 'General case' 0 CA--C 1.56 1.338 0 N-CA-C 114.01 1.115 . . . . 0.0 114.01 -178.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -49.41 -24.5 2.0 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 114.296 1.221 . . . . 0.0 114.296 -176.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' THR . . . . . . . . . . . . . 98.9 m -62.24 -42.8 99.64 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 -178.268 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 88.1 t -60.83 -45.53 97.87 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 N-CA-C 115.61 1.707 . . . . 0.0 115.61 -175.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . -23.12 -69.08 0.02 OUTLIER Glycine 0 CA--C 1.55 2.275 0 N-CA-C 116.197 1.239 . . . . 0.0 116.197 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' MET . . . . . . . . . . . . . 39.6 mtp -65.4 -36.49 84.12 Favored 'General case' 0 N--CA 1.485 1.317 0 N-CA-C 115.073 1.509 . . . . 0.0 115.073 -176.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -33.35 -77.15 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -175.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -61.83 -47.48 84.9 Favored 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 118.9 -1.12 . . . . 0.0 113.74 -176.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -46.73 -73.7 0.04 OUTLIER 'General case' 0 CA--C 1.561 1.379 0 N-CA-C 116.199 1.925 . . . . 0.0 116.199 -177.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' SER . . . . . . . . . . . . . 2.7 t -30.44 -33.78 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 117.202 2.297 . . . . 0.0 117.202 -174.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 43.8 tp -63.12 -42.21 99.49 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 115.269 1.581 . . . . 0.0 115.269 -176.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -29.26 -43.36 0.05 OUTLIER Glycine 0 CA--C 1.545 1.925 0 N-CA-C 115.946 1.139 . . . . 0.0 115.946 -175.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 32.1 mttm -65.65 -40.53 92.56 Favored 'General case' 0 CA--C 1.559 1.306 0 N-CA-C 115.087 1.514 . . . . 0.0 115.087 -174.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . -58.68 -40.53 94.92 Favored Glycine 0 N--CA 1.484 1.889 0 N-CA-C 117.603 1.801 . . . . 0.0 117.603 -173.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' THR . . . . . . . . . . . . . 25.3 p -71.28 -15.58 62.43 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 118.481 1.14 . . . . 0.0 112.548 -176.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 41' ' ' MET . . . . . . . . . . . . . 81.9 mmm -63.32 -39.84 95.68 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 115.923 1.823 . . . . 0.0 115.923 -174.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 42' ' ' ARG . . . . . . . . . . . . . 89.1 mmt-85 -63.28 -41.66 99.02 Favored 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 119.617 -0.833 . . . . 0.0 113.131 -175.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 21.3 mm -63.11 -43.85 99.15 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 44' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -63.61 -26.07 68.52 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.622 -178.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 45' ' ' ARG . . . . . 0.684 ' NH1' HH12 ' H' ' 45' ' ' ARG . 1.0 OUTLIER -70.27 -44.19 68.93 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 118.701 -1.2 . . . . 0.0 112.76 179.945 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 46' ' ' ASN . . . . . 0.561 ' OD1' ' CD2' ' G' ' 26' ' ' TRP . 1.5 t-20 -75.42 -77.23 0.13 Allowed 'General case' 0 N--CA 1.466 0.359 0 N-CA-C 115.817 1.784 . . . . 0.0 115.817 -173.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 47' ' ' ALA . . . . . . . . . . . . . . . -43.01 -45.86 5.29 Favored 'General case' 0 CA--C 1.518 -0.261 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.889 -176.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 48' ' ' TYR . . . . . . . . . . . . . 69.4 m-85 -96.21 131.48 42.64 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 49' ' ' GLY . . . . . . . . . . . . . . . -152.44 -25.45 0.05 OUTLIER Glycine 0 N--CA 1.466 0.697 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 -178.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 50' ' ' SER . . . . . . . . . . . . . 58.6 m -103.1 97.99 8.0 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 51' ' ' MET . . . . . . . . . . . . . 67.2 mtm -65.42 -38.02 88.67 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 108.733 -0.839 . . . . 0.0 108.733 176.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . -46.79 107.76 0.23 Allowed Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.89 -33.91 88.49 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.71 -173.55 49.35 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 55' ' ' SER . . . . . . . . . . . . . 93.2 p -74.04 163.24 28.14 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.896 0.379 . . . . 0.0 110.681 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 56' ' ' LEU . . . . . . . . . . . . . 50.3 tp -87.37 133.15 33.76 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.177 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 57' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -67.49 132.3 47.33 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.147 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 58' ' ' GLY . . . . . . . . . . . . . . . 83.78 15.09 71.29 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 59' ' ' SER . . . . . . . . . . . . . 71.9 p . . . . . 0 C--N 1.325 -0.49 0 CA-C-O 117.942 -1.027 . . . . 0.0 110.718 -179.954 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 1' ' ' MET . . . . . . . . . . . . . 7.2 ttp . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 2' ' ' SER . . . . . . . . . . . . . 6.1 m -46.67 138.67 5.85 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.662 178.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.41 163.28 8.08 Favored Glycine 0 CA--C 1.535 1.288 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 -178.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 4' ' ' GLY . . . . . . . . . . . . . . . 78.37 15.71 80.55 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 121.006 -0.616 . . . . 0.0 113.522 178.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.46 74.7 1.92 Allowed Glycine 0 N--CA 1.473 1.155 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 6' ' ' VAL . . . . . . . . . . . . . 26.8 m -111.13 2.38 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.287 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 7' ' ' PHE . . . . . 0.445 ' O ' ' N ' ' D' ' 9' ' ' ASP . 7.0 m-85 -79.69 -82.2 0.11 Allowed 'General case' 0 C--O 1.21 -0.984 0 CA-C-N 118.664 0.666 . . . . 0.0 111.38 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 8' ' ' THR . . . . . . . . . . . . . 87.8 m -25.65 -40.47 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 9' ' ' ASP . . . . . 0.445 ' N ' ' O ' ' D' ' 7' ' ' PHE . 25.5 t70 -64.35 -32.33 73.9 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -179.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 10' ' ' ILE . . . . . 0.48 ' O ' ' N ' ' D' ' 14' ' ' ALA . 38.1 mt -62.45 -43.4 98.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 O-C-N 121.548 -0.72 . . . . 0.0 109.539 -178.597 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 11' ' ' LEU . . . . . . . . . . . . . 40.5 tp -59.84 -40.94 90.22 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 12' ' ' ALA . . . . . . . . . . . . . . . -62.35 -35.5 79.31 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 176.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 13' ' ' ALA . . . . . . . . . . . . . . . -90.9 -5.78 55.03 Favored 'General case' 0 C--O 1.199 -1.583 0 N-CA-C 114.847 1.425 . . . . 0.0 114.847 -178.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 14' ' ' ALA . . . . . 0.48 ' N ' ' O ' ' D' ' 10' ' ' ILE . . . -94.45 -12.9 26.84 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.055 -1.653 . . . . 0.0 107.727 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 15' ' ' GLY . . . . . . . . . . . . . . . -100.28 -48.9 1.5 Allowed Glycine 0 CA--C 1.525 0.68 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 16' ' ' ARG . . . . . . . . . . . . . 77.1 ttt-85 -63.71 -43.33 96.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.267 -0.467 . . . . 0.0 110.933 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 17' ' ' ILE . . . . . . . . . . . . . 17.9 mt -64.11 -42.98 97.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.229 -177.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 18' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -55.92 -19.34 11.74 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.162 -178.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 19' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -66.33 -36.86 83.99 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.001 0.429 . . . . 0.0 111.036 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 20' ' ' VAL . . . . . . . . . . . . . 96.8 t -66.66 -49.34 75.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-O 120.916 0.389 . . . . 0.0 111.99 -178.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 21' ' ' MET . . . . . . . . . . . . . 94.8 mmm -65.13 -43.89 90.45 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 22' ' ' VAL . . . . . . . . . . . . . 12.9 p -68.94 -33.85 61.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.201 -177.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 23' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -65.43 -40.33 93.16 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 111.972 0.36 . . . . 0.0 111.972 -178.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 24' ' ' GLY . . . . . . . . . . . . . . . -96.41 21.5 45.19 Favored Glycine 0 CA--C 1.539 1.561 0 N-CA-C 111.946 -0.462 . . . . 0.0 111.946 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 25' ' ' HIS . . . . . . . . . . . . . 4.4 t-80 -103.57 -6.41 21.73 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.082 0.553 . . . . 0.0 111.526 -178.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 26' ' ' TRP . . . . . . . . . . . . . 98.5 m95 -105.44 -35.22 7.56 Favored 'General case' 0 N--CA 1.485 1.306 0 N-CA-C 114.163 1.171 . . . . 0.0 114.163 -178.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 27' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -51.26 -25.4 5.61 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 114.014 1.116 . . . . 0.0 114.014 -176.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 28' ' ' THR . . . . . . . . . . . . . 31.8 m -61.17 -43.35 99.02 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 29' ' ' VAL . . . . . . . . . . . . . 92.1 t -62.14 -46.02 97.41 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.821 0 N-CA-C 115.653 1.723 . . . . 0.0 115.653 -174.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 30' ' ' GLY . . . . . . . . . . . . . . . -22.34 -70.08 0.01 OUTLIER Glycine 0 CA--C 1.54 1.652 0 N-CA-C 115.736 1.054 . . . . 0.0 115.736 -177.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 31' ' ' MET . . . . . . . . . . . . . 85.2 mtp -65.98 -36.64 83.86 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 115.058 1.503 . . . . 0.0 115.058 -176.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -30.0 -77.41 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -176.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 33' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -61.73 -46.26 90.4 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.771 -0.771 . . . . 0.0 113.011 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 34' ' ' ASP . . . . . 0.498 ' O ' ' N ' ' D' ' 36' ' ' LEU . 31.9 t70 -49.3 -82.04 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.176 0 N-CA-C 116.676 2.102 . . . . 0.0 116.676 -177.337 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 35' ' ' SER . . . . . . . . . . . . . 8.2 t -22.23 -36.31 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 -176.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . 0.498 ' N ' ' O ' ' D' ' 34' ' ' ASP . 43.0 tp -61.01 -42.33 98.25 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.141 1.163 . . . . 0.0 114.141 -176.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -27.34 -44.54 0.03 OUTLIER Glycine 0 CA--C 1.552 2.366 0 N-CA-C 115.959 1.143 . . . . 0.0 115.959 -176.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 38' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -65.02 -41.48 95.26 Favored 'General case' 0 CA--C 1.557 1.249 0 N-CA-C 115.69 1.737 . . . . 0.0 115.69 -175.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 39' ' ' GLY . . . . . . . . . . . . . . . -56.19 -41.19 85.9 Favored Glycine 0 N--CA 1.479 1.551 0 N-CA-C 117.09 1.596 . . . . 0.0 117.09 -173.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 40' ' ' THR . . . . . . . . . . . . . 35.7 p -70.46 -16.37 62.92 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 114.037 1.125 . . . . 0.0 114.037 -176.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 41' ' ' MET . . . . . . . . . . . . . 65.8 mmm -63.79 -40.08 95.81 Favored 'General case' 0 CA--C 1.55 0.976 0 N-CA-C 116.42 2.007 . . . . 0.0 116.42 -174.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 42' ' ' ARG . . . . . . . . . . . . . 88.6 mmt-85 -62.94 -42.06 99.69 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 119.131 -1.028 . . . . 0.0 113.102 -175.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 20.2 mm -61.05 -43.19 95.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 44' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -64.85 -27.99 69.25 Favored 'General case' 0 CA--C 1.561 1.398 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.914 -178.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 45' ' ' ARG . . . . . 0.772 HH12 HH12 ' E' ' 45' ' ' ARG . 0.8 OUTLIER -71.11 -39.26 72.19 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 119.118 0.872 . . . . 0.0 112.275 179.75 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' D' D ' 46' ' ' ASN . . . . . 0.542 ' OD1' ' CE3' ' F' ' 26' ' ' TRP . 8.6 t-20 -80.16 -74.04 0.33 Allowed 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -172.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 47' ' ' ALA . . . . . . . . . . . . . . . -48.77 -41.39 32.26 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.064 -175.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 48' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -97.47 135.53 39.2 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 178.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 49' ' ' GLY . . . . . . . . . . . . . . . -156.97 -26.59 0.03 OUTLIER Glycine 0 N--CA 1.465 0.571 0 N-CA-C 111.673 -0.571 . . . . 0.0 111.673 -178.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 50' ' ' SER . . . . . . . . . . . . . 58.5 m -102.71 95.76 6.42 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -178.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 51' ' ' MET . . . . . . . . . . . . . 67.9 mtm -63.62 -38.96 93.1 Favored 'General case' 0 CA--C 1.533 0.31 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 177.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . -43.49 107.23 0.11 Allowed Glycine 0 CA--C 1.531 1.049 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.981 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.27 -34.49 90.05 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.29 -173.42 51.73 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 55' ' ' SER . . . . . . . . . . . . . 87.4 p -75.36 163.65 27.23 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.912 0.387 . . . . 0.0 111.655 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 56' ' ' LEU . . . . . 0.406 ' O ' ' OXT' ' D' ' 59' ' ' SER . 50.5 tp -87.75 130.55 34.8 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.901 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 57' ' ' ARG . . . . . . . . . . . . . 65.0 ttt180 -66.58 134.07 51.61 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.817 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.08 14.51 76.89 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.871 -0.891 . . . . 0.0 110.871 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 59' ' ' SER . . . . . 0.406 ' OXT' ' O ' ' D' ' 56' ' ' LEU . 71.8 p . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.865 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 1' ' ' MET . . . . . . . . . . . . . 67.1 ttp . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 2' ' ' SER . . . . . . . . . . . . . 6.6 m -48.99 137.34 13.1 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.131 0.491 . . . . 0.0 110.164 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.08 165.95 16.4 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.78 14.92 82.05 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.804 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.65 75.3 1.66 Allowed Glycine 0 N--CA 1.475 1.27 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 6' ' ' VAL . . . . . . . . . . . . . 17.9 m -112.27 1.87 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 113.337 0.866 . . . . 0.0 113.337 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 7' ' ' PHE . . . . . 0.464 ' O ' ' N ' ' E' ' 9' ' ' ASP . 7.8 m-85 -79.03 -83.08 0.09 Allowed 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.783 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 8' ' ' THR . . . . . . . . . . . . . 97.8 m -23.52 -42.23 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.842 1.053 . . . . 0.0 113.842 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 9' ' ' ASP . . . . . 0.464 ' N ' ' O ' ' E' ' 7' ' ' PHE . 25.7 t70 -62.74 -39.32 93.72 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 113.308 0.855 . . . . 0.0 113.308 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 10' ' ' ILE . . . . . 0.416 ' N ' ' O ' ' E' ' 7' ' ' PHE . 57.3 mt -53.77 -42.79 53.62 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.837 0 O-C-N 121.871 -0.518 . . . . 0.0 110.239 -178.423 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 11' ' ' LEU . . . . . . . . . . . . . 40.5 tp -61.08 -41.2 96.19 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 119.843 -0.743 . . . . 0.0 110.332 178.116 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.87 -38.35 87.94 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 13' ' ' ALA . . . . . 0.405 ' O ' ' CG1' ' E' ' 17' ' ' ILE . . . -74.85 -41.8 59.18 Favored 'General case' 0 CA--C 1.553 1.084 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.09 -23.09 66.3 Favored 'General case' 0 CA--C 1.512 -0.499 0 O-C-N 121.354 -0.841 . . . . 0.0 110.699 -178.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 15' ' ' GLY . . . . . . . . . . . . . . . -90.18 -45.82 4.31 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 16' ' ' ARG . . . . . . . . . . . . . 77.2 ttt-85 -69.64 -42.92 73.65 Favored 'General case' 0 CA--C 1.542 0.669 0 CA-C-N 115.465 -0.368 . . . . 0.0 111.561 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 17' ' ' ILE . . . . . 0.405 ' CG1' ' O ' ' E' ' 13' ' ' ALA . 1.1 mm -62.3 -44.38 99.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 CA-C-O 120.975 0.417 . . . . 0.0 111.432 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 18' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -57.97 -19.11 28.14 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.333 -178.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 19' ' ' GLU . . . . . . . . . . . . . 89.8 mt-10 -65.77 -37.04 85.25 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.216 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 20' ' ' VAL . . . . . . . . . . . . . 95.6 t -66.96 -48.47 79.41 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.8 -178.491 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 21' ' ' MET . . . . . . . . . . . . . 94.9 mmm -64.93 -43.16 93.67 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 22' ' ' VAL . . . . . . . . . . . . . 12.0 p -70.35 -30.67 44.05 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -177.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 23' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -68.05 -41.28 82.28 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.14 0.793 . . . . 0.0 113.14 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 24' ' ' GLY . . . . . . . . . . . . . . . -95.66 16.94 60.23 Favored Glycine 0 N--CA 1.479 1.511 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 25' ' ' HIS . . . . . 0.416 ' O ' ' CG ' ' E' ' 25' ' ' HIS . 6.5 t-80 -97.3 -3.95 39.59 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 123.309 0.644 . . . . 0.0 111.827 -178.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 26' ' ' TRP . . . . . . . . . . . . . 98.4 m95 -107.69 -39.34 5.62 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 113.591 0.96 . . . . 0.0 113.591 -177.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 27' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -45.48 -30.15 1.33 Allowed 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -177.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 28' ' ' THR . . . . . . . . . . . . . 71.7 m -61.67 -43.05 99.6 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 113.78 1.03 . . . . 0.0 113.78 -177.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 29' ' ' VAL . . . . . . . . . . . . . 86.0 t -60.78 -45.48 97.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -175.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 30' ' ' GLY . . . . . . . . . . . . . . . -25.05 -70.33 0.03 OUTLIER Glycine 0 CA--C 1.543 1.819 0 N-CA-C 115.87 1.108 . . . . 0.0 115.87 -176.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 31' ' ' MET . . . . . . . . . . . . . 95.3 mtp -65.67 -36.83 84.78 Favored 'General case' 0 CA--C 1.544 0.716 0 N-CA-C 115.062 1.504 . . . . 0.0 115.062 -176.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -29.86 -75.9 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -177.595 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 33' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -62.59 -46.57 87.69 Favored 'General case' 0 CA--C 1.552 1.027 0 N-CA-C 113.991 1.108 . . . . 0.0 113.991 -178.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 34' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -58.72 -53.26 60.37 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 117.729 2.492 . . . . 0.0 117.729 -174.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 35' ' ' SER . . . . . . . . . . . . . 33.8 t -45.2 -43.09 9.88 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 114.936 1.458 . . . . 0.0 114.936 -174.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 36' ' ' LEU . . . . . 0.524 ' O ' ' N ' ' E' ' 38' ' ' LYS . 38.2 tp -48.63 -54.78 13.33 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 114.921 1.452 . . . . 0.0 114.921 -177.585 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -10.59 -49.98 0.01 OUTLIER Glycine 0 CA--C 1.551 2.291 0 N-CA-C 116.616 1.406 . . . . 0.0 116.616 -177.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 38' ' ' LYS . . . . . 0.524 ' N ' ' O ' ' E' ' 36' ' ' LEU . 62.6 mttm -64.12 -42.62 96.77 Favored 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 116.063 1.875 . . . . 0.0 116.063 -175.074 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 39' ' ' GLY . . . . . . . . . . . . . . . -56.86 -30.75 60.34 Favored Glycine 0 N--CA 1.484 1.895 0 N-CA-C 116.741 1.457 . . . . 0.0 116.741 -174.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 40' ' ' THR . . . . . . . . . . . . . 29.9 p -79.85 -15.21 57.83 Favored 'General case' 0 CA--C 1.55 0.971 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -176.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 41' ' ' MET . . . . . . . . . . . . . 69.3 mmm -64.59 -39.49 93.82 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 114.996 1.48 . . . . 0.0 114.996 -176.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 42' ' ' ARG . . . . . . . . . . . . . 87.7 mmt-85 -63.98 -35.09 79.56 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 43' ' ' ILE . . . . . . . . . . . . . 18.2 mm -71.98 -29.38 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 44' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -73.62 -29.68 62.51 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 113.934 -1.485 . . . . 0.0 112.009 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 45' ' ' ARG . . . . . 0.772 HH12 HH12 ' D' ' 45' ' ' ARG . 13.1 ttm-85 -78.89 -18.27 54.18 Favored 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -177.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 46' ' ' ASN . . . . . 0.569 ' OD1' ' CE3' ' A' ' 26' ' ' TRP . 26.0 t-20 -95.76 -87.6 0.28 Allowed 'General case' 0 N--CA 1.473 0.711 0 O-C-N 121.112 -0.992 . . . . 0.0 112.013 -177.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 47' ' ' ALA . . . . . . . . . . . . . . . -36.69 -36.31 0.11 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.638 -177.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 48' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -104.71 138.68 40.65 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 49' ' ' GLY . . . . . . . . . . . . . . . -164.19 -24.18 0.02 OUTLIER Glycine 0 N--CA 1.468 0.826 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.353 -178.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 50' ' ' SER . . . . . . . . . . . . . 53.7 m -103.15 93.61 5.09 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 122.366 -0.49 . . . . 0.0 111.943 -178.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 51' ' ' MET . . . . . . . . . . . . . 68.9 mtm -63.51 -40.39 96.93 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.997 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 52' ' ' GLY . . . . . . . . . . . . . . . -44.44 109.72 0.3 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.434 -0.666 . . . . 0.0 111.434 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.3 -34.19 89.24 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 110.356 -1.097 . . . . 0.0 110.356 178.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 54' ' ' GLY . . . . . . . . . . . . . . . 85.08 -174.35 49.32 Favored Glycine 0 CA--C 1.529 0.967 0 N-CA-C 112.077 -0.409 . . . . 0.0 112.077 179.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 55' ' ' SER . . . . . . . . . . . . . 85.8 p -73.19 159.56 33.29 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 120.86 0.362 . . . . 0.0 110.665 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 56' ' ' LEU . . . . . 0.404 ' O ' ' OXT' ' E' ' 59' ' ' SER . 51.4 tp -84.99 131.4 34.48 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.622 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 57' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -66.81 135.19 53.56 Favored 'General case' 0 CA--C 1.508 -0.651 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.48 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.28 16.31 76.56 Favored Glycine 0 CA--C 1.532 1.122 0 CA-C-N 115.184 -0.917 . . . . 0.0 110.824 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 59' ' ' SER . . . . . 0.404 ' OXT' ' O ' ' E' ' 56' ' ' LEU . 65.9 p . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.735 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 1' ' ' MET . . . . . . . . . . . . . 61.5 ttp . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 2' ' ' SER . . . . . . . . . . . . . 6.6 m -53.16 134.71 38.77 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 121.45 -0.781 . . . . 0.0 110.287 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . 76.09 166.98 23.17 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 4' ' ' GLY . . . . . . . . . . . . . . . 78.01 13.89 82.89 Favored Glycine 0 CA--C 1.531 1.075 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 179.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 5' ' ' GLY . . . . . . . . . . . . . . . -87.64 72.44 2.49 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 179.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 6' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' F' ' 7' ' ' PHE . 16.8 m -110.42 -6.99 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 112.52 0.563 . . . . 0.0 112.52 -179.177 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 7' ' ' PHE . . . . . 0.658 ' O ' ' N ' ' F' ' 9' ' ' ASP . 2.3 m-85 -71.68 -121.24 0.0 OUTLIER 'General case' 0 C--O 1.188 -2.162 0 N-CA-C 103.044 -2.946 . . . . 0.0 103.044 174.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 8' ' ' THR . . . . . 0.422 ' O ' ' O ' ' F' ' 9' ' ' ASP . 60.2 m 22.51 -58.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 125.822 1.649 . . . . 0.0 115.327 176.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 9' ' ' ASP . . . . . 0.658 ' N ' ' O ' ' F' ' 7' ' ' PHE . 19.7 t70 -50.8 -86.7 0.0 OUTLIER 'General case' 0 C--O 1.153 -3.999 0 CA-C-O 116.24 -1.838 . . . . 0.0 107.862 174.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 10' ' ' ILE . . . . . 0.485 ' O ' ' N ' ' F' ' 13' ' ' ALA . 58.0 mt 0.01 -64.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.531 0 CA-C-N 120.028 1.286 . . . . 0.0 113.453 177.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 11' ' ' LEU . . . . . 0.493 ' N ' ' O ' ' F' ' 9' ' ' ASP . 27.2 tp -48.81 -43.18 38.07 Favored 'General case' 0 N--CA 1.478 0.94 0 O-C-N 122.086 -0.384 . . . . 0.0 111.058 177.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 12' ' ' ALA . . . . . 0.489 ' N ' ' O ' ' F' ' 9' ' ' ASP . . . -60.71 -39.98 90.56 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 177.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 13' ' ' ALA . . . . . 0.485 ' N ' ' O ' ' F' ' 10' ' ' ILE . . . -72.66 -46.66 52.82 Favored 'General case' 0 C--O 1.214 -0.791 0 CA-C-N 115.02 -0.991 . . . . 0.0 112.522 179.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.06 -35.25 69.12 Favored 'General case' 0 C--N 1.32 -0.694 0 O-C-N 120.734 -1.229 . . . . 0.0 108.96 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.29 -48.22 19.96 Favored Glycine 0 CA--C 1.533 1.175 0 N-CA-C 111.236 -0.745 . . . . 0.0 111.236 178.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 16' ' ' ARG . . . . . . . . . . . . . 72.2 ttt-85 -70.16 -44.74 68.19 Favored 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 113.45 0.908 . . . . 0.0 113.45 -177.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mm -62.57 -44.14 99.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.268 -177.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 18' ' ' PHE . . . . . . . . . . . . . 37.6 t80 -57.9 -18.58 23.81 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.393 -178.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 19' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -67.59 -36.61 81.21 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.188 0.518 . . . . 0.0 110.065 -179.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 20' ' ' VAL . . . . . . . . . . . . . 86.8 t -66.29 -48.51 80.84 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.904 -178.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 21' ' ' MET . . . . . . . . . . . . . 97.8 mmm -65.86 -44.24 86.04 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -178.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 22' ' ' VAL . . . . . . . . . . . . . 14.2 p -69.78 -27.6 33.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 O-C-N 123.317 0.386 . . . . 0.0 111.438 -178.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 23' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -70.79 -41.44 71.65 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 113.43 0.9 . . . . 0.0 113.43 -177.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 24' ' ' GLY . . . . . . . . . . . . . . . -95.27 10.36 69.53 Favored Glycine 0 N--CA 1.479 1.538 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 25' ' ' HIS . . . . . . . . . . . . . 6.4 t-80 -87.1 -8.38 57.08 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 114.794 -0.703 . . . . 0.0 111.579 -178.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 26' ' ' TRP . . . . . 0.552 ' O ' ' N ' ' F' ' 28' ' ' THR . 97.7 m95 -101.74 -60.76 1.48 Allowed 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -176.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 27' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -21.94 -34.92 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 115.073 1.508 . . . . 0.0 115.073 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 28' ' ' THR . . . . . 0.552 ' N ' ' O ' ' F' ' 26' ' ' TRP . 19.3 m -60.51 -44.61 95.84 Favored 'General case' 0 CA--C 1.558 1.277 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.606 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 29' ' ' VAL . . . . . . . . . . . . . 92.9 t -60.66 -45.06 98.13 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 114.219 1.192 . . . . 0.0 114.219 -175.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 30' ' ' GLY . . . . . . . . . . . . . . . -25.88 -69.82 0.04 OUTLIER Glycine 0 CA--C 1.543 1.832 0 N-CA-C 116.144 1.217 . . . . 0.0 116.144 -176.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 31' ' ' MET . . . . . . . . . . . . . 94.6 mtp -67.59 -30.81 70.51 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 114.203 1.186 . . . . 0.0 114.203 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 tp -37.91 -67.54 0.19 Allowed 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -176.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 33' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -68.35 -43.84 76.58 Favored 'General case' 0 CA--C 1.556 1.179 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -178.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 34' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -61.31 -44.26 97.5 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 116.924 2.194 . . . . 0.0 116.924 -174.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 35' ' ' SER . . . . . . . . . . . . . 14.5 t -54.57 -44.44 72.94 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 114.652 1.352 . . . . 0.0 114.652 -174.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 36' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' F' ' 38' ' ' LYS . 30.9 tp -44.45 -65.76 0.48 Allowed 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 114.604 1.335 . . . . 0.0 114.604 -178.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 2.77 -58.19 0.0 OUTLIER Glycine 0 CA--C 1.549 2.214 0 N-CA-C 117.17 1.628 . . . . 0.0 117.17 -178.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 38' ' ' LYS . . . . . 0.545 ' N ' ' O ' ' F' ' 36' ' ' LEU . 65.4 mttm -61.13 -41.68 97.17 Favored 'General case' 0 CA--C 1.554 1.121 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -174.344 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 39' ' ' GLY . . . . . . . . . . . . . . . -56.95 -22.97 44.05 Favored Glycine 0 CA--C 1.542 1.78 0 N-CA-C 117.154 1.622 . . . . 0.0 117.154 -175.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 40' ' ' THR . . . . . . . . . . . . . 6.2 p -87.96 -13.43 41.79 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 119.272 1.536 . . . . 0.0 112.27 -177.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 41' ' ' MET . . . . . . . . . . . . . 53.9 mmm -65.68 -37.51 86.69 Favored 'General case' 0 CA--C 1.554 1.105 0 N-CA-C 115.386 1.624 . . . . 0.0 115.386 -177.112 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 42' ' ' ARG . . . . . . . . . . . . . 88.8 mmt-85 -65.49 -31.49 72.58 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 -175.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 43' ' ' ILE . . . . . . . . . . . . . 31.3 mm -76.0 -35.02 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 44' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -64.47 -39.49 93.91 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-N 113.9 -1.5 . . . . 0.0 112.124 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 45' ' ' ARG . . . . . . . . . . . . . 8.8 ttm-85 -70.36 -18.59 63.07 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 114.164 1.172 . . . . 0.0 114.164 -177.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 46' ' ' ASN . . . . . 0.558 ' O ' ' N ' ' F' ' 48' ' ' TYR . 17.3 t-20 -93.36 -100.02 0.14 Allowed 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 118.724 0.693 . . . . 0.0 109.954 -178.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 47' ' ' ALA . . . . . . . . . . . . . . . -22.63 -37.02 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 -179.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 48' ' ' TYR . . . . . 0.558 ' N ' ' O ' ' F' ' 46' ' ' ASN . 78.4 m-85 -107.28 143.78 35.03 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.198 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.28 -20.81 0.02 OUTLIER Glycine 0 CA--C 1.526 0.738 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.958 -178.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 50' ' ' SER . . . . . . . . . . . . . 53.4 m -105.42 91.39 3.75 Favored 'General case' 0 N--CA 1.48 1.032 0 O-C-N 122.306 -0.526 . . . . 0.0 111.402 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 51' ' ' MET . . . . . . . . . . . . . 68.8 mtm -63.11 -39.82 95.82 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.149 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 52' ' ' GLY . . . . . . . . . . . . . . . -41.67 111.28 0.28 Allowed Glycine 0 CA--C 1.531 1.079 0 C-N-CA 121.212 -0.518 . . . . 0.0 111.971 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.15 -35.39 91.92 Favored Glycine 0 CA--C 1.529 0.953 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 178.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.3 -176.71 52.87 Favored Glycine 0 N--CA 1.462 0.379 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -72.52 157.71 37.08 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 56' ' ' LEU . . . . . . . . . . . . . 51.5 tp -84.44 131.23 34.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.042 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 57' ' ' ARG . . . . . . . . . . . . . 42.5 ttt180 -64.83 135.18 55.48 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.936 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.44 17.32 73.88 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 59' ' ' SER . . . . . . . . . . . . . 77.5 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.72 -179.946 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 1' ' ' MET . . . . . 0.501 ' SD ' ' OBD' ' C' ' 101' ' ' BCL . 54.1 ttp . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 2' ' ' SER . . . . . . . . . . . . . 7.1 m -56.59 134.46 54.43 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 120.803 -1.185 . . . . 0.0 109.695 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . 76.24 165.95 21.22 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.55 13.95 80.78 Favored Glycine 0 N--CA 1.461 0.302 0 C-N-CA 121.347 -0.454 . . . . 0.0 113.007 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.5 76.23 1.78 Allowed Glycine 0 CA--C 1.528 0.88 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 6' ' ' VAL . . . . . . . . . . . . . 16.3 m -116.44 6.93 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 N-CA-C 112.33 0.493 . . . . 0.0 112.33 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 7' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -86.37 -63.0 1.39 Allowed 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 8' ' ' THR . . . . . 0.473 ' O ' ' O ' ' G' ' 9' ' ' ASP . 89.7 m -38.61 -38.23 0.38 Allowed 'General case' 0 CA--C 1.505 -0.764 0 CA-C-N 114.529 -1.214 . . . . 0.0 112.658 -178.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 9' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' G' ' 11' ' ' LEU . 25.1 t70 -67.25 -115.68 0.0 OUTLIER 'General case' 0 C--O 1.168 -3.228 0 N-CA-C 103.732 -2.692 . . . . 0.0 103.732 176.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 10' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' G' ' 13' ' ' ALA . 43.7 mt 34.66 -70.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 CA-C-N 121.156 1.798 . . . . 0.0 112.505 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 11' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' G' ' 9' ' ' ASP . 38.1 tp -49.82 -42.24 46.67 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 119.629 1.104 . . . . 0.0 110.386 175.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.74 -37.79 85.52 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 13' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' G' ' 10' ' ' ILE . . . -73.73 -50.58 20.04 Favored 'General case' 0 C--O 1.205 -1.284 0 CA-C-N 115.12 -0.945 . . . . 0.0 112.776 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 14' ' ' ALA . . . . . . . . . . . . . . . -55.03 -39.19 68.88 Favored 'General case' 0 C--O 1.22 -0.488 0 O-C-N 120.755 -1.216 . . . . 0.0 108.638 -179.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.6 -44.6 70.83 Favored Glycine 0 CA--C 1.537 1.436 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 178.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 16' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -73.95 -49.15 25.94 Favored 'General case' 0 C--O 1.218 -0.577 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -178.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 17' ' ' ILE . . . . . . . . . . . . . 2.1 mm -55.99 -46.15 80.48 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.083 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 18' ' ' PHE . . . . . . . . . . . . . 53.5 t80 -55.62 -22.81 24.26 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.907 -177.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 19' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -63.97 -36.5 84.18 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.486 0.66 . . . . 0.0 109.946 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 20' ' ' VAL . . . . . . . . . . . . . 86.2 t -66.94 -47.92 81.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 C-N-CA 120.068 -0.653 . . . . 0.0 111.933 -178.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 21' ' ' MET . . . . . . . . . . . . . 87.6 mmm -65.83 -43.95 87.03 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -177.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 22' ' ' VAL . . . . . . . . . . . . . 12.7 p -70.81 -29.15 36.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.727 -0.669 . . . . 0.0 112.373 -177.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 23' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -69.95 -38.43 76.12 Favored 'General case' 0 CA--C 1.539 0.537 0 N-CA-C 112.031 0.382 . . . . 0.0 112.031 -177.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 24' ' ' GLY . . . . . . . . . . . . . . . -95.38 2.73 65.54 Favored Glycine 0 N--CA 1.473 1.155 0 N-CA-C 111.141 -0.783 . . . . 0.0 111.141 -179.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 25' ' ' HIS . . . . . . . . . . . . . 17.7 t-80 -75.23 -27.72 59.61 Favored 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 123.227 0.611 . . . . 0.0 110.538 179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 26' ' ' TRP . . . . . 0.567 ' O ' ' N ' ' G' ' 28' ' ' THR . 97.4 m95 -80.6 -120.85 0.02 OUTLIER 'General case' 0 C--O 1.194 -1.819 0 CA-C-O 115.867 -2.016 . . . . 0.0 106.63 178.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 27' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 45.1 -52.37 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.349 0 N-CA-C 116.646 2.091 . . . . 0.0 116.646 177.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 28' ' ' THR . . . . . 0.567 ' N ' ' O ' ' G' ' 26' ' ' TRP . 19.9 m -57.14 -42.89 81.82 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -178.593 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 29' ' ' VAL . . . . . . . . . . . . . 92.1 t -60.6 -45.11 97.84 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -176.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 30' ' ' GLY . . . . . . . . . . . . . . . -27.04 -69.37 0.05 OUTLIER Glycine 0 CA--C 1.542 1.78 0 N-CA-C 115.702 1.041 . . . . 0.0 115.702 -176.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 31' ' ' MET . . . . . . . . . . . . . 99.0 mtp -74.83 -7.95 54.97 Favored 'General case' 0 CA--C 1.55 0.947 0 N-CA-C 115.48 1.659 . . . . 0.0 115.48 -176.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 32' ' ' LEU . . . . . . . . . . . . . 17.9 tp -59.95 -50.87 72.04 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 119.663 1.12 . . . . 0.0 113.306 -177.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 33' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -80.72 -41.6 23.34 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 34' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -63.65 -38.69 92.06 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 116.766 2.136 . . . . 0.0 116.766 -175.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 35' ' ' SER . . . . . . . . . . . . . 12.9 t -59.48 -42.5 92.23 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 113.718 1.007 . . . . 0.0 113.718 -175.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 36' ' ' LEU . . . . . 0.553 ' O ' ' N ' ' G' ' 38' ' ' LYS . 21.6 tp -44.2 -72.65 0.06 Allowed 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 112.794 0.664 . . . . 0.0 112.794 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 10.51 -61.44 0.0 OUTLIER Glycine 0 CA--C 1.55 2.263 0 N-CA-C 117.259 1.664 . . . . 0.0 117.259 -178.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 38' ' ' LYS . . . . . 0.553 ' N ' ' O ' ' G' ' 36' ' ' LEU . 65.1 mttm -60.51 -41.25 93.96 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -174.575 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 39' ' ' GLY . . . . . . . . . . . . . . . -59.03 -13.98 22.28 Favored Glycine 0 CA--C 1.542 1.729 0 N-CA-C 116.744 1.458 . . . . 0.0 116.744 -175.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 40' ' ' THR . . . . . . . . . . . . . 20.4 p -96.24 -13.68 23.24 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 119.584 1.692 . . . . 0.0 111.835 -178.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 41' ' ' MET . . . . . . . . . . . . . 84.3 mmm -65.77 -37.13 85.48 Favored 'General case' 0 CA--C 1.55 0.972 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 -177.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 42' ' ' ARG . . . . . . . . . . . . . 88.9 mmt-85 -65.36 -31.36 72.43 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 115.141 1.534 . . . . 0.0 115.141 -175.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 43' ' ' ILE . . . . . . . . . . . . . 31.0 mm -78.25 -36.15 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 44' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -63.91 -39.97 95.4 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-N 114.541 -1.208 . . . . 0.0 110.633 178.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 45' ' ' ARG . . . . . . . . . . . . . 2.8 ttm-85 -61.54 -39.06 89.71 Favored 'General case' 0 N--CA 1.464 0.242 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.799 -177.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 46' ' ' ASN . . . . . 0.462 ' CG ' ' H ' ' G' ' 47' ' ' ALA . 12.6 t-20 -86.94 -168.49 2.26 Favored 'General case' 0 C--O 1.196 -1.761 0 N-CA-C 103.761 -2.681 . . . . 0.0 103.761 177.189 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 47' ' ' ALA . . . . . 0.462 ' H ' ' CG ' ' G' ' 46' ' ' ASN . . . 53.05 -39.82 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 114.967 1.469 . . . . 0.0 114.967 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 48' ' ' TYR . . . . . 0.455 ' N ' ' O ' ' G' ' 46' ' ' ASN . 71.5 m-85 -119.68 141.17 49.61 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.31 -16.46 0.02 OUTLIER Glycine 0 C--N 1.313 -0.709 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -178.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 50' ' ' SER . . . . . . . . . . . . . 56.4 m -107.01 90.97 3.46 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-O 121.206 0.527 . . . . 0.0 111.492 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 51' ' ' MET . . . . . . . . . . . . . 67.8 mtm -63.35 -38.82 92.65 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.757 178.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 52' ' ' GLY . . . . . . . . . . . . . . . -43.12 113.14 0.61 Allowed Glycine 0 CA--C 1.533 1.187 0 CA-C-N 116.386 -0.37 . . . . 0.0 112.44 -178.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.95 -34.52 90.16 Favored Glycine 0 N--CA 1.469 0.875 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 54' ' ' GLY . . . . . . . . . . . . . . . 78.53 -172.77 55.28 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 -179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 55' ' ' SER . . . . . . . . . . . . . 87.0 p -75.58 161.95 28.7 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.916 0.389 . . . . 0.0 111.319 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 56' ' ' LEU . . . . . 0.418 ' O ' ' OXT' ' G' ' 59' ' ' SER . 54.7 tp -89.37 130.34 35.75 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.398 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 57' ' ' ARG . . . . . . . . . . . . . 25.4 ttt85 -64.48 135.62 56.25 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.612 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.13 18.07 75.33 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 59' ' ' SER . . . . . 0.418 ' OXT' ' O ' ' G' ' 56' ' ' LEU . 82.2 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.906 -1.045 . . . . 0.0 111.062 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 1' ' ' MET . . . . . . . . . . . . . 45.0 ttp . . . . . 0 N--CA 1.487 1.406 0 CA-C-O 122.424 1.107 . . . . 0.0 108.222 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 2' ' ' SER . . . . . . . . . . . . . 8.4 m -69.74 134.64 48.84 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 120.024 -1.673 . . . . 0.0 109.054 179.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.87 170.67 22.25 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.65 12.78 83.25 Favored Glycine 0 CA--C 1.528 0.85 0 C-N-CA 121.119 -0.562 . . . . 0.0 111.979 178.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.66 76.65 1.55 Allowed Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 6' ' ' VAL . . . . . . . . . . . . . 16.3 m -120.76 18.23 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.156 0 C-N-CA 122.85 0.46 . . . . 0.0 112.048 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 7' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -97.11 -42.3 7.92 Favored 'General case' 0 N--CA 1.483 1.214 0 CA-C-O 121.681 0.753 . . . . 0.0 110.127 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 8' ' ' THR . . . . . . . . . . . . . 17.5 m -59.04 -43.8 91.7 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.569 -1.196 . . . . 0.0 111.154 -177.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 9' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -63.46 -40.16 96.39 Favored 'General case' 0 CA--C 1.554 1.103 0 N-CA-C 113.722 1.008 . . . . 0.0 113.722 -178.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 10' ' ' ILE . . . . . . . . . . . . . 68.5 mt -48.2 -43.69 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 O-C-N 120.632 -1.293 . . . . 0.0 111.685 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 11' ' ' LEU . . . . . . . . . . . . . 41.1 tp -60.22 -42.05 94.36 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.204 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.75 -39.0 87.09 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.112 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 13' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' H' ' 17' ' ' ILE . . . -71.53 -47.75 53.15 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 112.661 0.615 . . . . 0.0 112.661 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.22 -40.56 86.2 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 -179.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.2 -40.59 94.93 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 109.766 -1.333 . . . . 0.0 109.766 177.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 16' ' ' ARG . . . . . . . . . . . . . 72.4 ttt-85 -74.33 -76.95 0.12 Allowed 'General case' 0 C--O 1.212 -0.892 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.166 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 17' ' ' ILE . . . . . 0.403 ' N ' ' O ' ' H' ' 13' ' ' ALA . 1.1 mm -29.18 -48.42 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 113.611 0.967 . . . . 0.0 113.611 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 18' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -53.76 -21.17 6.72 Favored 'General case' 0 C--O 1.224 -0.28 0 C-N-CA 120.782 -0.367 . . . . 0.0 111.984 -176.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 19' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -65.97 -38.31 88.22 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.831 0.824 . . . . 0.0 110.028 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 20' ' ' VAL . . . . . . . . . . . . . 98.4 t -66.46 -47.73 82.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.923 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 21' ' ' MET . . . . . . . . . . . . . 89.5 mmm -65.99 -44.26 85.37 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -178.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 22' ' ' VAL . . . . . . . . . . . . . 12.1 p -70.01 -31.82 49.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -178.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 23' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -69.04 -35.48 76.65 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -177.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 24' ' ' GLY . . . . . . . . . . . . . . . -97.41 2.41 60.91 Favored Glycine 0 N--CA 1.478 1.464 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 25' ' ' HIS . . . . . . . . . . . . . 12.4 t-80 -79.67 -20.53 46.41 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.073 -0.564 . . . . 0.0 112.258 -178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 26' ' ' TRP . . . . . 0.563 ' O ' ' N ' ' H' ' 28' ' ' THR . 97.2 m95 -86.64 -68.59 0.73 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 114.147 1.166 . . . . 0.0 114.147 -175.565 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 27' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -13.01 -37.04 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 117.224 2.305 . . . . 0.0 117.224 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 28' ' ' THR . . . . . 0.563 ' N ' ' O ' ' H' ' 26' ' ' TRP . 37.5 m -58.7 -42.8 89.48 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 114.576 1.325 . . . . 0.0 114.576 -178.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 29' ' ' VAL . . . . . . . . . . . . . 57.8 t -60.99 -45.69 98.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -176.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 30' ' ' GLY . . . . . . . . . . . . . . . -25.52 -67.39 0.05 OUTLIER Glycine 0 CA--C 1.541 1.693 0 N-CA-C 115.339 0.895 . . . . 0.0 115.339 -177.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 31' ' ' MET . . . . . . . . . . . . . 98.8 mtp -76.74 -6.36 51.87 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 115.493 1.664 . . . . 0.0 115.493 -176.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 32' ' ' LEU . . . . . . . . . . . . . 34.0 tp -61.64 -44.6 96.67 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 114.743 1.386 . . . . 0.0 114.743 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 33' ' ' PHE . . . . . . . . . . . . . 45.8 t80 -91.29 -37.98 12.94 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 120.828 -1.17 . . . . 0.0 111.931 -179.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 34' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -63.48 -39.08 93.49 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 116.044 1.868 . . . . 0.0 116.044 -176.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 35' ' ' SER . . . . . 0.451 ' OG ' ' CB ' ' B' ' 12' ' ' ALA . 6.9 t -58.93 -44.74 91.41 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 -175.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 36' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' H' ' 38' ' ' LYS . 12.9 tp -40.82 -72.87 0.06 Allowed 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 -178.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 10.63 -60.74 0.0 OUTLIER Glycine 0 CA--C 1.543 1.803 0 N-CA-C 117.795 1.878 . . . . 0.0 117.795 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 38' ' ' LYS . . . . . 0.538 ' N ' ' O ' ' H' ' 36' ' ' LEU . 64.9 mttm -61.84 -39.52 92.14 Favored 'General case' 0 CA--C 1.55 0.959 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -174.415 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 39' ' ' GLY . . . . . . . . . . . . . . . -58.31 -22.23 50.07 Favored Glycine 0 CA--C 1.542 1.78 0 N-CA-C 116.513 1.365 . . . . 0.0 116.513 -175.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 40' ' ' THR . . . . . . . . . . . . . 5.5 p -90.24 -15.05 32.11 Favored 'General case' 0 N--CA 1.485 1.309 0 CA-C-N 119.054 1.427 . . . . 0.0 113.123 -177.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 41' ' ' MET . . . . . . . . . . . . . 82.8 mmm -64.96 -39.51 93.59 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 115.623 1.712 . . . . 0.0 115.623 -175.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 42' ' ' ARG . . . . . . . . . . . . . 88.3 mmt-85 -62.48 -36.32 82.13 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -174.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 43' ' ' ILE . . . . . . . . . . . . . 25.5 mm -72.13 -37.92 61.32 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.83 0 CA-C-O 122.052 0.929 . . . . 0.0 108.999 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 44' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 -62.02 -39.93 93.96 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 114.376 -1.284 . . . . 0.0 110.25 178.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 45' ' ' ARG . . . . . 0.684 HH12 ' NH1' ' C' ' 45' ' ' ARG . 0.0 OUTLIER -60.18 -43.32 95.97 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 112.702 0.63 . . . . 0.0 112.702 -177.219 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' H' H ' 46' ' ' ASN . . . . . 0.594 ' OD1' ' CZ3' ' B' ' 26' ' ' TRP . 25.0 t-20 -74.0 -89.83 0.02 OUTLIER 'General case' 0 C--O 1.216 -0.667 0 C-N-CA 119.832 -0.747 . . . . 0.0 112.724 -177.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 47' ' ' ALA . . . . . . . . . . . . . . . -33.85 -21.21 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 115.2 1.556 . . . . 0.0 115.2 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 48' ' ' TYR . . . . . 0.52 ' N ' ' O ' ' H' ' 46' ' ' ASN . 76.1 m-85 -123.45 142.3 51.13 Favored 'General case' 0 N--CA 1.487 1.379 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.33 -20.33 0.02 OUTLIER Glycine 0 CA--C 1.522 0.497 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.883 -178.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 50' ' ' SER . . . . . . . . . . . . . 49.6 m -102.49 91.82 4.4 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-O 121.321 0.581 . . . . 0.0 111.38 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 51' ' ' MET . . . . . . . . . . . . . 68.3 mtm -64.3 -38.17 90.1 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.483 178.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 52' ' ' GLY . . . . . . . . . . . . . . . -47.81 109.53 0.48 Allowed Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.695 -0.562 . . . . 0.0 111.695 -179.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.85 -33.49 87.38 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.15 -171.32 53.43 Favored Glycine 0 CA--C 1.535 1.305 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 55' ' ' SER . . . . . . . . . . . . . 87.2 p -74.38 160.58 30.84 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.085 0.469 . . . . 0.0 110.891 -179.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 56' ' ' LEU . . . . . . . . . . . . . 53.5 tp -87.15 131.5 34.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.809 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 57' ' ' ARG . . . . . . . . . . . . . 11.9 ttm-85 -63.97 135.95 56.92 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.703 -179.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.35 19.13 72.42 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 121.459 -0.401 . . . . 0.0 112.457 178.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 59' ' ' SER . . . . . . . . . . . . . 77.5 p . . . . . 0 C--N 1.325 -0.484 0 CA-C-O 118.162 -0.923 . . . . 0.0 109.974 179.754 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 1' ' ' MET . . . . . . . . . . . . . 14.7 ttp . . . . . 0 N--CA 1.488 1.459 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 2' ' ' SER . . . . . . . . . . . . . 10.7 m -78.21 131.39 37.12 Favored 'General case' 0 N--CA 1.463 0.223 0 O-C-N 120.793 -1.192 . . . . 0.0 108.507 178.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.0 175.83 29.71 Favored Glycine 0 CA--C 1.519 0.291 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 4' ' ' GLY . . . . . . . . . . . . . . . 78.26 9.76 86.73 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.58 72.07 1.97 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 110.107 -1.197 . . . . 0.0 110.107 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 6' ' ' VAL . . . . . . . . . . . . . 16.0 m -117.78 21.66 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 122.807 0.443 . . . . 0.0 111.262 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 7' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -97.89 -43.3 7.16 Favored 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 121.761 0.791 . . . . 0.0 111.191 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 8' ' ' THR . . . . . . . . . . . . . 18.8 m -59.75 -42.68 93.74 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 114.356 -1.293 . . . . 0.0 111.861 -177.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 9' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -65.84 -23.05 66.6 Favored 'General case' 0 CA--C 1.552 1.042 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -179.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 10' ' ' ILE . . . . . . . . . . . . . 61.6 mt -62.09 -44.44 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 CA-C-N 119.405 1.002 . . . . 0.0 110.357 -178.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 11' ' ' LEU . . . . . . . . . . . . . 30.7 tp -60.63 -42.99 98.02 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 177.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.08 -40.21 88.75 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 13' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' I' ' 17' ' ' ILE . . . -70.25 -48.65 55.97 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 115.235 -0.893 . . . . 0.0 112.313 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.56 -43.1 89.23 Favored 'General case' 0 CA--C 1.512 -0.491 0 CA-C-O 121.314 0.578 . . . . 0.0 109.566 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.75 -37.06 93.06 Favored Glycine 0 C--O 1.221 -0.676 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 177.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 16' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -78.98 -69.1 0.6 Allowed 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.49 -179.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 17' ' ' ILE . . . . . 0.494 ' N ' ' O ' ' I' ' 13' ' ' ALA . 18.8 mt -40.43 -43.08 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.575 0 N-CA-C 112.53 0.567 . . . . 0.0 112.53 -178.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 18' ' ' PHE . . . . . . . . . . . . . 61.9 t80 -51.01 -20.23 1.3 Allowed 'General case' 0 CA--C 1.492 -1.27 0 C-N-CA 119.385 -0.926 . . . . 0.0 111.329 -176.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 19' ' ' GLU . . . . . 0.413 ' N ' ' C ' ' I' ' 17' ' ' ILE . 93.8 mt-10 -66.34 -37.68 85.9 Favored 'General case' 0 C--N 1.319 -0.752 0 O-C-N 125.189 1.555 . . . . 0.0 111.933 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 20' ' ' VAL . . . . . . . . . . . . . 92.7 t -66.55 -46.67 85.69 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 C-N-CA 119.966 -0.694 . . . . 0.0 111.939 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 21' ' ' MET . . . . . . . . . . . . . 89.9 mmm -65.52 -45.83 81.98 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.088 0.773 . . . . 0.0 113.088 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 22' ' ' VAL . . . . . . . . . . . . . 14.8 p -70.26 -28.71 36.57 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.998 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.804 -178.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 23' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -76.38 -17.59 59.3 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 24' ' ' GLY . . . . . . . . . . . . . . . -111.2 -4.58 27.23 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 25' ' ' HIS . . . . . . . . . . . . . 19.5 t-80 -67.83 -37.3 81.75 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-N 113.135 -1.532 . . . . 0.0 112.052 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 26' ' ' TRP . . . . . 0.569 ' O ' ' N ' ' I' ' 28' ' ' THR . 96.7 m95 -74.64 -67.52 0.62 Allowed 'General case' 0 C--O 1.216 -0.676 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 -174.031 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 27' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -17.59 -31.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 117.336 2.347 . . . . 0.0 117.336 -177.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 28' ' ' THR . . . . . 0.569 ' N ' ' O ' ' I' ' 26' ' ' TRP . 99.4 m -61.0 -43.67 98.55 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -178.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 29' ' ' VAL . . . . . . . . . . . . . 84.9 t -60.97 -45.24 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 115.24 1.57 . . . . 0.0 115.24 -175.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 30' ' ' GLY . . . . . . . . . . . . . . . -29.05 -64.48 0.11 Allowed Glycine 0 CA--C 1.534 1.254 0 N-CA-C 115.534 0.974 . . . . 0.0 115.534 -175.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 31' ' ' MET . . . . . . . . . . . . . 98.8 mtp -77.25 -6.19 52.18 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 115.034 1.494 . . . . 0.0 115.034 -176.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 32' ' ' LEU . . . . . . . . . . . . . 26.7 tp -60.36 -48.3 82.34 Favored 'General case' 0 CA--C 1.544 0.742 0 N-CA-C 114.094 1.146 . . . . 0.0 114.094 -177.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 33' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -89.18 -38.21 14.45 Favored 'General case' 0 N--CA 1.479 0.981 0 O-C-N 121.814 -0.554 . . . . 0.0 112.34 -177.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 34' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -62.14 -44.04 97.5 Favored 'General case' 0 CA--C 1.546 0.791 0 N-CA-C 115.539 1.681 . . . . 0.0 115.539 -176.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 35' ' ' SER . . . . . . . . . . . . . 21.3 t -49.25 -59.1 3.97 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 -176.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 36' ' ' LEU . . . . . 0.561 ' O ' ' N ' ' I' ' 38' ' ' LYS . 27.8 tp -26.06 -75.41 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 6.22 -58.11 0.0 OUTLIER Glycine 0 CA--C 1.543 1.782 0 N-CA-C 117.254 1.661 . . . . 0.0 117.254 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 38' ' ' LYS . . . . . 0.561 ' N ' ' O ' ' I' ' 36' ' ' LEU . 63.5 mttm -61.84 -37.49 84.65 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 114.444 1.275 . . . . 0.0 114.444 -175.152 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.45 -27.08 65.22 Favored Glycine 0 CA--C 1.553 2.44 0 N-CA-C 116.816 1.486 . . . . 0.0 116.816 -175.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 40' ' ' THR . . . . . . . . . . . . . 1.9 p -86.66 -13.92 44.12 Favored 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 119.009 1.404 . . . . 0.0 112.41 -176.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 41' ' ' MET . . . . . . . . . . . . . 87.8 mmm -66.34 -39.45 89.21 Favored 'General case' 0 CA--C 1.553 1.071 0 N-CA-C 115.665 1.728 . . . . 0.0 115.665 -176.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 42' ' ' ARG . . . . . . . . . . . . . 87.6 mmt-85 -61.39 -34.56 75.55 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 -175.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 43' ' ' ILE . . . . . . . . . . . . . 33.3 mm -79.1 -36.66 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 CA-C-N 118.608 0.64 . . . . 0.0 110.0 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 44' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -61.71 -40.34 94.68 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.151 178.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.04 -47.78 84.43 Favored 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -179.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 46' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -73.43 -54.58 7.95 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 115.814 1.783 . . . . 0.0 115.814 -174.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 47' ' ' ALA . . . . . . . . . . . . . . . -70.37 -9.57 56.62 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -176.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 48' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -128.99 144.62 51.24 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.56 -29.42 0.02 OUTLIER Glycine 0 CA--C 1.532 1.15 0 C-N-CA 119.947 -1.121 . . . . 0.0 112.834 -177.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 50' ' ' SER . . . . . . . . . . . . . 35.3 m -97.07 94.05 6.94 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-O 121.3 0.571 . . . . 0.0 110.222 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 51' ' ' MET . . . . . . . . . . . . . 66.3 mtm -64.78 -35.27 80.55 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.439 -0.8 . . . . 0.0 109.958 178.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 52' ' ' GLY . . . . . . . . . . . . . . . -51.75 107.36 0.44 Allowed Glycine 0 CA--C 1.521 0.465 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.023 -179.28 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.94 -34.54 90.21 Favored Glycine 0 C--O 1.231 -0.064 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.31 -170.27 48.71 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.972 -0.451 . . . . 0.0 111.972 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 55' ' ' SER . . . . . . . . . . . . . 86.8 p -73.6 160.48 31.56 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.897 0.38 . . . . 0.0 110.263 -179.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 56' ' ' LEU . . . . . . . . . . . . . 54.4 tp -89.22 133.24 34.51 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.823 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 57' ' ' ARG . . . . . . . . . . . . . 13.9 ttm-85 -63.95 136.43 57.33 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 120.184 -0.607 . . . . 0.0 110.757 -179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.06 18.83 73.87 Favored Glycine 0 N--CA 1.468 0.783 0 N-CA-C 112.167 -0.373 . . . . 0.0 112.167 178.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 59' ' ' SER . . . . . . . . . . . . . 88.0 p . . . . . 0 C--N 1.323 -0.584 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.541 179.769 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' J' J ' 1' ' ' MET . . . . . 0.506 ' SD ' ' OBD' ' B' ' 101' ' ' BCL . 0.0 OUTLIER . . . . . 0 N--CA 1.483 1.179 0 CA-C-O 124.917 2.294 . . . . 0.0 106.704 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 2' ' ' SER . . . . . . . . . . . . . 13.0 m -77.64 131.23 37.67 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 119.883 -1.761 . . . . 0.0 108.981 179.178 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 3' ' ' GLY . . . . . . . . . . . . . . . 71.43 179.6 31.3 Favored Glycine 0 C--O 1.23 -0.123 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 4' ' ' GLY . . . . . 0.457 ' O ' ' CZ ' ' J' ' 7' ' ' PHE . . . 78.69 7.06 88.35 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.71 67.34 2.46 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 6' ' ' VAL . . . . . . . . . . . . . 15.4 m -112.31 20.44 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 123.143 0.577 . . . . 0.0 111.256 -179.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 7' ' ' PHE . . . . . 0.558 ' CD2' ' CD2' ' M' ' 7' ' ' PHE . 0.9 OUTLIER -95.13 -54.88 3.27 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 122.405 1.098 . . . . 0.0 111.697 -178.68 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' J' J ' 8' ' ' THR . . . . . . . . . . . . . 4.7 m -49.31 -43.28 43.36 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 113.145 -1.843 . . . . 0.0 111.045 -175.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 9' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -66.37 -22.26 66.25 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 113.426 0.899 . . . . 0.0 113.426 -179.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 10' ' ' ILE . . . . . 0.429 HG22 HD13 ' J' ' 10' ' ' ILE . 63.0 mt -62.57 -43.31 98.33 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.818 0 C-N-CA 119.121 -1.032 . . . . 0.0 110.219 179.298 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 11' ' ' LEU . . . . . . . . . . . . . 24.0 tp -60.45 -43.37 96.92 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.87 -40.82 94.41 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.94 -48.68 65.26 Favored 'General case' 0 C--O 1.214 -0.813 0 CA-C-N 114.653 -1.158 . . . . 0.0 112.92 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 14' ' ' ALA . . . . . . . . . . . . . . . -60.95 -42.1 97.57 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.95 -41.82 95.13 Favored Glycine 0 C--O 1.217 -0.967 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.969 178.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 16' ' ' ARG . . . . . . . . . . . . . 76.0 ttt-85 -76.41 -49.35 16.95 Favored 'General case' 0 C--O 1.215 -0.73 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.852 -178.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 17' ' ' ILE . . . . . 0.432 ' C ' ' N ' ' J' ' 19' ' ' GLU . 92.6 mt -60.55 -43.13 93.83 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.057 -176.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 18' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -48.56 -19.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.026 -178.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 19' ' ' GLU . . . . . 0.432 ' N ' ' C ' ' J' ' 17' ' ' ILE . 96.1 mt-10 -67.72 -37.07 81.73 Favored 'General case' 0 C--O 1.221 -0.425 0 O-C-N 124.09 0.868 . . . . 0.0 111.43 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 20' ' ' VAL . . . . . . . . . . . . . 80.6 t -65.47 -45.77 91.88 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 C-N-CA 120.111 -0.636 . . . . 0.0 111.235 -178.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 21' ' ' MET . . . . . 0.443 ' CE ' ' O1A' ' J' ' 101' ' ' BCL . 97.4 mmm -63.63 -54.01 42.54 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.404 0.891 . . . . 0.0 113.404 -179.086 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 22' ' ' VAL . . . . . . . . . . . . . 13.2 p -63.89 -30.11 49.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 114.919 -1.037 . . . . 0.0 112.689 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 23' ' ' GLU . . . . . . . . . . . . . 64.8 tt0 -82.37 4.81 22.47 Favored 'General case' 0 N--CA 1.48 1.028 0 CA-C-O 122.06 0.934 . . . . 0.0 111.45 -177.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 24' ' ' GLY . . . . . . . . . . . . . . . -128.76 -11.55 2.91 Favored Glycine 0 N--CA 1.483 1.769 0 N-CA-C 107.984 -2.046 . . . . 0.0 107.984 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 25' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' J' ' 26' ' ' TRP . 22.8 t-80 -64.08 -47.41 80.18 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 112.498 -1.851 . . . . 0.0 110.441 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 26' ' ' TRP . . . . . 0.575 ' CD2' ' OD1' ' B' ' 46' ' ' ASN . 94.3 m95 -64.38 -128.66 0.0 OUTLIER 'General case' 0 C--O 1.197 -1.672 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 27' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 50.46 -45.87 0.01 OUTLIER 'General case' 0 CA--C 1.574 1.891 0 N-CA-C 115.908 1.818 . . . . 0.0 115.908 178.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 28' ' ' THR . . . . . 0.473 ' N ' ' O ' ' J' ' 26' ' ' TRP . 93.2 m -59.91 -44.05 94.51 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 119.375 0.989 . . . . 0.0 112.46 -178.115 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 29' ' ' VAL . . . . . . . . . . . . . 95.0 t -55.43 -68.16 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.474 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -177.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 30' ' ' GLY . . . . . . . . . . . . . . . -5.67 -73.19 0.01 OUTLIER Glycine 0 CA--C 1.546 1.984 0 N-CA-C 116.419 1.327 . . . . 0.0 116.419 -178.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 31' ' ' MET . . . . . . . . . . . . . 92.4 mtp -68.82 -24.53 64.4 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 114.538 1.31 . . . . 0.0 114.538 -176.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 32' ' ' LEU . . . . . . . . . . . . . 15.4 tp -43.37 -63.84 0.75 Allowed 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -176.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 33' ' ' PHE . . . . . . . . . . . . . 36.2 t80 -73.65 -42.84 60.83 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 114.711 1.374 . . . . 0.0 114.711 -177.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 34' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -58.23 -46.93 85.03 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 115.818 1.785 . . . . 0.0 115.818 -175.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 35' ' ' SER . . . . . . . . . . . . . 32.9 t -45.52 -67.06 0.32 Allowed 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -177.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 36' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' J' ' 38' ' ' LYS . 37.4 tp -17.91 -67.31 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 114.876 1.435 . . . . 0.0 114.876 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -7.71 -48.72 0.0 OUTLIER Glycine 0 CA--C 1.546 2.0 0 N-CA-C 116.985 1.554 . . . . 0.0 116.985 -176.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 38' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' J' ' 36' ' ' LEU . 64.6 mttm -68.44 -25.27 64.93 Favored 'General case' 0 CA--C 1.556 1.197 0 N-CA-C 114.035 1.124 . . . . 0.0 114.035 -175.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 39' ' ' GLY . . . . . . . . . . . . . . . -67.17 -35.0 87.8 Favored Glycine 0 CA--C 1.547 2.076 0 N-CA-C 116.607 1.403 . . . . 0.0 116.607 -176.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 40' ' ' THR . . . . . . . . . . . . . 2.8 p -81.54 -13.62 57.85 Favored 'General case' 0 N--CA 1.482 1.167 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -175.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 41' ' ' MET . . . . . . . . . . . . . 88.8 mmm -66.77 -39.87 88.0 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -176.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 42' ' ' ARG . . . . . . . . . . . . . 84.0 mmt-85 -61.55 -32.18 72.24 Favored 'General case' 0 CA--C 1.543 0.69 0 N-CA-C 115.168 1.544 . . . . 0.0 115.168 -175.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 43' ' ' ILE . . . . . . . . . . . . . 30.8 mm -84.47 -36.71 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 O-C-N 121.519 -0.738 . . . . 0.0 109.407 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 44' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -61.93 -41.21 97.69 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.72 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 45' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' J' ' 48' ' ' TYR . 8.0 ttp180 -60.95 -56.61 19.08 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 113.978 1.103 . . . . 0.0 113.978 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 46' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -64.97 -48.61 73.41 Favored 'General case' 0 CA--C 1.551 1.005 0 N-CA-C 115.948 1.833 . . . . 0.0 115.948 -175.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 47' ' ' ALA . . . . . . . . . . . . . . . -72.3 -15.17 61.89 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-N 118.839 0.745 . . . . 0.0 112.764 -176.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 48' ' ' TYR . . . . . 0.479 ' O ' ' O ' ' J' ' 45' ' ' ARG . 79.6 m-85 -124.0 151.31 43.85 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.24 -29.37 0.04 OUTLIER Glycine 0 C--N 1.319 -0.4 0 C-N-CA 119.134 -1.508 . . . . 0.0 111.776 -177.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 50' ' ' SER . . . . . . . . . . . . . 26.2 m -94.88 99.23 11.31 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.162 0.506 . . . . 0.0 110.631 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 51' ' ' MET . . . . . . . . . . . . . 69.3 mtm -70.52 -32.51 70.0 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.593 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 52' ' ' GLY . . . . . . . . . . . . . . . -58.04 105.79 0.69 Allowed Glycine 0 CA--C 1.525 0.702 0 CA-C-N 114.988 -1.005 . . . . 0.0 111.454 -178.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.24 -33.46 87.31 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 178.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.16 -165.51 45.23 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -75.35 162.12 28.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.026 0.441 . . . . 0.0 111.463 -179.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 56' ' ' LEU . . . . . . . . . . . . . 54.6 tp -90.16 131.43 36.01 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.505 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 57' ' ' ARG . . . . . . . . . . . . . 17.6 ttm-85 -61.99 136.23 57.87 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 120.379 -0.528 . . . . 0.0 110.702 -179.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.83 19.29 73.37 Favored Glycine 0 CA--C 1.527 0.791 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.037 178.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 59' ' ' SER . . . . . . . . . . . . . 93.5 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.681 179.851 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' K' K ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.74 0 CA-C-O 124.548 2.118 . . . . 0.0 107.037 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 2' ' ' SER . . . . . . . . . . . . . 6.6 m -47.65 132.66 14.02 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 119.433 -2.042 . . . . 0.0 111.513 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.01 169.86 25.39 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.9 8.23 86.95 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.877 -0.489 . . . . 0.0 111.877 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.93 66.63 3.07 Favored Glycine 0 N--CA 1.468 0.822 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 6' ' ' VAL . . . . . . . . . . . . . 16.2 m -107.91 3.1 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 123.066 0.546 . . . . 0.0 111.761 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 7' ' ' PHE . . . . . 0.619 ' O ' ' N ' ' K' ' 9' ' ' ASP . 0.2 OUTLIER -78.54 -126.24 0.01 OUTLIER 'General case' 0 C--O 1.197 -1.662 0 N-CA-C 101.117 -3.66 . . . . 0.0 101.117 175.149 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' K' K ' 8' ' ' THR . . . . . . . . . . . . . 1.8 m 28.98 -63.37 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 115.444 1.646 . . . . 0.0 115.444 176.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 9' ' ' ASP . . . . . 0.619 ' N ' ' O ' ' K' ' 7' ' ' PHE . 28.0 t70 -61.2 -23.67 65.77 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 10' ' ' ILE . . . . . 0.429 HG22 HD13 ' K' ' 10' ' ' ILE . 93.4 mt -62.34 -42.82 96.96 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.912 0 N-CA-C 106.895 -1.521 . . . . 0.0 106.895 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 11' ' ' LEU . . . . . . . . . . . . . 39.9 tp -60.17 -42.14 94.32 Favored 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 12' ' ' ALA . . . . . . . . . . . . . . . -62.7 -38.13 89.21 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.4 -0.818 . . . . 0.0 108.834 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 13' ' ' ALA . . . . . . . . . . . . . . . -70.29 -50.89 34.77 Favored 'General case' 0 C--O 1.208 -1.113 0 CA-C-N 114.948 -1.024 . . . . 0.0 113.041 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.9 -45.29 86.67 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.362 -0.606 . . . . 0.0 109.362 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 15' ' ' GLY . . . . . . . . . . . . . . . -64.2 -47.17 87.68 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 120.455 -0.879 . . . . 0.0 111.108 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 16' ' ' ARG . . . . . . . . . . . . . 73.4 ttt-85 -69.24 -44.17 72.53 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-O 120.7 0.286 . . . . 0.0 111.1 -178.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 17' ' ' ILE . . . . . . . . . . . . . 94.3 mt -64.0 -43.52 97.63 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.74 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -177.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 18' ' ' PHE . . . . . . . . . . . . . 52.9 t80 -50.19 -20.45 1.03 Allowed 'General case' 0 C--N 1.311 -1.08 0 C-N-CA 120.024 -0.67 . . . . 0.0 110.437 -178.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 19' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -66.14 -38.72 88.82 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.516 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 20' ' ' VAL . . . . . . . . . . . . . 79.0 t -64.26 -47.9 87.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 C-N-CA 119.786 -0.765 . . . . 0.0 112.574 -177.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 21' ' ' MET . . . . . . . . . . . . . 96.7 mmm -64.0 -53.18 54.14 Favored 'General case' 0 C--O 1.211 -0.962 0 N-CA-C 112.581 0.585 . . . . 0.0 112.581 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 22' ' ' VAL . . . . . . . . . . . . . 12.6 p -63.63 -28.32 44.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.89 -177.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 23' ' ' GLU . . . . . . . . . . . . . 68.6 tt0 -84.99 1.05 49.25 Favored 'General case' 0 N--CA 1.48 1.035 0 CA-C-O 121.54 0.686 . . . . 0.0 111.361 -177.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.24 -11.99 4.95 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.451 -1.86 . . . . 0.0 108.451 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 25' ' ' HIS . . . . . . . . . . . . . 19.8 t-80 -66.48 -44.59 82.24 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 113.359 -1.421 . . . . 0.0 113.195 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 26' ' ' TRP . . . . . 0.578 ' O ' ' N ' ' K' ' 28' ' ' THR . 99.2 m95 -64.14 -69.02 0.3 Allowed 'General case' 0 C--O 1.216 -0.67 0 N-CA-C 115.51 1.67 . . . . 0.0 115.51 -175.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 27' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -16.12 -33.63 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 117.39 2.367 . . . . 0.0 117.39 -178.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 28' ' ' THR . . . . . 0.578 ' N ' ' O ' ' K' ' 26' ' ' TRP . 34.2 m -60.27 -45.08 94.54 Favored 'General case' 0 CA--C 1.544 0.739 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 29' ' ' VAL . . . . . . . . . . . . . 83.2 t -53.71 -74.55 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.547 0.943 . . . . 0.0 113.547 -176.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 30' ' ' GLY . . . . . . . . . . . . . . . 2.59 -74.8 0.0 OUTLIER Glycine 0 CA--C 1.54 1.647 0 N-CA-C 116.615 1.406 . . . . 0.0 116.615 -178.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 31' ' ' MET . . . . . . . . . . . . . 74.6 mtp -63.85 -36.4 83.8 Favored 'General case' 0 CA--C 1.543 0.71 0 N-CA-C 113.382 0.882 . . . . 0.0 113.382 -176.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 32' ' ' LEU . . . . . . . . . . . . . 8.2 tp -32.27 -68.2 0.1 Allowed 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 -176.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 33' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -68.86 -44.13 73.97 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -178.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 34' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -59.78 -45.99 90.59 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 117.385 2.365 . . . . 0.0 117.385 -173.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 35' ' ' SER . . . . . . . . . . . . . 34.1 t -51.52 -52.59 45.58 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.267 0.94 . . . . 0.0 113.398 -175.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 36' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' K' ' 38' ' ' LYS . 40.0 tp -30.67 -54.4 0.2 Allowed 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -178.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -26.31 -27.31 0.0 OUTLIER Glycine 0 CA--C 1.55 2.271 0 N-CA-C 117.188 1.635 . . . . 0.0 117.188 -175.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 38' ' ' LYS . . . . . 0.531 ' N ' ' O ' ' K' ' 36' ' ' LEU . 56.2 mttm -85.88 -9.05 57.61 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 119.366 1.583 . . . . 0.0 114.776 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 39' ' ' GLY . . . . . . . . . . . . . . . -86.24 -31.86 18.5 Favored Glycine 0 N--CA 1.494 2.519 0 CA-C-N 119.143 0.883 . . . . 0.0 115.237 -177.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 40' ' ' THR . . . . . . . . . . . . . 6.4 p -77.96 -14.61 59.47 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 114.074 1.139 . . . . 0.0 114.074 -176.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 41' ' ' MET . . . . . . . . . . . . . 90.1 mmm -65.94 -38.8 89.57 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 115.371 1.619 . . . . 0.0 115.371 -176.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 42' ' ' ARG . . . . . . . . . . . . . 83.8 mmt-85 -70.36 -15.32 62.85 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 115.719 1.748 . . . . 0.0 115.719 -174.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 43' ' ' ILE . . . . . . . . . . . . . 23.7 mm -98.1 -33.04 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 44' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -63.85 -40.32 96.3 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 114.609 -1.178 . . . . 0.0 109.273 177.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 45' ' ' ARG . . . . . 0.515 ' O ' ' O ' ' K' ' 48' ' ' TYR . 14.0 ttp180 -61.96 -88.86 0.01 OUTLIER 'General case' 0 C--O 1.192 -1.95 0 C-N-CA 119.302 -0.959 . . . . 0.0 109.99 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 46' ' ' ASN . . . . . 0.557 ' OD1' ' CZ3' ' I' ' 26' ' ' TRP . 10.7 t-20 -30.02 -63.54 0.13 Allowed 'General case' 0 CA--C 1.564 1.484 0 N-CA-C 118.506 2.78 . . . . 0.0 118.506 -178.233 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 47' ' ' ALA . . . . . . . . . . . . . . . -59.49 -27.57 66.25 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 119.582 1.083 . . . . 0.0 112.269 -175.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 48' ' ' TYR . . . . . 0.515 ' O ' ' O ' ' K' ' 45' ' ' ARG . 82.9 m-85 -114.5 153.19 30.45 Favored 'General case' 0 C--O 1.202 -1.405 0 CA-C-O 121.416 0.627 . . . . 0.0 109.671 179.356 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 49' ' ' GLY . . . . . . . . . . . . . . . -175.94 -24.38 0.03 OUTLIER Glycine 0 C--N 1.312 -0.776 0 O-C-N 120.056 -1.653 . . . . 0.0 110.899 -179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 50' ' ' SER . . . . . . . . . . . . . 31.8 m -97.5 97.46 9.1 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 121.021 0.439 . . . . 0.0 111.407 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 51' ' ' MET . . . . . . . . . . . . . 68.9 mtm -69.28 -34.36 74.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.245 -0.889 . . . . 0.0 109.95 178.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 52' ' ' GLY . . . . . . . . . . . . . . . -55.96 106.71 0.67 Allowed Glycine 0 CA--C 1.52 0.401 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.685 -178.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.36 -34.54 90.24 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.28 -168.44 48.41 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 55' ' ' SER . . . . . . . . . . . . . 90.7 p -74.2 161.16 30.23 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.009 0.433 . . . . 0.0 110.812 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 56' ' ' LEU . . . . . . . . . . . . . 54.8 tp -89.67 131.97 35.39 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.221 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 57' ' ' ARG . . . . . . . . . . . . . 18.1 ttm-85 -62.73 138.33 58.49 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 120.466 -0.494 . . . . 0.0 111.056 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.49 17.53 75.62 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 111.51 -0.636 . . . . 0.0 111.51 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 59' ' ' SER . . . . . . . . . . . . . 92.3 p . . . . . 0 C--N 1.323 -0.574 0 CA-C-O 117.978 -1.01 . . . . 0.0 110.999 179.903 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' L' L ' 1' ' ' MET . . . . . . . . . . . . . 6.3 ttp . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 124.806 2.241 . . . . 0.0 106.839 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' L' L ' 2' ' ' SER . . . . . . . . . . . . . 8.8 m -58.88 136.63 57.9 Favored 'General case' 0 C--N 1.319 -0.756 0 O-C-N 118.606 -2.559 . . . . 0.0 109.909 178.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.09 163.23 10.95 Favored Glycine 0 CA--C 1.537 1.418 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.52 9.94 82.56 Favored Glycine 0 CA--C 1.533 1.184 0 C-N-CA 121.576 -0.345 . . . . 0.0 113.484 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.72 67.43 2.73 Favored Glycine 0 N--CA 1.471 1.005 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 6' ' ' VAL . . . . . . . . . . . . . 16.8 m -109.42 4.73 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -178.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 7' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -81.98 -72.62 0.43 Allowed 'General case' 0 C--O 1.207 -1.148 0 CA-C-O 121.68 0.753 . . . . 0.0 110.462 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 8' ' ' THR . . . . . 0.482 ' H ' ' HG1' ' L' ' 8' ' ' THR . 9.6 m -32.43 -34.35 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -178.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 9' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -76.65 -21.92 54.77 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 113.359 0.874 . . . . 0.0 113.359 -177.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 10' ' ' ILE . . . . . 0.423 ' O ' ' N ' ' L' ' 14' ' ' ALA . 94.4 mt -62.85 -43.21 98.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 -178.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 11' ' ' LEU . . . . . . . . . . . . . 46.0 tp -60.01 -42.42 94.27 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 12' ' ' ALA . . . . . . . . . . . . . . . -62.65 -37.62 87.07 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 177.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 13' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' L' ' 16' ' ' ARG . . . -68.48 -76.24 0.09 Allowed 'General case' 0 C--O 1.206 -1.192 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.769 179.04 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 14' ' ' ALA . . . . . 0.423 ' N ' ' O ' ' L' ' 10' ' ' ILE . . . -32.29 -48.1 0.17 Allowed 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 112.114 0.412 . . . . 0.0 112.114 179.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.95 -45.5 82.66 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 16' ' ' ARG . . . . . 0.47 ' N ' ' O ' ' L' ' 13' ' ' ALA . 65.3 ttt-85 -68.83 -44.04 74.29 Favored 'General case' 0 C--O 1.224 -0.272 0 CA-C-O 120.739 0.304 . . . . 0.0 111.361 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 17' ' ' ILE . . . . . 0.421 HD13 HG21 ' L' ' 17' ' ' ILE . 95.2 mt -64.51 -45.69 94.91 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.813 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -177.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 18' ' ' PHE . . . . . . . . . . . . . 49.3 t80 -48.47 -19.69 0.35 Allowed 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.564 -0.71 . . . . 0.0 110.873 -178.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 19' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -65.31 -38.45 90.23 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 120.82 0.343 . . . . 0.0 110.788 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 20' ' ' VAL . . . . . . . . . . . . . 88.6 t -64.75 -46.8 91.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 112.778 0.659 . . . . 0.0 112.778 -177.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 21' ' ' MET . . . . . . . . . . . . . 97.0 mmm -66.22 -61.46 2.01 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.725 0.774 . . . . 0.0 110.447 -179.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 22' ' ' VAL . . . . . . . . . . . . . 11.6 p -54.53 -34.83 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 CA-C-N 115.238 -0.892 . . . . 0.0 112.118 -177.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 23' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -69.07 -29.28 67.37 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -178.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 24' ' ' GLY . . . . . . . . . . . . . . . -98.86 -8.67 53.91 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 25' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 -67.1 -43.05 83.49 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -178.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 26' ' ' TRP . . . . . 0.416 ' O ' ' N ' ' L' ' 28' ' ' THR . 99.7 m95 -68.25 -47.49 67.61 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 116.429 2.011 . . . . 0.0 116.429 -175.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 27' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -36.68 -24.45 0.01 OUTLIER 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 115.878 1.807 . . . . 0.0 115.878 -176.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 28' ' ' THR . . . . . 0.416 ' N ' ' O ' ' L' ' 26' ' ' TRP . 77.5 m -63.58 -44.29 94.5 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 114.299 1.222 . . . . 0.0 114.299 -178.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 29' ' ' VAL . . . . . . . . . . . . . 60.7 t -55.13 -72.36 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 N-CA-C 114.325 1.231 . . . . 0.0 114.325 -176.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 30' ' ' GLY . . . . . . . . . . . . . . . 0.32 -73.6 0.0 OUTLIER Glycine 0 CA--C 1.539 1.538 0 N-CA-C 116.577 1.391 . . . . 0.0 116.577 -177.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 31' ' ' MET . . . . . . . . . . . . . 62.8 mtp -64.59 -36.96 85.92 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 113.904 1.075 . . . . 0.0 113.904 -176.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 tp -32.9 -67.32 0.12 Allowed 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 114.295 1.221 . . . . 0.0 114.295 -175.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 33' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -69.18 -43.09 74.93 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 114.541 1.311 . . . . 0.0 114.541 -178.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 34' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -63.61 -36.32 83.42 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 118.462 2.764 . . . . 0.0 118.462 -173.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 35' ' ' SER . . . . . . . . . . . . . 27.1 t -61.92 -35.36 78.15 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 119.563 1.074 . . . . 0.0 113.448 -175.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 36' ' ' LEU . . . . . 0.511 ' O ' ' N ' ' L' ' 38' ' ' LYS . 48.6 tp -52.98 -41.76 64.89 Favored 'General case' 0 CA--C 1.551 0.983 0 N-CA-C 115.893 1.812 . . . . 0.0 115.893 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -39.7 -12.54 0.01 OUTLIER Glycine 0 CA--C 1.543 1.784 0 N-CA-C 116.202 1.241 . . . . 0.0 116.202 -176.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 38' ' ' LYS . . . . . 0.511 ' N ' ' O ' ' L' ' 36' ' ' LEU . 55.3 mttm -96.2 -7.47 35.61 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-N 119.645 1.722 . . . . 0.0 114.301 -176.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 39' ' ' GLY . . . . . . . . . . . . . . . -90.4 -30.3 12.48 Favored Glycine 0 CA--C 1.538 1.518 0 C-N-CA 120.543 -0.837 . . . . 0.0 114.644 -177.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 40' ' ' THR . . . . . . . . . . . . . 18.6 p -76.25 -17.02 59.68 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -176.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 41' ' ' MET . . . . . . . . . . . . . 91.0 mmm -64.92 -36.78 85.49 Favored 'General case' 0 CA--C 1.554 1.133 0 N-CA-C 116.114 1.894 . . . . 0.0 116.114 -176.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 42' ' ' ARG . . . . . . . . . . . . . 82.8 mmt-85 -73.2 -7.98 53.79 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 116.368 1.988 . . . . 0.0 116.368 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 43' ' ' ILE . . . . . . . . . . . . . 24.2 mm -105.08 -32.47 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 44' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -64.9 -40.3 94.87 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 113.989 -1.459 . . . . 0.0 110.225 177.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 45' ' ' ARG . . . . . 0.441 ' O ' ' O ' ' L' ' 48' ' ' TYR . 29.4 ttp180 -69.89 -47.54 62.13 Favored 'General case' 0 C--O 1.216 -0.707 0 N-CA-C 116.349 1.981 . . . . 0.0 116.349 -177.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 46' ' ' ASN . . . . . 0.544 ' OD1' ' CE3' ' N' ' 26' ' ' TRP . 7.3 t-20 -70.56 -49.93 42.79 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 120.177 1.353 . . . . 0.0 114.605 -177.462 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 47' ' ' ALA . . . . . . . . . . . . . . . -63.56 -34.38 77.68 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.104 -0.638 . . . . 0.0 111.924 -176.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 48' ' ' TYR . . . . . 0.441 ' O ' ' O ' ' L' ' 45' ' ' ARG . 80.8 m-85 -109.84 146.24 35.39 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.15 -19.7 0.02 OUTLIER Glycine 0 N--CA 1.46 0.289 0 C-N-CA 119.794 -1.194 . . . . 0.0 111.207 -178.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 50' ' ' SER . . . . . . . . . . . . . 47.2 m -102.74 94.11 5.44 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.281 0.562 . . . . 0.0 110.52 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 51' ' ' MET . . . . . . . . . . . . . 62.9 mtm -66.44 -36.49 82.92 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.429 178.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 52' ' ' GLY . . . . . . . . . . . . . . . -52.27 108.53 0.68 Allowed Glycine 0 CA--C 1.526 0.76 0 CA-C-N 115.097 -0.956 . . . . 0.0 112.086 -178.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.84 -34.7 90.63 Favored Glycine 0 CA--C 1.53 0.984 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.4 -170.34 50.47 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 55' ' ' SER . . . . . . . . . . . . . 88.1 p -74.86 161.65 29.36 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.969 0.414 . . . . 0.0 110.905 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 56' ' ' LEU . . . . . . . . . . . . . 58.0 tp -89.92 130.49 36.13 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.519 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 57' ' ' ARG . . . . . . . . . . . . . 15.6 ttm-85 -61.84 137.72 58.27 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.153 -0.619 . . . . 0.0 110.262 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.93 16.97 73.63 Favored Glycine 0 CA--C 1.522 0.511 0 C-N-CA 121.208 -0.52 . . . . 0.0 111.973 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 59' ' ' SER . . . . . . . . . . . . . 89.7 p . . . . . 0 C--N 1.325 -0.488 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.755 179.932 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' M' M ' 1' ' ' MET . . . . . 0.519 ' SD ' ' OBD' ' A' ' 101' ' ' BCL . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 124.117 1.913 . . . . 0.0 106.851 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 2' ' ' SER . . . . . . . . . . . . . 12.3 m -82.48 132.24 35.21 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.21 171.29 21.01 Favored Glycine 0 CA--C 1.535 1.282 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.71 9.14 86.73 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.989 -0.444 . . . . 0.0 111.989 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.08 66.76 2.72 Favored Glycine 0 N--CA 1.468 0.782 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 6' ' ' VAL . . . . . . . . . . . . . 16.3 m -107.24 2.44 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -178.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 7' ' ' PHE . . . . . 0.558 ' CD2' ' CD2' ' J' ' 7' ' ' PHE . 0.1 OUTLIER -84.35 -58.2 2.84 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 122.357 1.075 . . . . 0.0 112.173 -178.066 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' M' M ' 8' ' ' THR . . . . . . . . . . . . . 25.3 m -47.14 -22.64 0.39 Allowed 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 113.006 -1.906 . . . . 0.0 111.857 -174.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 9' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -86.2 -19.72 29.6 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 10' ' ' ILE . . . . . 0.424 HG22 HD13 ' M' ' 10' ' ' ILE . 95.9 mt -63.39 -42.62 96.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 11' ' ' LEU . . . . . . . . . . . . . 58.7 tp -60.57 -42.5 96.75 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 115.058 -0.974 . . . . 0.0 108.786 179.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 12' ' ' ALA . . . . . 0.433 ' CB ' ' OG ' ' A' ' 35' ' ' SER . . . -61.17 -37.83 84.33 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 177.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 13' ' ' ALA . . . . . 0.675 ' O ' ' N ' ' M' ' 15' ' ' GLY . . . -73.26 -141.5 0.01 OUTLIER 'General case' 0 C--O 1.173 -2.954 0 N-CA-C 102.314 -3.217 . . . . 0.0 102.314 171.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 14' ' ' ALA . . . . . . . . . . . . . . . 42.14 -74.95 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.19 0 CA-C-N 122.372 2.351 . . . . 0.0 111.94 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 15' ' ' GLY . . . . . 0.675 ' N ' ' O ' ' M' ' 13' ' ' ALA . . . -62.74 -47.98 84.83 Favored Glycine 0 CA--C 1.548 2.134 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 176.431 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 16' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -64.57 -43.28 94.4 Favored 'General case' 0 N--CA 1.484 1.23 0 N-CA-C 106.327 -1.731 . . . . 0.0 106.327 178.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 17' ' ' ILE . . . . . 0.562 ' CG2' ' H ' ' M' ' 18' ' ' PHE . 84.3 mt -69.92 -162.95 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.201 -1.479 0 N-CA-C 101.25 -3.611 . . . . 0.0 101.25 175.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 18' ' ' PHE . . . . . 0.562 ' H ' ' CG2' ' M' ' 17' ' ' ILE . 24.5 t80 64.31 -34.08 0.15 Allowed 'General case' 1 C--N 1.241 -4.134 0 O-C-N 120.142 -1.599 . . . . 0.0 109.524 -176.59 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' M' M ' 19' ' ' GLU . . . . . 0.557 ' N ' ' O ' ' M' ' 17' ' ' ILE . 69.6 mt-10 -62.43 -37.17 84.83 Favored 'General case' 0 C--N 1.377 1.77 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 20' ' ' VAL . . . . . . . . . . . . . 89.8 t -67.45 -46.61 83.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.066 0 CA-C-N 114.921 -1.036 . . . . 0.0 112.172 -178.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 21' ' ' MET . . . . . 0.4 ' CE ' ' O1A' ' M' ' 101' ' ' BCL . 98.3 mmm -67.61 -48.11 67.74 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 22' ' ' VAL . . . . . . . . . . . . . 12.2 p -66.09 -37.06 78.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.92 0.867 . . . . 0.0 112.29 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 23' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -68.03 -36.5 80.03 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.826 -177.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 24' ' ' GLY . . . . . . . . . . . . . . . -92.82 -7.5 62.77 Favored Glycine 0 N--CA 1.474 1.178 0 N-CA-C 110.026 -1.229 . . . . 0.0 110.026 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 25' ' ' HIS . . . . . . . . . . . . . 10.8 t-80 -68.2 -46.45 70.59 Favored 'General case' 0 CA--C 1.559 1.301 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 -179.033 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 26' ' ' TRP . . . . . 0.584 ' CE3' ' OD1' ' A' ' 46' ' ' ASN . 97.6 m95 -66.94 -42.61 85.0 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 117.35 2.352 . . . . 0.0 117.35 -176.392 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 27' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -39.93 -21.88 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.16 0 N-CA-C 114.982 1.475 . . . . 0.0 114.982 -176.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 28' ' ' THR . . . . . . . . . . . . . 86.3 m -63.87 -42.97 97.4 Favored 'General case' 0 CA--C 1.554 1.123 0 N-CA-C 114.588 1.329 . . . . 0.0 114.588 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 29' ' ' VAL . . . . . . . . . . . . . 57.7 t -61.97 -46.25 96.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 N-CA-C 116.424 2.009 . . . . 0.0 116.424 -174.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 30' ' ' GLY . . . . . . . . . . . . . . . -28.81 -66.89 0.09 OUTLIER Glycine 0 CA--C 1.541 1.695 0 N-CA-C 115.742 1.057 . . . . 0.0 115.742 -174.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 31' ' ' MET . . . . . . . . . . . . . 21.5 mtp -64.81 -38.74 91.99 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -175.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 32' ' ' LEU . . . . . . . . . . . . . 10.8 tp -34.61 -66.79 0.16 Allowed 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 114.31 1.226 . . . . 0.0 114.31 -175.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 33' ' ' PHE . . . . . . . . . . . . . 24.1 t80 -69.04 -43.51 74.57 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -177.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 34' ' ' ASP . . . . . . . . . . . . . 34.8 t70 -63.23 -39.66 95.26 Favored 'General case' 0 CA--C 1.559 1.325 0 N-CA-C 117.979 2.585 . . . . 0.0 117.979 -174.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 35' ' ' SER . . . . . . . . . . . . . 6.4 t -60.53 -25.03 65.82 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 114.412 1.264 . . . . 0.0 114.412 -175.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 36' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' M' ' 38' ' ' LYS . 48.2 tp -62.72 -41.72 99.3 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 116.458 2.022 . . . . 0.0 116.458 -177.116 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -45.16 -5.88 0.01 OUTLIER Glycine 0 CA--C 1.539 1.565 0 N-CA-C 116.026 1.17 . . . . 0.0 116.026 -174.491 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 38' ' ' LYS . . . . . 0.459 ' N ' ' O ' ' M' ' 36' ' ' LEU . 62.6 mttm -100.4 -9.56 22.08 Favored 'General case' 0 N--CA 1.495 1.812 0 CA-C-N 119.696 1.748 . . . . 0.0 113.195 -176.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 39' ' ' GLY . . . . . . . . . . . . . . . -91.19 -24.84 25.78 Favored Glycine 0 N--CA 1.483 1.809 0 O-C-N 121.494 -0.754 . . . . 0.0 113.977 -177.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -77.56 -19.03 56.34 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -177.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 41' ' ' MET . . . . . . . . . . . . . 90.4 mmm -65.25 -38.78 91.41 Favored 'General case' 0 CA--C 1.559 1.308 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -176.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 42' ' ' ARG . . . . . . . . . . . . . 88.4 mmt-85 -66.68 -21.66 66.09 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 -174.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 43' ' ' ILE . . . . . . . . . . . . . 29.4 mm -90.44 -34.71 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 44' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -64.08 -40.68 96.77 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 114.819 -1.082 . . . . 0.0 111.602 179.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 45' ' ' ARG . . . . . . . . . . . . . 17.0 ttp180 -65.01 -44.61 88.64 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 116.492 2.034 . . . . 0.0 116.492 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 46' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -74.43 -51.88 13.67 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 115.23 1.567 . . . . 0.0 115.23 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 47' ' ' ALA . . . . . . . . . . . . . . . -64.49 -34.52 78.41 Favored 'General case' 0 C--O 1.22 -0.454 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.838 -178.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 48' ' ' TYR . . . . . . . . . . . . . 78.5 m-85 -110.67 134.86 52.07 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 49' ' ' GLY . . . . . . . . . . . . . . . -160.65 -12.91 0.03 OUTLIER Glycine 0 CA--C 1.52 0.374 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.445 -178.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 50' ' ' SER . . . . . . . . . . . . . 58.7 m -107.91 94.82 5.28 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-O 121.033 0.444 . . . . 0.0 110.715 -179.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 51' ' ' MET . . . . . . . . . . . . . 65.4 mtm -66.2 -37.26 85.17 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.231 178.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 52' ' ' GLY . . . . . . . . . . . . . . . -51.43 109.8 0.88 Allowed Glycine 0 CA--C 1.524 0.654 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.404 -178.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.02 -34.19 89.26 Favored Glycine 0 CA--C 1.535 1.323 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.02 -169.75 52.21 Favored Glycine 0 N--CA 1.476 1.303 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 55' ' ' SER . . . . . . . . . . . . . 86.4 p -76.16 162.71 27.76 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.068 0.461 . . . . 0.0 111.259 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 56' ' ' LEU . . . . . . . . . . . . . 60.6 tp -89.96 128.41 36.23 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.32 179.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 57' ' ' ARG . . . . . . . . . . . . . 13.1 ttm-85 -61.43 138.92 58.28 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.912 -179.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.97 15.56 77.07 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 59' ' ' SER . . . . . . . . . . . . . 90.1 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.864 -1.065 . . . . 0.0 110.698 179.842 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' N' N ' 1' ' ' MET . . . . . . . . . . . . 0.261 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 124.866 2.27 . . . . 0.0 107.15 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 2' ' ' SER . . . . . . . . . . . . . 10.8 m -82.08 130.08 34.98 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 120.329 -1.482 . . . . 0.0 109.576 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 3' ' ' GLY . . . . . . . . . . . . . . . 70.76 177.21 23.47 Favored Glycine 0 N--CA 1.468 0.801 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.41 10.89 85.98 Favored Glycine 0 CA--C 1.521 0.437 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.66 63.5 3.26 Favored Glycine 0 N--CA 1.469 0.848 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 6' ' ' VAL . . . . . . . . . . . . . 22.3 m -105.9 -0.81 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -178.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 7' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -81.34 -47.04 13.81 Favored 'General case' 0 N--CA 1.484 1.273 0 CA-C-N 119.142 0.883 . . . . 0.0 111.889 -178.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 8' ' ' THR . . . . . . . . . . . . . 25.6 m -59.55 -28.21 66.91 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 114.608 -1.178 . . . . 0.0 112.777 -174.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 9' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -78.7 -19.63 52.0 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 10' ' ' ILE . . . . . 0.403 HG22 HD13 ' N' ' 10' ' ' ILE . 92.7 mt -64.17 -42.79 96.64 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 119.774 -0.77 . . . . 0.0 109.237 -178.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 11' ' ' LEU . . . . . . . . . . . . . 48.1 tp -60.04 -43.28 95.47 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.0 -35.36 74.88 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 178.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 13' ' ' ALA . . . . . 0.544 ' O ' ' N ' ' N' ' 16' ' ' ARG . . . -71.91 -78.83 0.08 Allowed 'General case' 0 C--O 1.193 -1.872 0 CA-C-O 118.339 -0.838 . . . . 0.0 109.5 178.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 14' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' N' ' 13' ' ' ALA . . . -25.49 -49.55 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.332 0 O-C-N 123.806 0.691 . . . . 0.0 112.777 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.15 -47.58 52.2 Favored Glycine 0 CA--C 1.536 1.395 0 N-CA-C 111.509 -0.637 . . . . 0.0 111.509 177.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 16' ' ' ARG . . . . . 0.544 ' N ' ' O ' ' N' ' 13' ' ' ALA . 66.7 ttt-85 -69.69 -41.19 75.77 Favored 'General case' 0 C--O 1.2 -1.508 0 CA-C-O 121.504 0.669 . . . . 0.0 109.601 179.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 17' ' ' ILE . . . . . 0.423 HG21 HD13 ' N' ' 17' ' ' ILE . 96.6 mt -68.54 -50.66 54.19 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.954 0 O-C-N 119.981 -1.699 . . . . 0.0 110.996 -177.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 18' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -49.03 -21.26 0.66 Allowed 'General case' 0 C--N 1.309 -1.178 0 O-C-N 120.983 -1.073 . . . . 0.0 110.558 -176.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 19' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -58.1 -37.24 74.15 Favored 'General case' 0 CA--C 1.547 0.849 0 CA-C-O 121.733 0.778 . . . . 0.0 109.909 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 20' ' ' VAL . . . . . . . . . . . . . 87.0 t -68.73 -48.71 69.87 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 21' ' ' MET . . . . . . . . . . . . . 97.7 mmm -64.2 -44.31 92.34 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.578 0.704 . . . . 0.0 112.782 -177.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 22' ' ' VAL . . . . . . . . . . . . . 13.5 p -68.49 -35.41 70.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.055 -0.975 . . . . 0.0 112.324 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 23' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.84 -42.49 85.65 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 120.166 -0.613 . . . . 0.0 112.306 -176.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.25 -12.13 74.09 Favored Glycine 0 CA--C 1.533 1.188 0 N-CA-C 111.675 -0.57 . . . . 0.0 111.675 -179.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 25' ' ' HIS . . . . . . . . . . . . . 5.5 t-80 -63.65 -47.8 79.84 Favored 'General case' 0 CA--C 1.555 1.162 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -178.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 26' ' ' TRP . . . . . 0.544 ' CE3' ' OD1' ' L' ' 46' ' ' ASN . 98.7 m95 -65.12 -40.46 94.53 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 117.888 2.551 . . . . 0.0 117.888 -177.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 27' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -42.26 -24.73 0.06 Allowed 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 115.254 1.576 . . . . 0.0 115.254 -176.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 28' ' ' THR . . . . . . . . . . . . . 77.3 m -61.99 -42.62 99.34 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -177.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 29' ' ' VAL . . . . . . . . . . . . . 79.2 t -61.49 -47.11 94.89 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.178 0 N-CA-C 116.54 2.052 . . . . 0.0 116.54 -173.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 30' ' ' GLY . . . . . . . . . . . . . . . -29.79 -63.49 0.15 Allowed Glycine 0 CA--C 1.544 1.872 0 N-CA-C 116.479 1.352 . . . . 0.0 116.479 -176.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 31' ' ' MET . . . . . . . . . . . . . 78.6 mmm -64.3 -37.47 87.62 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 114.009 1.115 . . . . 0.0 114.009 -176.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 32' ' ' LEU . . . . . . . . . . . . . 13.7 tp -41.19 -64.79 0.5 Allowed 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 -174.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 33' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -69.69 -44.66 69.99 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -177.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 34' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -61.34 -45.55 93.96 Favored 'General case' 0 CA--C 1.557 1.242 0 N-CA-C 118.516 2.784 . . . . 0.0 118.516 -173.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 35' ' ' SER . . . . . . . . . . . . . 5.1 t -56.32 -25.48 49.0 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 114.163 1.172 . . . . 0.0 114.163 -175.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 36' ' ' LEU . . . . . 0.472 ' O ' ' N ' ' N' ' 38' ' ' LYS . 46.6 tp -62.19 -41.7 98.59 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 115.831 1.789 . . . . 0.0 115.831 -176.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -42.25 -11.59 0.01 OUTLIER Glycine 0 CA--C 1.546 1.983 0 N-CA-C 116.016 1.166 . . . . 0.0 116.016 -174.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 38' ' ' LYS . . . . . 0.472 ' N ' ' O ' ' N' ' 36' ' ' LEU . 31.9 mttm -95.47 -16.13 22.45 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-N 120.168 1.984 . . . . 0.0 114.8 -176.326 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 39' ' ' GLY . . . . . . . . . . . . . . . -86.16 -22.79 47.17 Favored Glycine 0 N--CA 1.476 1.331 0 C-N-CA 120.527 -0.844 . . . . 0.0 113.654 -177.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 40' ' ' THR . . . . . . . . . . . . . 26.2 p -76.27 -22.45 55.07 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 113.523 0.935 . . . . 0.0 113.523 -177.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 41' ' ' MET . . . . . . . . . . . . . 89.6 mmm -62.48 -41.57 98.88 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 117.192 2.293 . . . . 0.0 117.192 -176.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 42' ' ' ARG . . . . . . . . . . . . . 89.0 mmt-85 -61.91 -37.12 83.45 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 115.653 1.723 . . . . 0.0 115.653 -174.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 43' ' ' ILE . . . . . . . . . . . . . 31.7 mm -74.92 -33.23 29.31 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 119.117 0.871 . . . . 0.0 109.066 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 44' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -63.68 -40.36 96.62 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.49 -1.232 . . . . 0.0 111.554 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 45' ' ' ARG . . . . . . . . . . . . . 4.3 ttp180 -64.82 -44.02 91.22 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 115.742 1.756 . . . . 0.0 115.742 -177.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 46' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.98 -55.67 5.52 Favored 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 115.911 1.819 . . . . 0.0 115.911 -175.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 47' ' ' ALA . . . . . . . . . . . . . . . -63.61 -36.36 83.57 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.279 -0.568 . . . . 0.0 112.012 -176.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 48' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -108.41 113.53 26.66 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 49' ' ' GLY . . . . . . . . . . . . . . . -138.65 -9.46 1.0 Allowed Glycine 0 N--CA 1.48 1.577 0 N-CA-C 111.654 -0.578 . . . . 0.0 111.654 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 50' ' ' SER . . . . . . . . . . . . . 58.4 m -110.87 102.8 11.28 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 117.279 0.54 . . . . 0.0 111.599 -179.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 51' ' ' MET . . . . . . . . . . . . . 67.1 mtm -73.64 -36.44 65.42 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.583 0.706 . . . . 0.0 110.111 177.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 52' ' ' GLY . . . . . . . . . . . . . . . -51.35 108.84 0.65 Allowed Glycine 0 CA--C 1.52 0.406 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.044 -178.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.29 -34.71 90.69 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.97 -174.24 51.06 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 55' ' ' SER . . . . . . . . . . . . . 87.3 p -74.73 161.95 29.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.017 0.437 . . . . 0.0 110.386 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 56' ' ' LEU . . . . . . . . . . . . . 57.8 tp -88.75 129.22 35.6 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.816 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 57' ' ' ARG . . . . . . . . . . . . . 11.6 ttm-85 -62.05 137.9 58.31 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.065 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 58' ' ' GLY . . . . . . . . . . . . . . . 81.49 16.03 74.64 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.68 -0.568 . . . . 0.0 111.68 179.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 59' ' ' SER . . . . . . . . . . . . . 89.2 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.628 179.924 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' BCL . . . . . 0.519 ' OBD' ' SD ' ' M' ' 1' ' ' MET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 101' ' ' BCL . . . . . 0.506 ' OBD' ' SD ' ' J' ' 1' ' ' MET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 101' ' ' BCL . . . . . 0.501 ' OBD' ' SD ' ' G' ' 1' ' ' MET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 101' ' ' BCL . . . . . 0.468 ' O2A' ' C4 ' ' D' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 101' ' ' BCL . . . . . 0.444 ' O2A' ' C4 ' ' E' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 101' ' ' BCL . . . . . 0.432 ' O2A' ' C4 ' ' F' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 101' ' ' BCL . . . . . 0.494 ' C4 ' ' O2A' ' G' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 101' ' ' BCL . . . . . 0.469 ' O2A' ' C4 ' ' H' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 101' ' ' BCL . . . . . 0.472 ' O2A' ' C4 ' ' I' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 101' ' ' BCL . . . . . 0.486 ' O2A' ' C4 ' ' J' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 101' ' ' BCL . . . . . 0.471 ' O2A' ' C4 ' ' K' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 101' ' ' BCL . . . . . 0.504 ' C4 ' ' O2A' ' L' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 101' ' ' BCL . . . . . 0.512 ' O2A' ' C4 ' ' M' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 101' ' ' BCL . . . . . 0.523 ' C4 ' ' O2A' ' N' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.163 0 CA-C-O 124.188 1.947 . . . . 0.0 109.349 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.3 m -74.79 133.41 41.94 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 120.352 -1.468 . . . . 0.0 110.972 -177.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.71 179.32 8.71 Favored Glycine 0 CA--C 1.533 1.169 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.36 13.69 82.62 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 111.705 -0.558 . . . . 0.0 111.705 178.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.57 54.19 3.44 Favored Glycine 0 N--CA 1.47 0.93 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 30.0 m -88.02 -10.83 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 113.999 1.111 . . . . 0.0 113.999 -179.061 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -71.54 -56.58 5.62 Favored 'General case' 0 CA--C 1.552 1.052 0 N-CA-C 115.51 1.671 . . . . 0.0 115.51 -175.852 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.8 m -51.98 -42.41 62.91 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.752 -174.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -62.05 -25.04 67.45 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 63.5 mt -62.92 -43.05 98.72 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.093 0 C-N-CA 118.428 -1.309 . . . . 0.0 110.16 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 32.1 tp -58.02 -42.92 86.32 Favored 'General case' 0 CA--C 1.49 -1.353 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.743 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -58.99 -35.42 73.19 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -74.61 -49.03 23.15 Favored 'General case' 0 C--O 1.196 -1.738 0 CA-C-N 114.415 -1.266 . . . . 0.0 113.827 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.08 -40.25 76.57 Favored 'General case' 0 C--N 1.318 -0.768 0 O-C-N 121.366 -0.834 . . . . 0.0 110.218 -178.167 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.83 -48.58 33.37 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.578 -0.82 . . . . 0.0 111.257 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 70.4 ttt-85 -68.45 -42.67 78.46 Favored 'General case' 0 CA--C 1.554 1.116 0 CA-C-N 115.006 -0.597 . . . . 0.0 112.119 -177.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 93.3 mt -67.06 -44.45 88.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 O-C-N 120.893 -1.13 . . . . 0.0 110.339 -177.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.509 ' O ' HG12 ' A' ' 22' ' ' VAL . 22.8 t80 -57.43 -18.82 19.99 Favored 'General case' 0 N--CA 1.442 -0.869 0 C-N-CA 118.793 -1.163 . . . . 0.0 109.359 -176.416 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -62.41 -30.49 71.25 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 124.71 1.256 . . . . 0.0 108.186 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 66.8 t -74.59 -49.23 31.52 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 98.1 mmm -63.83 -43.5 96.0 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-O 121.659 0.742 . . . . 0.0 111.833 -176.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.509 HG12 ' O ' ' A' ' 18' ' ' PHE . 13.2 p -67.15 -39.48 83.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 114.418 -1.265 . . . . 0.0 113.002 -178.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.481 ' N ' HG13 ' A' ' 22' ' ' VAL . 83.9 tt0 -64.12 -45.89 86.57 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -177.02 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.78 -28.7 70.36 Favored Glycine 0 CA--C 1.546 2.026 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.839 179.639 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -61.48 -38.25 86.61 Favored 'General case' 0 CA--C 1.571 1.783 0 N-CA-C 115.869 1.803 . . . . 0.0 115.869 -174.25 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.569 ' CE3' ' OD1' ' E' ' 46' ' ' ASN . 99.3 m95 -74.18 -32.53 63.12 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 117.716 2.487 . . . . 0.0 117.716 -177.126 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -49.47 -33.42 14.25 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 114.334 1.235 . . . . 0.0 114.334 -174.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 m -55.07 -40.43 70.34 Favored 'General case' 0 CA--C 1.564 1.484 0 N-CA-C 114.448 1.277 . . . . 0.0 114.448 -176.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.507 ' CG2' HBC1 ' A' ' 101' ' ' BCL . 55.2 t -60.88 -41.88 90.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 117.841 2.534 . . . . 0.0 117.841 -174.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -50.15 -45.35 43.17 Favored Glycine 0 CA--C 1.541 1.677 0 C-N-CA 120.549 -0.834 . . . . 0.0 115.128 -171.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 64.3 mmm -68.35 -33.11 73.68 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 119.13 1.465 . . . . 0.0 113.127 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 11.2 tp -51.35 -59.18 4.51 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 117.994 2.59 . . . . 0.0 117.994 -171.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 30.5 t80 -72.71 -43.05 63.5 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 120.478 1.49 . . . . 0.0 112.635 -179.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -59.68 -50.34 74.23 Favored 'General case' 0 CA--C 1.556 1.208 0 N-CA-C 118.375 2.731 . . . . 0.0 118.375 -173.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.433 ' OG ' ' CB ' ' M' ' 12' ' ' ALA . 4.8 t -53.1 -26.55 16.81 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -173.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.442 HD13 HD11 ' M' ' 11' ' ' LEU . 42.0 tp -63.5 -31.4 72.55 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 117.111 2.263 . . . . 0.0 117.111 -176.706 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -51.24 -29.22 21.63 Favored Glycine 0 CA--C 1.544 1.851 0 C-N-CA 118.161 -1.971 . . . . 0.0 114.246 -170.253 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 16.4 mttt -67.0 -38.48 86.09 Favored 'General case' 0 CA--C 1.555 1.17 0 N-CA-C 116.596 2.073 . . . . 0.0 116.596 -178.065 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -62.67 -33.65 87.34 Favored Glycine 0 CA--C 1.545 1.908 0 N-CA-C 116.125 1.21 . . . . 0.0 116.125 -174.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.1 p -71.47 -23.42 61.82 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 113.715 1.005 . . . . 0.0 113.715 -176.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' MET . . . . . . . . . . . . . 91.4 mmm -60.99 -41.57 96.73 Favored 'General case' 0 CA--C 1.553 1.079 0 N-CA-C 118.615 2.82 . . . . 0.0 118.615 -174.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 88.4 mmt-85 -63.88 -41.78 97.66 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-N 120.09 1.313 . . . . 0.0 114.119 -174.377 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 33.0 mm -63.86 -42.2 95.05 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.569 0 N-CA-C 108.193 -1.039 . . . . 0.0 108.193 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 -58.41 -39.62 80.21 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.53 178.077 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.8 ttp180 -63.33 -44.49 94.78 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 115.675 1.731 . . . . 0.0 115.675 -177.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.735 ' ND2' ' CE3' ' M' ' 26' ' ' TRP . 47.2 t-20 -73.47 -64.1 1.06 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 117.119 2.266 . . . . 0.0 117.119 -175.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -57.23 -34.63 68.77 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -174.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -99.08 34.37 2.14 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 118.695 2.85 . . . . 0.0 118.695 -174.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -69.85 -12.08 67.23 Favored Glycine 0 CA--C 1.564 3.124 0 N-CA-C 117.915 1.926 . . . . 0.0 117.915 -175.132 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 53.5 m -106.34 116.61 32.23 Favored 'General case' 0 N--CA 1.501 2.09 0 CA-C-N 120.916 2.358 . . . . 0.0 111.809 -178.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 68.2 mtm -86.75 -33.39 19.98 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.387 0.613 . . . . 0.0 110.417 178.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -55.06 107.22 0.68 Allowed Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.47 -34.56 90.27 Favored Glycine 0 N--CA 1.448 -0.545 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.57 -170.59 46.47 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.5 p -74.51 161.11 30.08 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-O 121.12 0.486 . . . . 0.0 111.244 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 59.0 tp -88.53 128.31 35.55 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.688 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 45.2 ttt85 -60.42 135.28 57.7 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.581 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.63 15.53 77.7 Favored Glycine 0 CA--C 1.526 0.749 0 C-N-CA 121.059 -0.591 . . . . 0.0 111.635 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 88.7 p . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.863 -1.065 . . . . 0.0 111.018 179.78 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.159 0 CA-C-O 123.649 1.69 . . . . 0.0 109.181 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 10.2 m -68.32 135.11 51.36 Favored 'General case' 0 C--N 1.326 -0.435 0 O-C-N 119.805 -1.809 . . . . 0.0 109.869 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . 70.19 172.12 10.36 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.44 16.68 80.48 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 121.444 -0.408 . . . . 0.0 113.017 178.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.11 53.49 3.57 Favored Glycine 0 N--CA 1.469 0.894 0 N-CA-C 110.546 -1.022 . . . . 0.0 110.546 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' B' ' 7' ' ' PHE . 30.9 m -84.76 -14.53 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 113.168 0.803 . . . . 0.0 113.168 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' PHE . . . . . 0.634 ' O ' ' N ' ' B' ' 9' ' ' ASP . 0.3 OUTLIER -66.67 -140.01 0.0 OUTLIER 'General case' 0 C--O 1.188 -2.183 0 N-CA-C 105.258 -2.127 . . . . 0.0 105.258 175.843 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 8' ' ' THR . . . . . . . . . . . . . 15.2 m 41.43 -66.16 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 176.471 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 9' ' ' ASP . . . . . 0.634 ' N ' ' O ' ' B' ' 7' ' ' PHE . 11.9 t70 -56.08 -26.6 50.12 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 123.944 0.897 . . . . 0.0 111.247 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' ILE . . . . . 0.4 ' O ' ' HB3' ' B' ' 13' ' ' ALA . 46.2 mt -63.66 -42.87 97.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 C-N-CA 117.885 -1.526 . . . . 0.0 108.873 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 11' ' ' LEU . . . . . . . . . . . . . 25.5 tp -58.78 -42.88 90.05 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.031 -0.668 . . . . 0.0 109.277 178.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' ALA . . . . . 0.451 ' CB ' ' OG ' ' H' ' 35' ' ' SER . . . -58.5 -35.21 71.88 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 178.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 13' ' ' ALA . . . . . 0.536 ' O ' ' N ' ' B' ' 16' ' ' ARG . . . -73.91 -75.95 0.14 Allowed 'General case' 0 C--O 1.209 -1.051 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.973 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' ALA . . . . . . . . . . . . . . . -30.95 -32.53 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 113.396 0.888 . . . . 0.0 113.396 -179.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' B' ' 13' ' ' ALA . . . -81.17 -49.02 5.74 Favored Glycine 0 CA--C 1.52 0.351 0 N-CA-C 109.176 -1.569 . . . . 0.0 109.176 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 16' ' ' ARG . . . . . 0.536 ' N ' ' O ' ' B' ' 13' ' ' ALA . 74.5 ttt-85 -67.99 -43.31 79.2 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 113.98 -1.11 . . . . 0.0 111.042 -179.003 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 88.4 mt -63.72 -43.49 98.04 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.899 0 C-N-CA 120.337 -0.545 . . . . 0.0 110.014 -177.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' PHE . . . . . 0.482 ' O ' HG12 ' B' ' 22' ' ' VAL . 6.8 t80 -57.5 -20.14 29.24 Favored 'General case' 0 CA--C 1.484 -1.559 0 C-N-CA 118.789 -1.164 . . . . 0.0 110.826 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 19' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -61.4 -33.96 74.57 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 119.009 -1.076 . . . . 0.0 110.203 178.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.38 -48.49 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.22 0 C-N-CA 119.808 -0.757 . . . . 0.0 112.892 -178.129 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' MET . . . . . . . . . . . . . 97.6 mmm -64.63 -44.27 91.03 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-O 121.42 0.629 . . . . 0.0 112.384 -176.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' VAL . . . . . 0.526 HG13 ' N ' ' B' ' 23' ' ' GLU . 14.3 p -67.35 -38.77 81.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 CA-C-N 115.434 -0.803 . . . . 0.0 112.915 -178.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 23' ' ' GLU . . . . . 0.526 ' N ' HG13 ' B' ' 22' ' ' VAL . 83.1 tt0 -64.35 -42.53 96.19 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -176.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 24' ' ' GLY . . . . . . . . . . . . . . . -91.03 13.83 65.13 Favored Glycine 0 N--CA 1.472 1.074 0 N-CA-C 112.605 -0.198 . . . . 0.0 112.605 -178.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 2.6 t-80 -100.36 -15.87 17.83 Favored 'General case' 0 CA--C 1.564 1.495 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -176.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' TRP . . . . . 0.594 ' CZ3' ' OD1' ' H' ' 46' ' ' ASN . 97.0 m95 -94.42 -33.65 13.05 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 -178.055 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -50.16 -24.25 2.67 Favored 'General case' 0 N--CA 1.482 1.16 0 N-CA-C 115.773 1.768 . . . . 0.0 115.773 -176.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' THR . . . . . . . . . . . . . 81.3 m -61.82 -41.51 97.87 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -178.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' VAL . . . . . 0.667 ' CG2' HBC1 ' B' ' 101' ' ' BCL . 68.7 t -61.27 -45.58 98.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 116.215 1.932 . . . . 0.0 116.215 -174.313 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 30' ' ' GLY . . . . . . . . . . . . . . . -27.73 -61.42 0.11 Allowed Glycine 0 CA--C 1.549 2.162 0 N-CA-C 115.255 0.862 . . . . 0.0 115.255 -176.255 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' MET . . . . . . . . . . . . . 4.2 mtp -67.73 -33.25 74.5 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 115.558 1.688 . . . . 0.0 115.558 -176.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 2.0 tp -41.78 -75.14 0.03 OUTLIER 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 114.862 1.43 . . . . 0.0 114.862 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -62.84 -44.96 94.73 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 119.346 -0.942 . . . . 0.0 113.519 -176.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -52.26 -70.73 0.08 Allowed 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -176.244 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 35' ' ' SER . . . . . . . . . . . . . 1.5 t -32.0 -33.23 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 117.059 2.244 . . . . 0.0 117.059 -174.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 47.4 tp -62.15 -44.34 96.83 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 116.434 2.013 . . . . 0.0 116.434 -175.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -29.49 -38.51 0.02 OUTLIER Glycine 0 CA--C 1.549 2.187 0 N-CA-C 115.857 1.103 . . . . 0.0 115.857 -173.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -66.1 -39.36 89.92 Favored 'General case' 0 CA--C 1.548 0.868 0 N-CA-C 115.607 1.706 . . . . 0.0 115.607 -174.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . -62.29 -32.64 83.47 Favored Glycine 0 N--CA 1.481 1.683 0 N-CA-C 117.047 1.579 . . . . 0.0 117.047 -174.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' THR . . . . . . . . . . . . . 7.2 p -76.0 -14.01 60.23 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 118.628 1.214 . . . . 0.0 112.941 -177.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 41' ' ' MET . . . . . . . . . . . . . 91.9 mmm -64.92 -41.13 95.81 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 42' ' ' ARG . . . . . 0.509 ' NH1' ' OE2' ' C' ' 23' ' ' GLU . 89.3 mmt-85 -64.83 -42.08 95.23 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 118.989 -1.085 . . . . 0.0 113.634 -174.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 26.3 mm -63.38 -42.66 97.13 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.913 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 44' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -60.52 -36.24 77.92 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.207 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 45' ' ' ARG . . . . . . . . . . . . . 2.0 ttp180 -62.58 -45.78 91.35 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 46' ' ' ASN . . . . . 0.725 ' ND2' ' CD2' ' J' ' 26' ' ' TRP . 33.0 t-20 -76.32 -69.84 0.48 Allowed 'General case' 0 N--CA 1.484 1.247 0 N-CA-C 116.658 2.096 . . . . 0.0 116.658 -175.336 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.09 -40.34 31.62 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 120.401 -0.519 . . . . 0.0 111.591 -174.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 48' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -104.68 114.97 29.53 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.08 -22.01 0.53 Allowed Glycine 0 N--CA 1.482 1.76 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 50' ' ' SER . . . . . . . . . . . . . 36.1 m -99.95 107.21 19.13 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 117.195 0.498 . . . . 0.0 111.314 -179.387 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 51' ' ' MET . . . . . . . . . . . . . 64.8 mtm -75.2 -34.49 61.5 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.838 177.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -52.39 107.06 0.44 Allowed Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 -178.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.02 -33.45 87.29 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.43 -171.07 47.32 Favored Glycine 0 N--CA 1.46 0.281 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 55' ' ' SER . . . . . . . . . . . . . 87.9 p -75.33 163.24 27.67 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.079 0.466 . . . . 0.0 111.631 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 56' ' ' LEU . . . . . . . . . . . . . 54.1 tp -88.03 130.55 34.95 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.626 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 39.3 ttt180 -63.61 132.4 51.05 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.13 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.89 16.05 76.0 Favored Glycine 0 CA--C 1.536 1.387 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 78.4 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.424 179.789 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.148 0 CA-C-O 124.162 1.934 . . . . 0.0 109.191 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 2' ' ' SER . . . . . . . . . . . . . 7.2 m -52.12 136.22 30.15 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 114.403 -1.272 . . . . 0.0 109.915 179.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.36 164.2 13.49 Favored Glycine 0 N--CA 1.438 -1.221 0 CA-C-N 115.098 -0.956 . . . . 0.0 110.894 -179.146 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.07 16.35 80.8 Favored Glycine 0 CA--C 1.532 1.107 0 C-N-CA 121.445 -0.407 . . . . 0.0 113.595 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.69 69.33 2.24 Favored Glycine 0 N--CA 1.473 1.162 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.101 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 6' ' ' VAL . . . . . . . . . . . . . 18.6 m -103.12 -6.16 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 7' ' ' PHE . . . . . 0.567 ' O ' ' N ' ' C' ' 9' ' ' ASP . 0.8 OUTLIER -71.63 -98.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 CA-C-O 117.058 -1.448 . . . . 0.0 109.278 -179.899 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 8' ' ' THR . . . . . . . . . . . . . 31.8 m -7.15 -49.63 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 116.067 1.877 . . . . 0.0 116.067 -179.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 9' ' ' ASP . . . . . 0.567 ' N ' ' O ' ' C' ' 7' ' ' PHE . 14.7 t70 -61.69 -27.05 68.42 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 117.872 0.305 . . . . 0.0 111.611 -179.238 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 10' ' ' ILE . . . . . . . . . . . . . 21.4 mt -65.12 -43.66 95.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 O-C-N 120.663 -1.273 . . . . 0.0 108.457 179.151 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 11' ' ' LEU . . . . . 0.437 ' O ' ' O ' ' C' ' 13' ' ' ALA . 41.3 tp -61.01 -40.03 92.0 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.473 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.4 -39.86 88.86 Favored 'General case' 0 C--O 1.234 0.238 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 177.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 13' ' ' ALA . . . . . 0.508 ' O ' ' N ' ' C' ' 15' ' ' GLY . . . -79.71 -158.78 0.18 Allowed 'General case' 0 C--O 1.175 -2.862 0 N-CA-C 101.643 -3.466 . . . . 0.0 101.643 174.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 14' ' ' ALA . . . . . . . . . . . . . . . 60.2 -38.85 0.09 Allowed 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 122.067 2.212 . . . . 0.0 113.135 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 15' ' ' GLY . . . . . 0.508 ' N ' ' O ' ' C' ' 13' ' ' ALA . . . -95.6 -48.01 2.42 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 106.314 -2.714 . . . . 0.0 106.314 178.202 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 16' ' ' ARG . . . . . . . . . . . . . 76.6 ttt-85 -65.35 -43.57 90.45 Favored 'General case' 0 C--N 1.353 0.752 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 76.6 mt -63.77 -42.95 97.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.657 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 18' ' ' PHE . . . . . 0.45 ' O ' HG12 ' C' ' 22' ' ' VAL . 6.6 t80 -56.79 -19.0 14.79 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.911 -0.715 . . . . 0.0 111.721 -177.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 19' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -65.66 -36.9 85.0 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-O 121.479 0.657 . . . . 0.0 110.655 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 20' ' ' VAL . . . . . . . . . . . . . 91.2 t -66.41 -47.78 82.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 C-N-CA 119.918 -0.713 . . . . 0.0 110.891 -178.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 21' ' ' MET . . . . . . . . . . . . . 97.0 mmm -66.64 -45.63 78.4 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 -177.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 22' ' ' VAL . . . . . 0.451 HG13 ' N ' ' C' ' 23' ' ' GLU . 14.7 p -67.08 -37.56 79.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.886 -178.765 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 23' ' ' GLU . . . . . 0.509 ' OE2' ' NH1' ' B' ' 42' ' ' ARG . 88.8 tt0 -61.78 -44.7 96.35 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 -178.108 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 24' ' ' GLY . . . . . . . . . . . . . . . -92.67 22.97 30.6 Favored Glycine 0 CA--C 1.547 2.048 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 25' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -107.92 -9.86 15.63 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 112.635 0.606 . . . . 0.0 112.635 -178.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 26' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -99.99 -36.21 9.45 Favored 'General case' 0 CA--C 1.56 1.338 0 N-CA-C 114.01 1.115 . . . . 0.0 114.01 -178.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 27' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -49.41 -24.5 2.0 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 114.296 1.221 . . . . 0.0 114.296 -176.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 28' ' ' THR . . . . . . . . . . . . . 98.9 m -62.24 -42.8 99.64 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 -178.268 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 88.1 t -60.83 -45.53 97.87 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 N-CA-C 115.61 1.707 . . . . 0.0 115.61 -175.023 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . -23.12 -69.08 0.02 OUTLIER Glycine 0 CA--C 1.55 2.275 0 N-CA-C 116.197 1.239 . . . . 0.0 116.197 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 31' ' ' MET . . . . . . . . . . . . . 39.6 mtp -65.4 -36.49 84.12 Favored 'General case' 0 N--CA 1.485 1.317 0 N-CA-C 115.073 1.509 . . . . 0.0 115.073 -176.364 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -33.35 -77.15 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -175.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 33' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -61.83 -47.48 84.9 Favored 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 118.9 -1.12 . . . . 0.0 113.74 -176.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 34' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -46.73 -73.7 0.04 OUTLIER 'General case' 0 CA--C 1.561 1.379 0 N-CA-C 116.199 1.925 . . . . 0.0 116.199 -177.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 35' ' ' SER . . . . . . . . . . . . . 2.7 t -30.44 -33.78 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 117.202 2.297 . . . . 0.0 117.202 -174.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 43.8 tp -63.12 -42.21 99.49 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 115.269 1.581 . . . . 0.0 115.269 -176.358 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -29.26 -43.36 0.05 OUTLIER Glycine 0 CA--C 1.545 1.925 0 N-CA-C 115.946 1.139 . . . . 0.0 115.946 -175.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 32.1 mttm -65.65 -40.53 92.56 Favored 'General case' 0 CA--C 1.559 1.306 0 N-CA-C 115.087 1.514 . . . . 0.0 115.087 -174.366 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . -58.68 -40.53 94.92 Favored Glycine 0 N--CA 1.484 1.889 0 N-CA-C 117.603 1.801 . . . . 0.0 117.603 -173.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 40' ' ' THR . . . . . . . . . . . . . 25.3 p -71.28 -15.58 62.43 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 118.481 1.14 . . . . 0.0 112.548 -176.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 41' ' ' MET . . . . . . . . . . . . . 81.9 mmm -63.32 -39.84 95.68 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 115.923 1.823 . . . . 0.0 115.923 -174.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 42' ' ' ARG . . . . . . . . . . . . . 89.1 mmt-85 -63.28 -41.66 99.02 Favored 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 119.617 -0.833 . . . . 0.0 113.131 -175.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 21.3 mm -63.11 -43.85 99.15 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 44' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -63.61 -26.07 68.52 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.622 -178.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 45' ' ' ARG . . . . . 0.709 ' NH1' HH12 ' H' ' 45' ' ' ARG . 1.0 OUTLIER -70.27 -44.19 68.93 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 118.701 -1.2 . . . . 0.0 112.76 179.945 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 46' ' ' ASN . . . . . 0.711 ' ND2' ' CD2' ' G' ' 26' ' ' TRP . 52.4 t30 -75.42 -77.23 0.13 Allowed 'General case' 0 N--CA 1.466 0.359 0 N-CA-C 115.817 1.784 . . . . 0.0 115.817 -173.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 47' ' ' ALA . . . . . . . . . . . . . . . -43.01 -45.86 5.29 Favored 'General case' 0 CA--C 1.518 -0.261 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.889 -176.109 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 48' ' ' TYR . . . . . . . . . . . . . 69.4 m-85 -96.21 131.48 42.64 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.645 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 49' ' ' GLY . . . . . . . . . . . . . . . -152.44 -25.45 0.05 OUTLIER Glycine 0 N--CA 1.466 0.697 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 -178.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 50' ' ' SER . . . . . . . . . . . . . 58.6 m -103.1 97.99 8.0 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 51' ' ' MET . . . . . . . . . . . . . 67.2 mtm -65.42 -38.02 88.67 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 108.733 -0.839 . . . . 0.0 108.733 176.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . -46.79 107.76 0.23 Allowed Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.89 -33.91 88.49 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.71 -173.55 49.35 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 55' ' ' SER . . . . . . . . . . . . . 93.2 p -74.04 163.24 28.14 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.896 0.379 . . . . 0.0 110.681 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 56' ' ' LEU . . . . . . . . . . . . . 50.3 tp -87.37 133.15 33.76 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.177 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 57' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -67.49 132.3 47.33 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.147 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 58' ' ' GLY . . . . . . . . . . . . . . . 83.78 15.09 71.29 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 59' ' ' SER . . . . . . . . . . . . . 71.9 p . . . . . 0 C--N 1.325 -0.49 0 CA-C-O 117.942 -1.027 . . . . 0.0 110.718 -179.954 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 1' ' ' MET . . . . . . . . . . . . . 7.2 ttp . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 2' ' ' SER . . . . . . . . . . . . . 6.1 m -46.67 138.67 5.85 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.662 178.405 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.41 163.28 8.08 Favored Glycine 0 CA--C 1.535 1.288 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 -178.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 4' ' ' GLY . . . . . . . . . . . . . . . 78.37 15.71 80.55 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 121.006 -0.616 . . . . 0.0 113.522 178.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.46 74.7 1.92 Allowed Glycine 0 N--CA 1.473 1.155 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 6' ' ' VAL . . . . . . . . . . . . . 26.8 m -111.13 2.38 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.287 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 7' ' ' PHE . . . . . 0.445 ' O ' ' N ' ' D' ' 9' ' ' ASP . 7.0 m-85 -79.69 -82.2 0.11 Allowed 'General case' 0 C--O 1.21 -0.984 0 CA-C-N 118.664 0.666 . . . . 0.0 111.38 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 8' ' ' THR . . . . . . . . . . . . . 87.8 m -25.65 -40.47 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 9' ' ' ASP . . . . . 0.445 ' N ' ' O ' ' D' ' 7' ' ' PHE . 25.5 t70 -64.35 -32.33 73.9 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -179.121 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 10' ' ' ILE . . . . . 0.48 ' O ' ' N ' ' D' ' 14' ' ' ALA . 38.1 mt -62.45 -43.4 98.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 O-C-N 121.548 -0.72 . . . . 0.0 109.539 -178.597 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 11' ' ' LEU . . . . . . . . . . . . . 40.5 tp -59.84 -40.94 90.22 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 12' ' ' ALA . . . . . . . . . . . . . . . -62.35 -35.5 79.31 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 176.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 13' ' ' ALA . . . . . . . . . . . . . . . -90.9 -5.78 55.03 Favored 'General case' 0 C--O 1.199 -1.583 0 N-CA-C 114.847 1.425 . . . . 0.0 114.847 -178.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 14' ' ' ALA . . . . . 0.48 ' N ' ' O ' ' D' ' 10' ' ' ILE . . . -94.45 -12.9 26.84 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.055 -1.653 . . . . 0.0 107.727 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 15' ' ' GLY . . . . . . . . . . . . . . . -100.28 -48.9 1.5 Allowed Glycine 0 CA--C 1.525 0.68 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 16' ' ' ARG . . . . . . . . . . . . . 77.1 ttt-85 -63.71 -43.33 96.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.267 -0.467 . . . . 0.0 110.933 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 17' ' ' ILE . . . . . . . . . . . . . 17.9 mt -64.11 -42.98 97.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.229 -177.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 18' ' ' PHE . . . . . 0.471 ' O ' HG12 ' D' ' 22' ' ' VAL . 9.0 t80 -55.92 -19.34 11.74 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.162 -178.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 19' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -66.33 -36.86 83.99 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.001 0.429 . . . . 0.0 111.036 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 20' ' ' VAL . . . . . . . . . . . . . 96.8 t -66.66 -49.34 75.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-O 120.916 0.389 . . . . 0.0 111.99 -178.209 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 21' ' ' MET . . . . . . . . . . . . . 94.8 mmm -65.13 -43.89 90.45 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 22' ' ' VAL . . . . . 0.471 HG12 ' O ' ' D' ' 18' ' ' PHE . 12.9 p -68.94 -33.85 61.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.201 -177.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 23' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -65.43 -40.33 93.16 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 111.972 0.36 . . . . 0.0 111.972 -178.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 24' ' ' GLY . . . . . . . . . . . . . . . -96.41 21.5 45.19 Favored Glycine 0 CA--C 1.539 1.561 0 N-CA-C 111.946 -0.462 . . . . 0.0 111.946 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 25' ' ' HIS . . . . . . . . . . . . . 4.4 t-80 -103.57 -6.41 21.73 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.082 0.553 . . . . 0.0 111.526 -178.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 26' ' ' TRP . . . . . . . . . . . . . 98.5 m95 -105.44 -35.22 7.56 Favored 'General case' 0 N--CA 1.485 1.306 0 N-CA-C 114.163 1.171 . . . . 0.0 114.163 -178.168 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 27' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -51.26 -25.4 5.61 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 114.014 1.116 . . . . 0.0 114.014 -176.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 28' ' ' THR . . . . . . . . . . . . . 31.8 m -61.17 -43.35 99.02 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.349 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 29' ' ' VAL . . . . . 0.662 HG21 HBC1 ' D' ' 101' ' ' BCL . 92.1 t -62.14 -46.02 97.41 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.821 0 N-CA-C 115.653 1.723 . . . . 0.0 115.653 -174.276 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 30' ' ' GLY . . . . . . . . . . . . . . . -22.34 -70.08 0.01 OUTLIER Glycine 0 CA--C 1.54 1.652 0 N-CA-C 115.736 1.054 . . . . 0.0 115.736 -177.013 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 31' ' ' MET . . . . . . . . . . . . . 85.2 mtp -65.98 -36.64 83.86 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 115.058 1.503 . . . . 0.0 115.058 -176.094 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -30.0 -77.41 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -176.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 33' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -61.73 -46.26 90.4 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.771 -0.771 . . . . 0.0 113.011 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 34' ' ' ASP . . . . . 0.498 ' O ' ' N ' ' D' ' 36' ' ' LEU . 31.9 t70 -49.3 -82.04 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.176 0 N-CA-C 116.676 2.102 . . . . 0.0 116.676 -177.337 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 35' ' ' SER . . . . . 0.417 ' OG ' ' HB1' ' F' ' 12' ' ' ALA . 8.2 t -22.23 -36.31 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 -176.04 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 36' ' ' LEU . . . . . 0.498 ' N ' ' O ' ' D' ' 34' ' ' ASP . 43.0 tp -61.01 -42.33 98.25 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.141 1.163 . . . . 0.0 114.141 -176.126 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -27.34 -44.54 0.03 OUTLIER Glycine 0 CA--C 1.552 2.366 0 N-CA-C 115.959 1.143 . . . . 0.0 115.959 -176.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 38' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -65.02 -41.48 95.26 Favored 'General case' 0 CA--C 1.557 1.249 0 N-CA-C 115.69 1.737 . . . . 0.0 115.69 -175.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 39' ' ' GLY . . . . . . . . . . . . . . . -56.19 -41.19 85.9 Favored Glycine 0 N--CA 1.479 1.551 0 N-CA-C 117.09 1.596 . . . . 0.0 117.09 -173.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 40' ' ' THR . . . . . . . . . . . . . 35.7 p -70.46 -16.37 62.92 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 114.037 1.125 . . . . 0.0 114.037 -176.119 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 41' ' ' MET . . . . . . . . . . . . . 65.8 mmm -63.79 -40.08 95.81 Favored 'General case' 0 CA--C 1.55 0.976 0 N-CA-C 116.42 2.007 . . . . 0.0 116.42 -174.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 42' ' ' ARG . . . . . . . . . . . . . 88.6 mmt-85 -62.94 -42.06 99.69 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 119.131 -1.028 . . . . 0.0 113.102 -175.282 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 20.2 mm -61.05 -43.19 95.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 44' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -64.85 -27.99 69.25 Favored 'General case' 0 CA--C 1.561 1.398 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.914 -178.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 45' ' ' ARG . . . . . 0.874 HH12 HH12 ' E' ' 45' ' ' ARG . 0.8 OUTLIER -71.11 -39.26 72.19 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 119.118 0.872 . . . . 0.0 112.275 179.75 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 46' ' ' ASN . . . . . 0.692 ' ND2' ' CE3' ' F' ' 26' ' ' TRP . 45.2 t30 -80.16 -74.04 0.33 Allowed 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -172.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 47' ' ' ALA . . . . . . . . . . . . . . . -48.77 -41.39 32.26 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.064 -175.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 48' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -97.47 135.53 39.2 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 178.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 49' ' ' GLY . . . . . . . . . . . . . . . -156.97 -26.59 0.03 OUTLIER Glycine 0 N--CA 1.465 0.571 0 N-CA-C 111.673 -0.571 . . . . 0.0 111.673 -178.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 50' ' ' SER . . . . . . . . . . . . . 58.5 m -102.71 95.76 6.42 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -178.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 51' ' ' MET . . . . . . . . . . . . . 67.9 mtm -63.62 -38.96 93.1 Favored 'General case' 0 CA--C 1.533 0.31 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 177.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . -43.49 107.23 0.11 Allowed Glycine 0 CA--C 1.531 1.049 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.981 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.27 -34.49 90.05 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.29 -173.42 51.73 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 55' ' ' SER . . . . . . . . . . . . . 87.4 p -75.36 163.65 27.23 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.912 0.387 . . . . 0.0 111.655 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 56' ' ' LEU . . . . . 0.406 ' O ' ' OXT' ' D' ' 59' ' ' SER . 50.5 tp -87.75 130.55 34.8 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.901 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 57' ' ' ARG . . . . . . . . . . . . . 65.0 ttt180 -66.58 134.07 51.61 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.817 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.08 14.51 76.89 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.871 -0.891 . . . . 0.0 110.871 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 59' ' ' SER . . . . . 0.406 ' OXT' ' O ' ' D' ' 56' ' ' LEU . 71.8 p . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.865 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 1' ' ' MET . . . . . . . . . . . . . 67.1 ttp . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 2' ' ' SER . . . . . . . . . . . . . 6.6 m -48.99 137.34 13.1 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.131 0.491 . . . . 0.0 110.164 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.08 165.95 16.4 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.78 14.92 82.05 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.804 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.65 75.3 1.66 Allowed Glycine 0 N--CA 1.475 1.27 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 6' ' ' VAL . . . . . . . . . . . . . 17.9 m -112.27 1.87 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 113.337 0.866 . . . . 0.0 113.337 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 7' ' ' PHE . . . . . 0.464 ' O ' ' N ' ' E' ' 9' ' ' ASP . 7.8 m-85 -79.03 -83.08 0.09 Allowed 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.783 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 8' ' ' THR . . . . . . . . . . . . . 97.8 m -23.52 -42.23 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.842 1.053 . . . . 0.0 113.842 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 9' ' ' ASP . . . . . 0.464 ' N ' ' O ' ' E' ' 7' ' ' PHE . 25.7 t70 -62.74 -39.32 93.72 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 113.308 0.855 . . . . 0.0 113.308 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 10' ' ' ILE . . . . . 0.416 ' N ' ' O ' ' E' ' 7' ' ' PHE . 57.3 mt -53.77 -42.79 53.62 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.837 0 O-C-N 121.871 -0.518 . . . . 0.0 110.239 -178.423 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 11' ' ' LEU . . . . . . . . . . . . . 40.5 tp -61.08 -41.2 96.19 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 119.843 -0.743 . . . . 0.0 110.332 178.116 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.87 -38.35 87.94 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 13' ' ' ALA . . . . . 0.405 ' O ' ' CG1' ' E' ' 17' ' ' ILE . . . -74.85 -41.8 59.18 Favored 'General case' 0 CA--C 1.553 1.084 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.09 -23.09 66.3 Favored 'General case' 0 CA--C 1.512 -0.499 0 O-C-N 121.354 -0.841 . . . . 0.0 110.699 -178.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 15' ' ' GLY . . . . . . . . . . . . . . . -90.18 -45.82 4.31 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 16' ' ' ARG . . . . . . . . . . . . . 77.2 ttt-85 -69.64 -42.92 73.65 Favored 'General case' 0 CA--C 1.542 0.669 0 CA-C-N 115.465 -0.368 . . . . 0.0 111.561 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 17' ' ' ILE . . . . . 0.405 ' CG1' ' O ' ' E' ' 13' ' ' ALA . 1.1 mm -62.3 -44.38 99.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 CA-C-O 120.975 0.417 . . . . 0.0 111.432 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 18' ' ' PHE . . . . . 0.493 ' O ' HG12 ' E' ' 22' ' ' VAL . 14.9 t80 -57.97 -19.11 28.14 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.333 -178.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 19' ' ' GLU . . . . . . . . . . . . . 89.8 mt-10 -65.77 -37.04 85.25 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.216 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 20' ' ' VAL . . . . . . . . . . . . . 95.6 t -66.96 -48.47 79.41 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.8 -178.491 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 21' ' ' MET . . . . . . . . . . . . . 94.9 mmm -64.93 -43.16 93.67 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 22' ' ' VAL . . . . . 0.493 HG12 ' O ' ' E' ' 18' ' ' PHE . 12.0 p -70.35 -30.67 44.05 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -177.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 23' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -68.05 -41.28 82.28 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.14 0.793 . . . . 0.0 113.14 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 24' ' ' GLY . . . . . . . . . . . . . . . -95.66 16.94 60.23 Favored Glycine 0 N--CA 1.479 1.511 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 25' ' ' HIS . . . . . 0.416 ' O ' ' CG ' ' E' ' 25' ' ' HIS . 6.5 t-80 -97.3 -3.95 39.59 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 123.309 0.644 . . . . 0.0 111.827 -178.786 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 26' ' ' TRP . . . . . . . . . . . . . 98.4 m95 -107.69 -39.34 5.62 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 113.591 0.96 . . . . 0.0 113.591 -177.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 27' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -45.48 -30.15 1.33 Allowed 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -177.087 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 28' ' ' THR . . . . . . . . . . . . . 71.7 m -61.67 -43.05 99.6 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 113.78 1.03 . . . . 0.0 113.78 -177.629 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 29' ' ' VAL . . . . . 0.607 HG21 HBC1 ' E' ' 101' ' ' BCL . 86.0 t -60.78 -45.48 97.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -175.216 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 30' ' ' GLY . . . . . . . . . . . . . . . -25.05 -70.33 0.03 OUTLIER Glycine 0 CA--C 1.543 1.819 0 N-CA-C 115.87 1.108 . . . . 0.0 115.87 -176.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 31' ' ' MET . . . . . . . . . . . . . 95.3 mtp -65.67 -36.83 84.78 Favored 'General case' 0 CA--C 1.544 0.716 0 N-CA-C 115.062 1.504 . . . . 0.0 115.062 -176.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -29.86 -75.9 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -177.595 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 33' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -62.59 -46.57 87.69 Favored 'General case' 0 CA--C 1.552 1.027 0 N-CA-C 113.991 1.108 . . . . 0.0 113.991 -178.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 34' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -58.72 -53.26 60.37 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 117.729 2.492 . . . . 0.0 117.729 -174.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 35' ' ' SER . . . . . . . . . . . . . 33.8 t -45.2 -43.09 9.88 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 114.936 1.458 . . . . 0.0 114.936 -174.596 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 36' ' ' LEU . . . . . 0.524 ' O ' ' N ' ' E' ' 38' ' ' LYS . 38.2 tp -48.63 -54.78 13.33 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 114.921 1.452 . . . . 0.0 114.921 -177.585 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -10.59 -49.98 0.01 OUTLIER Glycine 0 CA--C 1.551 2.291 0 N-CA-C 116.616 1.406 . . . . 0.0 116.616 -177.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 38' ' ' LYS . . . . . 0.524 ' N ' ' O ' ' E' ' 36' ' ' LEU . 62.6 mttm -64.12 -42.62 96.77 Favored 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 116.063 1.875 . . . . 0.0 116.063 -175.074 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 39' ' ' GLY . . . . . . . . . . . . . . . -56.86 -30.75 60.34 Favored Glycine 0 N--CA 1.484 1.895 0 N-CA-C 116.741 1.457 . . . . 0.0 116.741 -174.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 40' ' ' THR . . . . . . . . . . . . . 29.9 p -79.85 -15.21 57.83 Favored 'General case' 0 CA--C 1.55 0.971 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -176.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 41' ' ' MET . . . . . . . . . . . . . 69.3 mmm -64.59 -39.49 93.82 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 114.996 1.48 . . . . 0.0 114.996 -176.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 42' ' ' ARG . . . . . . . . . . . . . 87.7 mmt-85 -63.98 -35.09 79.56 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 43' ' ' ILE . . . . . . . . . . . . . 18.2 mm -71.98 -29.38 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 44' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -73.62 -29.68 62.51 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 113.934 -1.485 . . . . 0.0 112.009 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 45' ' ' ARG . . . . . 0.874 HH12 HH12 ' D' ' 45' ' ' ARG . 13.1 ttm-85 -78.89 -18.27 54.18 Favored 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -177.509 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 46' ' ' ASN . . . . . 0.569 ' OD1' ' CE3' ' A' ' 26' ' ' TRP . 26.0 t-20 -95.76 -87.6 0.28 Allowed 'General case' 0 N--CA 1.473 0.711 0 O-C-N 121.112 -0.992 . . . . 0.0 112.013 -177.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 47' ' ' ALA . . . . . . . . . . . . . . . -36.69 -36.31 0.11 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.638 -177.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 48' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -104.71 138.68 40.65 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 49' ' ' GLY . . . . . . . . . . . . . . . -164.19 -24.18 0.02 OUTLIER Glycine 0 N--CA 1.468 0.826 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.353 -178.414 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 50' ' ' SER . . . . . . . . . . . . . 53.7 m -103.15 93.61 5.09 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 122.366 -0.49 . . . . 0.0 111.943 -178.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 51' ' ' MET . . . . . . . . . . . . . 68.9 mtm -63.51 -40.39 96.93 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.997 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 52' ' ' GLY . . . . . . . . . . . . . . . -44.44 109.72 0.3 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.434 -0.666 . . . . 0.0 111.434 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.3 -34.19 89.24 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 110.356 -1.097 . . . . 0.0 110.356 178.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 54' ' ' GLY . . . . . . . . . . . . . . . 85.08 -174.35 49.32 Favored Glycine 0 CA--C 1.529 0.967 0 N-CA-C 112.077 -0.409 . . . . 0.0 112.077 179.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 55' ' ' SER . . . . . . . . . . . . . 85.8 p -73.19 159.56 33.29 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 120.86 0.362 . . . . 0.0 110.665 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 56' ' ' LEU . . . . . 0.404 ' O ' ' OXT' ' E' ' 59' ' ' SER . 51.4 tp -84.99 131.4 34.48 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.622 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 57' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -66.81 135.19 53.56 Favored 'General case' 0 CA--C 1.508 -0.651 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.48 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.28 16.31 76.56 Favored Glycine 0 CA--C 1.532 1.122 0 CA-C-N 115.184 -0.917 . . . . 0.0 110.824 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 59' ' ' SER . . . . . 0.404 ' OXT' ' O ' ' E' ' 56' ' ' LEU . 65.9 p . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.735 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 1' ' ' MET . . . . . . . . . . . . . 61.5 ttp . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 2' ' ' SER . . . . . . . . . . . . . 6.6 m -53.16 134.71 38.77 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 121.45 -0.781 . . . . 0.0 110.287 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . 76.09 166.98 23.17 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 4' ' ' GLY . . . . . . . . . . . . . . . 78.01 13.89 82.89 Favored Glycine 0 CA--C 1.531 1.075 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 179.319 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 5' ' ' GLY . . . . . . . . . . . . . . . -87.64 72.44 2.49 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 179.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 6' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' F' ' 7' ' ' PHE . 16.8 m -110.42 -6.99 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 112.52 0.563 . . . . 0.0 112.52 -179.177 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 7' ' ' PHE . . . . . 0.658 ' O ' ' N ' ' F' ' 9' ' ' ASP . 2.3 m-85 -71.68 -121.24 0.0 OUTLIER 'General case' 0 C--O 1.188 -2.162 0 N-CA-C 103.044 -2.946 . . . . 0.0 103.044 174.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 8' ' ' THR . . . . . 0.422 ' O ' ' O ' ' F' ' 9' ' ' ASP . 60.2 m 22.51 -58.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 125.822 1.649 . . . . 0.0 115.327 176.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 9' ' ' ASP . . . . . 0.658 ' N ' ' O ' ' F' ' 7' ' ' PHE . 19.7 t70 -50.8 -86.7 0.0 OUTLIER 'General case' 0 C--O 1.153 -3.999 0 CA-C-O 116.24 -1.838 . . . . 0.0 107.862 174.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 10' ' ' ILE . . . . . 0.485 ' O ' ' N ' ' F' ' 13' ' ' ALA . 58.0 mt 0.01 -64.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.531 0 CA-C-N 120.028 1.286 . . . . 0.0 113.453 177.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 11' ' ' LEU . . . . . 0.493 ' N ' ' O ' ' F' ' 9' ' ' ASP . 27.2 tp -48.81 -43.18 38.07 Favored 'General case' 0 N--CA 1.478 0.94 0 O-C-N 122.086 -0.384 . . . . 0.0 111.058 177.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 12' ' ' ALA . . . . . 0.489 ' N ' ' O ' ' F' ' 9' ' ' ASP . . . -60.71 -39.98 90.56 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 177.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 13' ' ' ALA . . . . . 0.485 ' N ' ' O ' ' F' ' 10' ' ' ILE . . . -72.66 -46.66 52.82 Favored 'General case' 0 C--O 1.214 -0.791 0 CA-C-N 115.02 -0.991 . . . . 0.0 112.522 179.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.06 -35.25 69.12 Favored 'General case' 0 C--N 1.32 -0.694 0 O-C-N 120.734 -1.229 . . . . 0.0 108.96 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.29 -48.22 19.96 Favored Glycine 0 CA--C 1.533 1.175 0 N-CA-C 111.236 -0.745 . . . . 0.0 111.236 178.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 16' ' ' ARG . . . . . . . . . . . . . 72.2 ttt-85 -70.16 -44.74 68.19 Favored 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 113.45 0.908 . . . . 0.0 113.45 -177.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mm -62.57 -44.14 99.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.268 -177.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 18' ' ' PHE . . . . . 0.519 ' O ' HG12 ' F' ' 22' ' ' VAL . 37.6 t80 -57.9 -18.58 23.81 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.393 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 19' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -67.59 -36.61 81.21 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.188 0.518 . . . . 0.0 110.065 -179.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 20' ' ' VAL . . . . . . . . . . . . . 86.8 t -66.29 -48.51 80.84 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.904 -178.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 21' ' ' MET . . . . . . . . . . . . . 97.8 mmm -65.86 -44.24 86.04 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -178.27 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 22' ' ' VAL . . . . . 0.519 HG12 ' O ' ' F' ' 18' ' ' PHE . 14.2 p -69.78 -27.6 33.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 O-C-N 123.317 0.386 . . . . 0.0 111.438 -178.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 23' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -70.79 -41.44 71.65 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 113.43 0.9 . . . . 0.0 113.43 -177.413 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 24' ' ' GLY . . . . . . . . . . . . . . . -95.27 10.36 69.53 Favored Glycine 0 N--CA 1.479 1.538 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 25' ' ' HIS . . . . . . . . . . . . . 6.4 t-80 -87.1 -8.38 57.08 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 114.794 -0.703 . . . . 0.0 111.579 -178.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 26' ' ' TRP . . . . . 0.692 ' CE3' ' ND2' ' D' ' 46' ' ' ASN . 97.7 m95 -101.74 -60.76 1.48 Allowed 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -176.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 27' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -21.94 -34.92 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 115.073 1.508 . . . . 0.0 115.073 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 28' ' ' THR . . . . . 0.552 ' N ' ' O ' ' F' ' 26' ' ' TRP . 19.3 m -60.51 -44.61 95.84 Favored 'General case' 0 CA--C 1.558 1.277 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.606 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 29' ' ' VAL . . . . . . . . . . . . . 92.9 t -60.66 -45.06 98.13 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 114.219 1.192 . . . . 0.0 114.219 -175.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 30' ' ' GLY . . . . . . . . . . . . . . . -25.88 -69.82 0.04 OUTLIER Glycine 0 CA--C 1.543 1.832 0 N-CA-C 116.144 1.217 . . . . 0.0 116.144 -176.308 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 31' ' ' MET . . . . . . . . . . . . . 94.6 mtp -67.59 -30.81 70.51 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 114.203 1.186 . . . . 0.0 114.203 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 tp -37.91 -67.54 0.19 Allowed 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -176.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 33' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -68.35 -43.84 76.58 Favored 'General case' 0 CA--C 1.556 1.179 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -178.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 34' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -61.31 -44.26 97.5 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 116.924 2.194 . . . . 0.0 116.924 -174.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 35' ' ' SER . . . . . . . . . . . . . 14.5 t -54.57 -44.44 72.94 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 114.652 1.352 . . . . 0.0 114.652 -174.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 36' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' F' ' 38' ' ' LYS . 30.9 tp -44.45 -65.76 0.48 Allowed 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 114.604 1.335 . . . . 0.0 114.604 -178.788 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 2.77 -58.19 0.0 OUTLIER Glycine 0 CA--C 1.549 2.214 0 N-CA-C 117.17 1.628 . . . . 0.0 117.17 -178.541 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 38' ' ' LYS . . . . . 0.545 ' N ' ' O ' ' F' ' 36' ' ' LEU . 65.4 mttm -61.13 -41.68 97.17 Favored 'General case' 0 CA--C 1.554 1.121 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -174.344 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 39' ' ' GLY . . . . . . . . . . . . . . . -56.95 -22.97 44.05 Favored Glycine 0 CA--C 1.542 1.78 0 N-CA-C 117.154 1.622 . . . . 0.0 117.154 -175.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 40' ' ' THR . . . . . . . . . . . . . 6.2 p -87.96 -13.43 41.79 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 119.272 1.536 . . . . 0.0 112.27 -177.389 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 41' ' ' MET . . . . . . . . . . . . . 53.9 mmm -65.68 -37.51 86.69 Favored 'General case' 0 CA--C 1.554 1.105 0 N-CA-C 115.386 1.624 . . . . 0.0 115.386 -177.112 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 42' ' ' ARG . . . . . . . . . . . . . 88.8 mmt-85 -65.49 -31.49 72.58 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 -175.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 43' ' ' ILE . . . . . . . . . . . . . 31.3 mm -76.0 -35.02 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 44' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -64.47 -39.49 93.91 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-N 113.9 -1.5 . . . . 0.0 112.124 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 45' ' ' ARG . . . . . . . . . . . . . 8.8 ttm-85 -70.36 -18.59 63.07 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 114.164 1.172 . . . . 0.0 114.164 -177.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 46' ' ' ASN . . . . . 0.558 ' O ' ' N ' ' F' ' 48' ' ' TYR . 17.3 t-20 -93.36 -100.02 0.14 Allowed 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 118.724 0.693 . . . . 0.0 109.954 -178.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 47' ' ' ALA . . . . . . . . . . . . . . . -22.63 -37.02 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 -179.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 48' ' ' TYR . . . . . 0.558 ' N ' ' O ' ' F' ' 46' ' ' ASN . 78.4 m-85 -107.28 143.78 35.03 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.198 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.28 -20.81 0.02 OUTLIER Glycine 0 CA--C 1.526 0.738 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.958 -178.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 50' ' ' SER . . . . . . . . . . . . . 53.4 m -105.42 91.39 3.75 Favored 'General case' 0 N--CA 1.48 1.032 0 O-C-N 122.306 -0.526 . . . . 0.0 111.402 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 51' ' ' MET . . . . . . . . . . . . . 68.8 mtm -63.11 -39.82 95.82 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.149 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 52' ' ' GLY . . . . . . . . . . . . . . . -41.67 111.28 0.28 Allowed Glycine 0 CA--C 1.531 1.079 0 C-N-CA 121.212 -0.518 . . . . 0.0 111.971 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.15 -35.39 91.92 Favored Glycine 0 CA--C 1.529 0.953 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 178.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.3 -176.71 52.87 Favored Glycine 0 N--CA 1.462 0.379 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -72.52 157.71 37.08 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 56' ' ' LEU . . . . . . . . . . . . . 51.5 tp -84.44 131.23 34.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.042 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 57' ' ' ARG . . . . . . . . . . . . . 42.5 ttt180 -64.83 135.18 55.48 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.936 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.44 17.32 73.88 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 59' ' ' SER . . . . . . . . . . . . . 77.5 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.72 -179.946 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 1' ' ' MET . . . . . 0.501 ' SD ' ' OBD' ' C' ' 101' ' ' BCL . 54.1 ttp . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 2' ' ' SER . . . . . . . . . . . . . 7.1 m -56.59 134.46 54.43 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 120.803 -1.185 . . . . 0.0 109.695 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . 76.24 165.95 21.22 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.55 13.95 80.78 Favored Glycine 0 N--CA 1.461 0.302 0 C-N-CA 121.347 -0.454 . . . . 0.0 113.007 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.5 76.23 1.78 Allowed Glycine 0 CA--C 1.528 0.88 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 6' ' ' VAL . . . . . . . . . . . . . 16.3 m -116.44 6.93 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 N-CA-C 112.33 0.493 . . . . 0.0 112.33 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 7' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -86.37 -63.0 1.39 Allowed 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 8' ' ' THR . . . . . 0.473 ' O ' ' O ' ' G' ' 9' ' ' ASP . 89.7 m -38.61 -38.23 0.38 Allowed 'General case' 0 CA--C 1.505 -0.764 0 CA-C-N 114.529 -1.214 . . . . 0.0 112.658 -178.525 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 9' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' G' ' 11' ' ' LEU . 25.1 t70 -67.25 -115.68 0.0 OUTLIER 'General case' 0 C--O 1.168 -3.228 0 N-CA-C 103.732 -2.692 . . . . 0.0 103.732 176.472 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 10' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' G' ' 13' ' ' ALA . 43.7 mt 34.66 -70.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 CA-C-N 121.156 1.798 . . . . 0.0 112.505 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 11' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' G' ' 9' ' ' ASP . 38.1 tp -49.82 -42.24 46.67 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 119.629 1.104 . . . . 0.0 110.386 175.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.74 -37.79 85.52 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.232 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 13' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' G' ' 10' ' ' ILE . . . -73.73 -50.58 20.04 Favored 'General case' 0 C--O 1.205 -1.284 0 CA-C-N 115.12 -0.945 . . . . 0.0 112.776 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 14' ' ' ALA . . . . . . . . . . . . . . . -55.03 -39.19 68.88 Favored 'General case' 0 C--O 1.22 -0.488 0 O-C-N 120.755 -1.216 . . . . 0.0 108.638 -179.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.6 -44.6 70.83 Favored Glycine 0 CA--C 1.537 1.436 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 178.024 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 16' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -73.95 -49.15 25.94 Favored 'General case' 0 C--O 1.218 -0.577 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -178.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 17' ' ' ILE . . . . . . . . . . . . . 2.1 mm -55.99 -46.15 80.48 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.083 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 18' ' ' PHE . . . . . 0.499 ' O ' HG12 ' G' ' 22' ' ' VAL . 53.5 t80 -55.62 -22.81 24.26 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.907 -177.173 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 19' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -63.97 -36.5 84.18 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.486 0.66 . . . . 0.0 109.946 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 20' ' ' VAL . . . . . . . . . . . . . 86.2 t -66.94 -47.92 81.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 C-N-CA 120.068 -0.653 . . . . 0.0 111.933 -178.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 21' ' ' MET . . . . . . . . . . . . . 87.6 mmm -65.83 -43.95 87.03 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -177.043 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 22' ' ' VAL . . . . . 0.499 HG12 ' O ' ' G' ' 18' ' ' PHE . 12.7 p -70.81 -29.15 36.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.727 -0.669 . . . . 0.0 112.373 -177.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 23' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -69.95 -38.43 76.12 Favored 'General case' 0 CA--C 1.539 0.537 0 N-CA-C 112.031 0.382 . . . . 0.0 112.031 -177.287 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 24' ' ' GLY . . . . . . . . . . . . . . . -95.38 2.73 65.54 Favored Glycine 0 N--CA 1.473 1.155 0 N-CA-C 111.141 -0.783 . . . . 0.0 111.141 -179.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 25' ' ' HIS . . . . . . . . . . . . . 17.7 t-80 -75.23 -27.72 59.61 Favored 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 123.227 0.611 . . . . 0.0 110.538 179.573 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 26' ' ' TRP . . . . . 0.711 ' CD2' ' ND2' ' C' ' 46' ' ' ASN . 97.4 m95 -80.6 -120.85 0.02 OUTLIER 'General case' 0 C--O 1.194 -1.819 0 CA-C-O 115.867 -2.016 . . . . 0.0 106.63 178.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 27' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 45.1 -52.37 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.349 0 N-CA-C 116.646 2.091 . . . . 0.0 116.646 177.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 28' ' ' THR . . . . . 0.567 ' N ' ' O ' ' G' ' 26' ' ' TRP . 19.9 m -57.14 -42.89 81.82 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -178.593 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 29' ' ' VAL . . . . . . . . . . . . . 92.1 t -60.6 -45.11 97.84 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -176.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 30' ' ' GLY . . . . . . . . . . . . . . . -27.04 -69.37 0.05 OUTLIER Glycine 0 CA--C 1.542 1.78 0 N-CA-C 115.702 1.041 . . . . 0.0 115.702 -176.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 31' ' ' MET . . . . . . . . . . . . . 99.0 mtp -74.83 -7.95 54.97 Favored 'General case' 0 CA--C 1.55 0.947 0 N-CA-C 115.48 1.659 . . . . 0.0 115.48 -176.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 32' ' ' LEU . . . . . . . . . . . . . 17.9 tp -59.95 -50.87 72.04 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 119.663 1.12 . . . . 0.0 113.306 -177.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 33' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -80.72 -41.6 23.34 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 179.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 34' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -63.65 -38.69 92.06 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 116.766 2.136 . . . . 0.0 116.766 -175.192 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 35' ' ' SER . . . . . . . . . . . . . 12.9 t -59.48 -42.5 92.23 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 113.718 1.007 . . . . 0.0 113.718 -175.121 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 36' ' ' LEU . . . . . 0.553 ' O ' ' N ' ' G' ' 38' ' ' LYS . 21.6 tp -44.2 -72.65 0.06 Allowed 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 112.794 0.664 . . . . 0.0 112.794 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 10.51 -61.44 0.0 OUTLIER Glycine 0 CA--C 1.55 2.263 0 N-CA-C 117.259 1.664 . . . . 0.0 117.259 -178.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 38' ' ' LYS . . . . . 0.553 ' N ' ' O ' ' G' ' 36' ' ' LEU . 65.1 mttm -60.51 -41.25 93.96 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -174.575 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 39' ' ' GLY . . . . . . . . . . . . . . . -59.03 -13.98 22.28 Favored Glycine 0 CA--C 1.542 1.729 0 N-CA-C 116.744 1.458 . . . . 0.0 116.744 -175.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 40' ' ' THR . . . . . . . . . . . . . 20.4 p -96.24 -13.68 23.24 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 119.584 1.692 . . . . 0.0 111.835 -178.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 41' ' ' MET . . . . . . . . . . . . . 84.3 mmm -65.77 -37.13 85.48 Favored 'General case' 0 CA--C 1.55 0.972 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 -177.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 42' ' ' ARG . . . . . . . . . . . . . 88.9 mmt-85 -65.36 -31.36 72.43 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 115.141 1.534 . . . . 0.0 115.141 -175.082 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 43' ' ' ILE . . . . . . . . . . . . . 31.0 mm -78.25 -36.15 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 44' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -63.91 -39.97 95.4 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-N 114.541 -1.208 . . . . 0.0 110.633 178.025 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 45' ' ' ARG . . . . . . . . . . . . . 2.8 ttm-85 -61.54 -39.06 89.71 Favored 'General case' 0 N--CA 1.464 0.242 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.799 -177.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 46' ' ' ASN . . . . . 0.455 ' O ' ' N ' ' G' ' 48' ' ' TYR . 12.6 t-20 -86.94 -168.49 2.26 Favored 'General case' 0 C--O 1.196 -1.761 0 N-CA-C 103.761 -2.681 . . . . 0.0 103.761 177.189 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 47' ' ' ALA . . . . . 0.42 ' H ' ' CG ' ' G' ' 46' ' ' ASN . . . 53.05 -39.82 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 114.967 1.469 . . . . 0.0 114.967 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 48' ' ' TYR . . . . . 0.455 ' N ' ' O ' ' G' ' 46' ' ' ASN . 71.5 m-85 -119.68 141.17 49.61 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 49' ' ' GLY . . . . . 0.424 ' H ' ' H ' ' G' ' 50' ' ' SER . . . -171.31 -16.46 0.02 OUTLIER Glycine 0 C--N 1.313 -0.709 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -178.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 50' ' ' SER . . . . . 0.424 ' H ' ' H ' ' G' ' 49' ' ' GLY . 56.4 m -107.01 90.97 3.46 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-O 121.206 0.527 . . . . 0.0 111.492 -179.496 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 51' ' ' MET . . . . . . . . . . . . . 67.8 mtm -63.35 -38.82 92.65 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.757 178.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 52' ' ' GLY . . . . . . . . . . . . . . . -43.12 113.14 0.61 Allowed Glycine 0 CA--C 1.533 1.187 0 CA-C-N 116.386 -0.37 . . . . 0.0 112.44 -178.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.95 -34.52 90.16 Favored Glycine 0 N--CA 1.469 0.875 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 54' ' ' GLY . . . . . . . . . . . . . . . 78.53 -172.77 55.28 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 -179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 55' ' ' SER . . . . . . . . . . . . . 87.0 p -75.58 161.95 28.7 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.916 0.389 . . . . 0.0 111.319 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 56' ' ' LEU . . . . . 0.418 ' O ' ' OXT' ' G' ' 59' ' ' SER . 54.7 tp -89.37 130.34 35.75 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.398 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 57' ' ' ARG . . . . . . . . . . . . . 25.4 ttt85 -64.48 135.62 56.25 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.612 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.13 18.07 75.33 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 59' ' ' SER . . . . . 0.418 ' OXT' ' O ' ' G' ' 56' ' ' LEU . 82.2 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.906 -1.045 . . . . 0.0 111.062 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 1' ' ' MET . . . . . . . . . . . . . 45.0 ttp . . . . . 0 N--CA 1.487 1.406 0 CA-C-O 122.424 1.107 . . . . 0.0 108.222 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 2' ' ' SER . . . . . . . . . . . . . 8.4 m -69.74 134.64 48.84 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 120.024 -1.673 . . . . 0.0 109.054 179.242 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.87 170.67 22.25 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.65 12.78 83.25 Favored Glycine 0 CA--C 1.528 0.85 0 C-N-CA 121.119 -0.562 . . . . 0.0 111.979 178.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.66 76.65 1.55 Allowed Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.503 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 6' ' ' VAL . . . . . . . . . . . . . 16.3 m -120.76 18.23 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.156 0 C-N-CA 122.85 0.46 . . . . 0.0 112.048 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 7' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -97.11 -42.3 7.92 Favored 'General case' 0 N--CA 1.483 1.214 0 CA-C-O 121.681 0.753 . . . . 0.0 110.127 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 8' ' ' THR . . . . . . . . . . . . . 17.5 m -59.04 -43.8 91.7 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.569 -1.196 . . . . 0.0 111.154 -177.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 9' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -63.46 -40.16 96.39 Favored 'General case' 0 CA--C 1.554 1.103 0 N-CA-C 113.722 1.008 . . . . 0.0 113.722 -178.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 10' ' ' ILE . . . . . . . . . . . . . 68.5 mt -48.2 -43.69 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 O-C-N 120.632 -1.293 . . . . 0.0 111.685 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 11' ' ' LEU . . . . . . . . . . . . . 41.1 tp -60.22 -42.05 94.36 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.204 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.75 -39.0 87.09 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.112 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 13' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' H' ' 17' ' ' ILE . . . -71.53 -47.75 53.15 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 112.661 0.615 . . . . 0.0 112.661 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.22 -40.56 86.2 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 -179.379 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.2 -40.59 94.93 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 109.766 -1.333 . . . . 0.0 109.766 177.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 16' ' ' ARG . . . . . . . . . . . . . 72.4 ttt-85 -74.33 -76.95 0.12 Allowed 'General case' 0 C--O 1.212 -0.892 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.166 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 17' ' ' ILE . . . . . 0.403 ' N ' ' O ' ' H' ' 13' ' ' ALA . 1.1 mm -29.18 -48.42 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 113.611 0.967 . . . . 0.0 113.611 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 18' ' ' PHE . . . . . 0.491 ' O ' HG12 ' H' ' 22' ' ' VAL . 56.4 t80 -53.76 -21.17 6.72 Favored 'General case' 0 C--O 1.224 -0.28 0 C-N-CA 120.782 -0.367 . . . . 0.0 111.984 -176.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 19' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -65.97 -38.31 88.22 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.831 0.824 . . . . 0.0 110.028 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 20' ' ' VAL . . . . . . . . . . . . . 98.4 t -66.46 -47.73 82.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.923 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 21' ' ' MET . . . . . . . . . . . . . 89.5 mmm -65.99 -44.26 85.37 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -178.012 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 22' ' ' VAL . . . . . 0.491 HG12 ' O ' ' H' ' 18' ' ' PHE . 12.1 p -70.01 -31.82 49.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -178.152 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 23' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -69.04 -35.48 76.65 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -177.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 24' ' ' GLY . . . . . . . . . . . . . . . -97.41 2.41 60.91 Favored Glycine 0 N--CA 1.478 1.464 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 25' ' ' HIS . . . . . . . . . . . . . 12.4 t-80 -79.67 -20.53 46.41 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.073 -0.564 . . . . 0.0 112.258 -178.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 26' ' ' TRP . . . . . 0.563 ' O ' ' N ' ' H' ' 28' ' ' THR . 97.2 m95 -86.64 -68.59 0.73 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 114.147 1.166 . . . . 0.0 114.147 -175.565 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 27' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -13.01 -37.04 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 117.224 2.305 . . . . 0.0 117.224 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 28' ' ' THR . . . . . 0.563 ' N ' ' O ' ' H' ' 26' ' ' TRP . 37.5 m -58.7 -42.8 89.48 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 114.576 1.325 . . . . 0.0 114.576 -178.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 29' ' ' VAL . . . . . 0.612 HG22 HBC1 ' H' ' 101' ' ' BCL . 57.8 t -60.99 -45.69 98.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -176.251 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 30' ' ' GLY . . . . . . . . . . . . . . . -25.52 -67.39 0.05 OUTLIER Glycine 0 CA--C 1.541 1.693 0 N-CA-C 115.339 0.895 . . . . 0.0 115.339 -177.197 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 31' ' ' MET . . . . . . . . . . . . . 98.8 mtp -76.74 -6.36 51.87 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 115.493 1.664 . . . . 0.0 115.493 -176.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 32' ' ' LEU . . . . . . . . . . . . . 34.0 tp -61.64 -44.6 96.67 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 114.743 1.386 . . . . 0.0 114.743 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 33' ' ' PHE . . . . . . . . . . . . . 45.8 t80 -91.29 -37.98 12.94 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 120.828 -1.17 . . . . 0.0 111.931 -179.723 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 34' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -63.48 -39.08 93.49 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 116.044 1.868 . . . . 0.0 116.044 -176.058 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 35' ' ' SER . . . . . 0.451 ' OG ' ' CB ' ' B' ' 12' ' ' ALA . 6.9 t -58.93 -44.74 91.41 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 -175.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 36' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' H' ' 38' ' ' LYS . 12.9 tp -40.82 -72.87 0.06 Allowed 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 -178.722 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 10.63 -60.74 0.0 OUTLIER Glycine 0 CA--C 1.543 1.803 0 N-CA-C 117.795 1.878 . . . . 0.0 117.795 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 38' ' ' LYS . . . . . 0.538 ' N ' ' O ' ' H' ' 36' ' ' LEU . 64.9 mttm -61.84 -39.52 92.14 Favored 'General case' 0 CA--C 1.55 0.959 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -174.415 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 39' ' ' GLY . . . . . . . . . . . . . . . -58.31 -22.23 50.07 Favored Glycine 0 CA--C 1.542 1.78 0 N-CA-C 116.513 1.365 . . . . 0.0 116.513 -175.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 40' ' ' THR . . . . . . . . . . . . . 5.5 p -90.24 -15.05 32.11 Favored 'General case' 0 N--CA 1.485 1.309 0 CA-C-N 119.054 1.427 . . . . 0.0 113.123 -177.406 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 41' ' ' MET . . . . . . . . . . . . . 82.8 mmm -64.96 -39.51 93.59 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 115.623 1.712 . . . . 0.0 115.623 -175.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 42' ' ' ARG . . . . . . . . . . . . . 88.3 mmt-85 -62.48 -36.32 82.13 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -174.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 43' ' ' ILE . . . . . . . . . . . . . 25.5 mm -72.13 -37.92 61.32 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.83 0 CA-C-O 122.052 0.929 . . . . 0.0 108.999 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 44' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 -62.02 -39.93 93.96 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 114.376 -1.284 . . . . 0.0 110.25 178.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 45' ' ' ARG . . . . . 0.709 HH12 ' NH1' ' C' ' 45' ' ' ARG . 0.0 OUTLIER -60.18 -43.32 95.97 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 112.702 0.63 . . . . 0.0 112.702 -177.219 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' H' H ' 46' ' ' ASN . . . . . 0.594 ' OD1' ' CZ3' ' B' ' 26' ' ' TRP . 25.0 t-20 -74.0 -89.83 0.02 OUTLIER 'General case' 0 C--O 1.216 -0.667 0 C-N-CA 119.832 -0.747 . . . . 0.0 112.724 -177.483 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 47' ' ' ALA . . . . . . . . . . . . . . . -33.85 -21.21 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 115.2 1.556 . . . . 0.0 115.2 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 48' ' ' TYR . . . . . 0.52 ' N ' ' O ' ' H' ' 46' ' ' ASN . 76.1 m-85 -123.45 142.3 51.13 Favored 'General case' 0 N--CA 1.487 1.379 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.33 -20.33 0.02 OUTLIER Glycine 0 CA--C 1.522 0.497 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.883 -178.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 50' ' ' SER . . . . . . . . . . . . . 49.6 m -102.49 91.82 4.4 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-O 121.321 0.581 . . . . 0.0 111.38 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 51' ' ' MET . . . . . . . . . . . . . 68.3 mtm -64.3 -38.17 90.1 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.483 178.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 52' ' ' GLY . . . . . . . . . . . . . . . -47.81 109.53 0.48 Allowed Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.695 -0.562 . . . . 0.0 111.695 -179.36 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.85 -33.49 87.38 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.15 -171.32 53.43 Favored Glycine 0 CA--C 1.535 1.305 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 55' ' ' SER . . . . . . . . . . . . . 87.2 p -74.38 160.58 30.84 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.085 0.469 . . . . 0.0 110.891 -179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 56' ' ' LEU . . . . . . . . . . . . . 53.5 tp -87.15 131.5 34.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.809 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 57' ' ' ARG . . . . . 0.407 ' HG3' HH21 ' H' ' 57' ' ' ARG . 11.9 ttm-85 -63.97 135.95 56.92 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.703 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.35 19.13 72.42 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 121.459 -0.401 . . . . 0.0 112.457 178.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 59' ' ' SER . . . . . . . . . . . . . 77.5 p . . . . . 0 C--N 1.325 -0.484 0 CA-C-O 118.162 -0.923 . . . . 0.0 109.974 179.754 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 1' ' ' MET . . . . . . . . . . . . . 14.7 ttp . . . . . 0 N--CA 1.488 1.459 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 2' ' ' SER . . . . . . . . . . . . . 10.7 m -78.21 131.39 37.12 Favored 'General case' 0 N--CA 1.463 0.223 0 O-C-N 120.793 -1.192 . . . . 0.0 108.507 178.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.0 175.83 29.71 Favored Glycine 0 CA--C 1.519 0.291 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 4' ' ' GLY . . . . . . . . . . . . . . . 78.26 9.76 86.73 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.58 72.07 1.97 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 110.107 -1.197 . . . . 0.0 110.107 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 6' ' ' VAL . . . . . . . . . . . . . 16.0 m -117.78 21.66 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 122.807 0.443 . . . . 0.0 111.262 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 7' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -97.89 -43.3 7.16 Favored 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 121.761 0.791 . . . . 0.0 111.191 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 8' ' ' THR . . . . . . . . . . . . . 18.8 m -59.75 -42.68 93.74 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 114.356 -1.293 . . . . 0.0 111.861 -177.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 9' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -65.84 -23.05 66.6 Favored 'General case' 0 CA--C 1.552 1.042 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -179.296 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 10' ' ' ILE . . . . . . . . . . . . . 61.6 mt -62.09 -44.44 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 CA-C-N 119.405 1.002 . . . . 0.0 110.357 -178.157 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 11' ' ' LEU . . . . . . . . . . . . . 30.7 tp -60.63 -42.99 98.02 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 177.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.08 -40.21 88.75 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 13' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' I' ' 17' ' ' ILE . . . -70.25 -48.65 55.97 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 115.235 -0.893 . . . . 0.0 112.313 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.56 -43.1 89.23 Favored 'General case' 0 CA--C 1.512 -0.491 0 CA-C-O 121.314 0.578 . . . . 0.0 109.566 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.75 -37.06 93.06 Favored Glycine 0 C--O 1.221 -0.676 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 177.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 16' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -78.98 -69.1 0.6 Allowed 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.49 -179.272 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 17' ' ' ILE . . . . . 0.494 ' N ' ' O ' ' I' ' 13' ' ' ALA . 18.8 mt -40.43 -43.08 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.575 0 N-CA-C 112.53 0.567 . . . . 0.0 112.53 -178.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 18' ' ' PHE . . . . . 0.491 ' O ' HG12 ' I' ' 22' ' ' VAL . 61.9 t80 -51.01 -20.23 1.3 Allowed 'General case' 0 CA--C 1.492 -1.27 0 C-N-CA 119.385 -0.926 . . . . 0.0 111.329 -176.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 19' ' ' GLU . . . . . 0.413 ' N ' ' C ' ' I' ' 17' ' ' ILE . 93.8 mt-10 -66.34 -37.68 85.9 Favored 'General case' 0 C--N 1.319 -0.752 0 O-C-N 125.189 1.555 . . . . 0.0 111.933 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 20' ' ' VAL . . . . . . . . . . . . . 92.7 t -66.55 -46.67 85.69 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 C-N-CA 119.966 -0.694 . . . . 0.0 111.939 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 21' ' ' MET . . . . . . . . . . . . . 89.9 mmm -65.52 -45.83 81.98 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.088 0.773 . . . . 0.0 113.088 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 22' ' ' VAL . . . . . 0.491 HG12 ' O ' ' I' ' 18' ' ' PHE . 14.8 p -70.26 -28.71 36.57 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.998 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.804 -178.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 23' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -76.38 -17.59 59.3 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.062 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 24' ' ' GLY . . . . . . . . . . . . . . . -111.2 -4.58 27.23 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 25' ' ' HIS . . . . . . . . . . . . . 19.5 t-80 -67.83 -37.3 81.75 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-N 113.135 -1.532 . . . . 0.0 112.052 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 26' ' ' TRP . . . . . 0.569 ' O ' ' N ' ' I' ' 28' ' ' THR . 96.7 m95 -74.64 -67.52 0.62 Allowed 'General case' 0 C--O 1.216 -0.676 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 -174.031 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 27' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -17.59 -31.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 117.336 2.347 . . . . 0.0 117.336 -177.326 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 28' ' ' THR . . . . . 0.569 ' N ' ' O ' ' I' ' 26' ' ' TRP . 99.4 m -61.0 -43.67 98.55 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -178.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 29' ' ' VAL . . . . . . . . . . . . . 84.9 t -60.97 -45.24 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 115.24 1.57 . . . . 0.0 115.24 -175.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 30' ' ' GLY . . . . . . . . . . . . . . . -29.05 -64.48 0.11 Allowed Glycine 0 CA--C 1.534 1.254 0 N-CA-C 115.534 0.974 . . . . 0.0 115.534 -175.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 31' ' ' MET . . . . . . . . . . . . . 98.8 mtp -77.25 -6.19 52.18 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 115.034 1.494 . . . . 0.0 115.034 -176.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 32' ' ' LEU . . . . . . . . . . . . . 26.7 tp -60.36 -48.3 82.34 Favored 'General case' 0 CA--C 1.544 0.742 0 N-CA-C 114.094 1.146 . . . . 0.0 114.094 -177.066 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 33' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -89.18 -38.21 14.45 Favored 'General case' 0 N--CA 1.479 0.981 0 O-C-N 121.814 -0.554 . . . . 0.0 112.34 -177.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 34' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -62.14 -44.04 97.5 Favored 'General case' 0 CA--C 1.546 0.791 0 N-CA-C 115.539 1.681 . . . . 0.0 115.539 -176.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 35' ' ' SER . . . . . . . . . . . . . 21.3 t -49.25 -59.1 3.97 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 -176.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 36' ' ' LEU . . . . . 0.561 ' O ' ' N ' ' I' ' 38' ' ' LYS . 27.8 tp -26.06 -75.41 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 6.22 -58.11 0.0 OUTLIER Glycine 0 CA--C 1.543 1.782 0 N-CA-C 117.254 1.661 . . . . 0.0 117.254 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 38' ' ' LYS . . . . . 0.561 ' N ' ' O ' ' I' ' 36' ' ' LEU . 63.5 mttm -61.84 -37.49 84.65 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 114.444 1.275 . . . . 0.0 114.444 -175.152 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.45 -27.08 65.22 Favored Glycine 0 CA--C 1.553 2.44 0 N-CA-C 116.816 1.486 . . . . 0.0 116.816 -175.349 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 40' ' ' THR . . . . . . . . . . . . . 1.9 p -86.66 -13.92 44.12 Favored 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 119.009 1.404 . . . . 0.0 112.41 -176.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 41' ' ' MET . . . . . . . . . . . . . 87.8 mmm -66.34 -39.45 89.21 Favored 'General case' 0 CA--C 1.553 1.071 0 N-CA-C 115.665 1.728 . . . . 0.0 115.665 -176.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 42' ' ' ARG . . . . . . . . . . . . . 87.6 mmt-85 -61.39 -34.56 75.55 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 -175.226 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 43' ' ' ILE . . . . . . . . . . . . . 33.3 mm -79.1 -36.66 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 CA-C-N 118.608 0.64 . . . . 0.0 110.0 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 44' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -61.71 -40.34 94.68 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.151 178.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.04 -47.78 84.43 Favored 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -179.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 46' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -73.43 -54.58 7.95 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 115.814 1.783 . . . . 0.0 115.814 -174.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 47' ' ' ALA . . . . . . . . . . . . . . . -70.37 -9.57 56.62 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -176.438 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 48' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -128.99 144.62 51.24 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.56 -29.42 0.02 OUTLIER Glycine 0 CA--C 1.532 1.15 0 C-N-CA 119.947 -1.121 . . . . 0.0 112.834 -177.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 50' ' ' SER . . . . . . . . . . . . . 35.3 m -97.07 94.05 6.94 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-O 121.3 0.571 . . . . 0.0 110.222 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 51' ' ' MET . . . . . . . . . . . . . 66.3 mtm -64.78 -35.27 80.55 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.439 -0.8 . . . . 0.0 109.958 178.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 52' ' ' GLY . . . . . . . . . . . . . . . -51.75 107.36 0.44 Allowed Glycine 0 CA--C 1.521 0.465 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.023 -179.28 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.94 -34.54 90.21 Favored Glycine 0 C--O 1.231 -0.064 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.31 -170.27 48.71 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.972 -0.451 . . . . 0.0 111.972 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 55' ' ' SER . . . . . . . . . . . . . 86.8 p -73.6 160.48 31.56 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.897 0.38 . . . . 0.0 110.263 -179.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 56' ' ' LEU . . . . . . . . . . . . . 54.4 tp -89.22 133.24 34.51 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.823 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 57' ' ' ARG . . . . . . . . . . . . . 13.9 ttm-85 -63.95 136.43 57.33 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 120.184 -0.607 . . . . 0.0 110.757 -179.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.06 18.83 73.87 Favored Glycine 0 N--CA 1.468 0.783 0 N-CA-C 112.167 -0.373 . . . . 0.0 112.167 178.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 59' ' ' SER . . . . . . . . . . . . . 88.0 p . . . . . 0 C--N 1.323 -0.584 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.541 179.769 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' J' J ' 1' ' ' MET . . . . . 0.506 ' SD ' ' OBD' ' B' ' 101' ' ' BCL . 0.0 OUTLIER . . . . . 0 N--CA 1.483 1.179 0 CA-C-O 124.917 2.294 . . . . 0.0 106.704 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 2' ' ' SER . . . . . . . . . . . . . 13.0 m -77.64 131.23 37.67 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 119.883 -1.761 . . . . 0.0 108.981 179.178 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 3' ' ' GLY . . . . . . . . . . . . . . . 71.43 179.6 31.3 Favored Glycine 0 C--O 1.23 -0.123 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 4' ' ' GLY . . . . . 0.457 ' O ' ' CZ ' ' J' ' 7' ' ' PHE . . . 78.69 7.06 88.35 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.71 67.34 2.46 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 6' ' ' VAL . . . . . . . . . . . . . 15.4 m -112.31 20.44 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 123.143 0.577 . . . . 0.0 111.256 -179.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 7' ' ' PHE . . . . . 0.558 ' CD2' ' CD2' ' M' ' 7' ' ' PHE . 0.9 OUTLIER -95.13 -54.88 3.27 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 122.405 1.098 . . . . 0.0 111.697 -178.68 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 8' ' ' THR . . . . . . . . . . . . . 4.7 m -49.31 -43.28 43.36 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 113.145 -1.843 . . . . 0.0 111.045 -175.252 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 9' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -66.37 -22.26 66.25 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 113.426 0.899 . . . . 0.0 113.426 -179.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 10' ' ' ILE . . . . . . . . . . . . . 63.0 mt -62.57 -43.31 98.33 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.818 0 C-N-CA 119.121 -1.032 . . . . 0.0 110.219 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 11' ' ' LEU . . . . . . . . . . . . . 24.0 tp -60.45 -43.37 96.92 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.87 -40.82 94.41 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.242 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.94 -48.68 65.26 Favored 'General case' 0 C--O 1.214 -0.813 0 CA-C-N 114.653 -1.158 . . . . 0.0 112.92 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 14' ' ' ALA . . . . . . . . . . . . . . . -60.95 -42.1 97.57 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.95 -41.82 95.13 Favored Glycine 0 C--O 1.217 -0.967 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.969 178.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 16' ' ' ARG . . . . . . . . . . . . . 76.0 ttt-85 -76.41 -49.35 16.95 Favored 'General case' 0 C--O 1.215 -0.73 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.852 -178.084 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 17' ' ' ILE . . . . . 0.432 ' C ' ' N ' ' J' ' 19' ' ' GLU . 92.6 mt -60.55 -43.13 93.83 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.057 -176.786 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 18' ' ' PHE . . . . . 0.538 ' O ' HG12 ' J' ' 22' ' ' VAL . 64.0 t80 -48.56 -19.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.026 -178.505 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 19' ' ' GLU . . . . . 0.432 ' N ' ' C ' ' J' ' 17' ' ' ILE . 96.1 mt-10 -67.72 -37.07 81.73 Favored 'General case' 0 C--O 1.221 -0.425 0 O-C-N 124.09 0.868 . . . . 0.0 111.43 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 20' ' ' VAL . . . . . . . . . . . . . 80.6 t -65.47 -45.77 91.88 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 C-N-CA 120.111 -0.636 . . . . 0.0 111.235 -178.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 21' ' ' MET . . . . . 0.443 ' CE ' ' O1A' ' J' ' 101' ' ' BCL . 97.4 mmm -63.63 -54.01 42.54 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.404 0.891 . . . . 0.0 113.404 -179.086 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 22' ' ' VAL . . . . . 0.538 HG12 ' O ' ' J' ' 18' ' ' PHE . 13.2 p -63.89 -30.11 49.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 114.919 -1.037 . . . . 0.0 112.689 -178.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 23' ' ' GLU . . . . . . . . . . . . . 64.8 tt0 -82.37 4.81 22.47 Favored 'General case' 0 N--CA 1.48 1.028 0 CA-C-O 122.06 0.934 . . . . 0.0 111.45 -177.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 24' ' ' GLY . . . . . . . . . . . . . . . -128.76 -11.55 2.91 Favored Glycine 0 N--CA 1.483 1.769 0 N-CA-C 107.984 -2.046 . . . . 0.0 107.984 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 25' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' J' ' 26' ' ' TRP . 22.8 t-80 -64.08 -47.41 80.18 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 112.498 -1.851 . . . . 0.0 110.441 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 26' ' ' TRP . . . . . 0.725 ' CD2' ' ND2' ' B' ' 46' ' ' ASN . 94.3 m95 -64.38 -128.66 0.0 OUTLIER 'General case' 0 C--O 1.197 -1.672 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 27' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 50.46 -45.87 0.01 OUTLIER 'General case' 0 CA--C 1.574 1.891 0 N-CA-C 115.908 1.818 . . . . 0.0 115.908 178.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 28' ' ' THR . . . . . 0.53 ' N ' ' O ' ' J' ' 26' ' ' TRP . 93.2 m -59.91 -44.05 94.51 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 119.375 0.989 . . . . 0.0 112.46 -178.115 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 29' ' ' VAL . . . . . . . . . . . . . 95.0 t -55.43 -68.16 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.474 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -177.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 30' ' ' GLY . . . . . . . . . . . . . . . -5.67 -73.19 0.01 OUTLIER Glycine 0 CA--C 1.546 1.984 0 N-CA-C 116.419 1.327 . . . . 0.0 116.419 -178.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 31' ' ' MET . . . . . . . . . . . . . 92.4 mtp -68.82 -24.53 64.4 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 114.538 1.31 . . . . 0.0 114.538 -176.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 32' ' ' LEU . . . . . . . . . . . . . 15.4 tp -43.37 -63.84 0.75 Allowed 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -176.101 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 33' ' ' PHE . . . . . . . . . . . . . 36.2 t80 -73.65 -42.84 60.83 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 114.711 1.374 . . . . 0.0 114.711 -177.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 34' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -58.23 -46.93 85.03 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 115.818 1.785 . . . . 0.0 115.818 -175.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 35' ' ' SER . . . . . . . . . . . . . 32.9 t -45.52 -67.06 0.32 Allowed 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -177.129 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 36' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' J' ' 38' ' ' LYS . 37.4 tp -17.91 -67.31 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 114.876 1.435 . . . . 0.0 114.876 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -7.71 -48.72 0.0 OUTLIER Glycine 0 CA--C 1.546 2.0 0 N-CA-C 116.985 1.554 . . . . 0.0 116.985 -176.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 38' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' J' ' 36' ' ' LEU . 64.6 mttm -68.44 -25.27 64.93 Favored 'General case' 0 CA--C 1.556 1.197 0 N-CA-C 114.035 1.124 . . . . 0.0 114.035 -175.332 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 39' ' ' GLY . . . . . . . . . . . . . . . -67.17 -35.0 87.8 Favored Glycine 0 CA--C 1.547 2.076 0 N-CA-C 116.607 1.403 . . . . 0.0 116.607 -176.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 40' ' ' THR . . . . . . . . . . . . . 2.8 p -81.54 -13.62 57.85 Favored 'General case' 0 N--CA 1.482 1.167 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -175.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 41' ' ' MET . . . . . . . . . . . . . 88.8 mmm -66.77 -39.87 88.0 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -176.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 42' ' ' ARG . . . . . . . . . . . . . 84.0 mmt-85 -61.55 -32.18 72.24 Favored 'General case' 0 CA--C 1.543 0.69 0 N-CA-C 115.168 1.544 . . . . 0.0 115.168 -175.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 43' ' ' ILE . . . . . . . . . . . . . 30.8 mm -84.47 -36.71 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 O-C-N 121.519 -0.738 . . . . 0.0 109.407 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 44' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -61.93 -41.21 97.69 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.72 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 45' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' J' ' 48' ' ' TYR . 8.0 ttp180 -60.95 -56.61 19.08 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 113.978 1.103 . . . . 0.0 113.978 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 46' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -64.97 -48.61 73.41 Favored 'General case' 0 CA--C 1.551 1.005 0 N-CA-C 115.948 1.833 . . . . 0.0 115.948 -175.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 47' ' ' ALA . . . . . . . . . . . . . . . -72.3 -15.17 61.89 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-N 118.839 0.745 . . . . 0.0 112.764 -176.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 48' ' ' TYR . . . . . 0.479 ' O ' ' O ' ' J' ' 45' ' ' ARG . 79.6 m-85 -124.0 151.31 43.85 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.24 -29.37 0.04 OUTLIER Glycine 0 C--N 1.319 -0.4 0 C-N-CA 119.134 -1.508 . . . . 0.0 111.776 -177.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 50' ' ' SER . . . . . . . . . . . . . 26.2 m -94.88 99.23 11.31 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.162 0.506 . . . . 0.0 110.631 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 51' ' ' MET . . . . . . . . . . . . . 69.3 mtm -70.52 -32.51 70.0 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.593 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 52' ' ' GLY . . . . . . . . . . . . . . . -58.04 105.79 0.69 Allowed Glycine 0 CA--C 1.525 0.702 0 CA-C-N 114.988 -1.005 . . . . 0.0 111.454 -178.472 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.24 -33.46 87.31 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 178.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.16 -165.51 45.23 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -75.35 162.12 28.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.026 0.441 . . . . 0.0 111.463 -179.26 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 56' ' ' LEU . . . . . . . . . . . . . 54.6 tp -90.16 131.43 36.01 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.505 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 57' ' ' ARG . . . . . . . . . . . . . 17.6 ttm-85 -61.99 136.23 57.87 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 120.379 -0.528 . . . . 0.0 110.702 -179.224 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.83 19.29 73.37 Favored Glycine 0 CA--C 1.527 0.791 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.037 178.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 59' ' ' SER . . . . . . . . . . . . . 93.5 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.681 179.851 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' K' K ' 1' ' ' MET . . . . . 0.418 ' O ' ' HG2' ' K' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.74 0 CA-C-O 124.548 2.118 . . . . 0.0 107.037 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 2' ' ' SER . . . . . . . . . . . . . 6.6 m -47.65 132.66 14.02 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 119.433 -2.042 . . . . 0.0 111.513 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.01 169.86 25.39 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.9 8.23 86.95 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.877 -0.489 . . . . 0.0 111.877 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.93 66.63 3.07 Favored Glycine 0 N--CA 1.468 0.822 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 6' ' ' VAL . . . . . . . . . . . . . 16.2 m -107.91 3.1 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 123.066 0.546 . . . . 0.0 111.761 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 7' ' ' PHE . . . . . 0.619 ' O ' ' N ' ' K' ' 9' ' ' ASP . 0.2 OUTLIER -78.54 -126.24 0.01 OUTLIER 'General case' 0 C--O 1.197 -1.662 0 N-CA-C 101.117 -3.66 . . . . 0.0 101.117 175.149 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' K' K ' 8' ' ' THR . . . . . . . . . . . . . 1.8 m 28.98 -63.37 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 115.444 1.646 . . . . 0.0 115.444 176.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 9' ' ' ASP . . . . . 0.619 ' N ' ' O ' ' K' ' 7' ' ' PHE . 28.0 t70 -61.2 -23.67 65.77 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 10' ' ' ILE . . . . . . . . . . . . . 93.4 mt -62.34 -42.82 96.96 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.912 0 N-CA-C 106.895 -1.521 . . . . 0.0 106.895 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 11' ' ' LEU . . . . . . . . . . . . . 39.9 tp -60.17 -42.14 94.32 Favored 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 12' ' ' ALA . . . . . . . . . . . . . . . -62.7 -38.13 89.21 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.4 -0.818 . . . . 0.0 108.834 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 13' ' ' ALA . . . . . . . . . . . . . . . -70.29 -50.89 34.77 Favored 'General case' 0 C--O 1.208 -1.113 0 CA-C-N 114.948 -1.024 . . . . 0.0 113.041 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.9 -45.29 86.67 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.362 -0.606 . . . . 0.0 109.362 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 15' ' ' GLY . . . . . . . . . . . . . . . -64.2 -47.17 87.68 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 120.455 -0.879 . . . . 0.0 111.108 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 16' ' ' ARG . . . . . . . . . . . . . 73.4 ttt-85 -69.24 -44.17 72.53 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-O 120.7 0.286 . . . . 0.0 111.1 -178.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 17' ' ' ILE . . . . . . . . . . . . . 94.3 mt -64.0 -43.52 97.63 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.74 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -177.663 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 18' ' ' PHE . . . . . 0.555 ' O ' HG12 ' K' ' 22' ' ' VAL . 52.9 t80 -50.19 -20.45 1.03 Allowed 'General case' 0 C--N 1.311 -1.08 0 C-N-CA 120.024 -0.67 . . . . 0.0 110.437 -178.047 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 19' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -66.14 -38.72 88.82 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.516 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 20' ' ' VAL . . . . . . . . . . . . . 79.0 t -64.26 -47.9 87.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 C-N-CA 119.786 -0.765 . . . . 0.0 112.574 -177.19 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 21' ' ' MET . . . . . . . . . . . . . 96.7 mmm -64.0 -53.18 54.14 Favored 'General case' 0 C--O 1.211 -0.962 0 N-CA-C 112.581 0.585 . . . . 0.0 112.581 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 22' ' ' VAL . . . . . 0.555 HG12 ' O ' ' K' ' 18' ' ' PHE . 12.6 p -63.63 -28.32 44.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.89 -177.057 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 23' ' ' GLU . . . . . . . . . . . . . 68.6 tt0 -84.99 1.05 49.25 Favored 'General case' 0 N--CA 1.48 1.035 0 CA-C-O 121.54 0.686 . . . . 0.0 111.361 -177.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.24 -11.99 4.95 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.451 -1.86 . . . . 0.0 108.451 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 25' ' ' HIS . . . . . . . . . . . . . 19.8 t-80 -66.48 -44.59 82.24 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 113.359 -1.421 . . . . 0.0 113.195 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 26' ' ' TRP . . . . . 0.578 ' O ' ' N ' ' K' ' 28' ' ' THR . 99.2 m95 -64.14 -69.02 0.3 Allowed 'General case' 0 C--O 1.216 -0.67 0 N-CA-C 115.51 1.67 . . . . 0.0 115.51 -175.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 27' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -16.12 -33.63 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 117.39 2.367 . . . . 0.0 117.39 -178.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 28' ' ' THR . . . . . 0.578 ' N ' ' O ' ' K' ' 26' ' ' TRP . 34.2 m -60.27 -45.08 94.54 Favored 'General case' 0 CA--C 1.544 0.739 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 29' ' ' VAL . . . . . 0.424 HG22 HBC1 ' K' ' 101' ' ' BCL . 83.2 t -53.71 -74.55 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.547 0.943 . . . . 0.0 113.547 -176.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 30' ' ' GLY . . . . . . . . . . . . . . . 2.59 -74.8 0.0 OUTLIER Glycine 0 CA--C 1.54 1.647 0 N-CA-C 116.615 1.406 . . . . 0.0 116.615 -178.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 31' ' ' MET . . . . . . . . . . . . . 74.6 mtp -63.85 -36.4 83.8 Favored 'General case' 0 CA--C 1.543 0.71 0 N-CA-C 113.382 0.882 . . . . 0.0 113.382 -176.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 32' ' ' LEU . . . . . . . . . . . . . 8.2 tp -32.27 -68.2 0.1 Allowed 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 -176.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 33' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -68.86 -44.13 73.97 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -178.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 34' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -59.78 -45.99 90.59 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 117.385 2.365 . . . . 0.0 117.385 -173.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 35' ' ' SER . . . . . . . . . . . . . 34.1 t -51.52 -52.59 45.58 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.267 0.94 . . . . 0.0 113.398 -175.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 36' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' K' ' 38' ' ' LYS . 40.0 tp -30.67 -54.4 0.2 Allowed 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -178.443 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -26.31 -27.31 0.0 OUTLIER Glycine 0 CA--C 1.55 2.271 0 N-CA-C 117.188 1.635 . . . . 0.0 117.188 -175.587 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 38' ' ' LYS . . . . . 0.531 ' N ' ' O ' ' K' ' 36' ' ' LEU . 56.2 mttm -85.88 -9.05 57.61 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 119.366 1.583 . . . . 0.0 114.776 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 39' ' ' GLY . . . . . . . . . . . . . . . -86.24 -31.86 18.5 Favored Glycine 0 N--CA 1.494 2.519 0 CA-C-N 119.143 0.883 . . . . 0.0 115.237 -177.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 40' ' ' THR . . . . . . . . . . . . . 6.4 p -77.96 -14.61 59.47 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 114.074 1.139 . . . . 0.0 114.074 -176.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 41' ' ' MET . . . . . . . . . . . . . 90.1 mmm -65.94 -38.8 89.57 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 115.371 1.619 . . . . 0.0 115.371 -176.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 42' ' ' ARG . . . . . . . . . . . . . 83.8 mmt-85 -70.36 -15.32 62.85 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 115.719 1.748 . . . . 0.0 115.719 -174.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 43' ' ' ILE . . . . . . . . . . . . . 23.7 mm -98.1 -33.04 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 44' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -63.85 -40.32 96.3 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 114.609 -1.178 . . . . 0.0 109.273 177.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 45' ' ' ARG . . . . . 0.515 ' O ' ' O ' ' K' ' 48' ' ' TYR . 14.0 ttp180 -61.96 -88.86 0.01 OUTLIER 'General case' 0 C--O 1.192 -1.95 0 C-N-CA 119.302 -0.959 . . . . 0.0 109.99 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 46' ' ' ASN . . . . . 0.557 ' OD1' ' CZ3' ' I' ' 26' ' ' TRP . 10.7 t-20 -30.02 -63.54 0.13 Allowed 'General case' 0 CA--C 1.564 1.484 0 N-CA-C 118.506 2.78 . . . . 0.0 118.506 -178.233 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 47' ' ' ALA . . . . . . . . . . . . . . . -59.49 -27.57 66.25 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 119.582 1.083 . . . . 0.0 112.269 -175.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 48' ' ' TYR . . . . . 0.515 ' O ' ' O ' ' K' ' 45' ' ' ARG . 82.9 m-85 -114.5 153.19 30.45 Favored 'General case' 0 C--O 1.202 -1.405 0 CA-C-O 121.416 0.627 . . . . 0.0 109.671 179.356 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 49' ' ' GLY . . . . . . . . . . . . . . . -175.94 -24.38 0.03 OUTLIER Glycine 0 C--N 1.312 -0.776 0 O-C-N 120.056 -1.653 . . . . 0.0 110.899 -179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 50' ' ' SER . . . . . . . . . . . . . 31.8 m -97.5 97.46 9.1 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 121.021 0.439 . . . . 0.0 111.407 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 51' ' ' MET . . . . . . . . . . . . . 68.9 mtm -69.28 -34.36 74.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.245 -0.889 . . . . 0.0 109.95 178.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 52' ' ' GLY . . . . . . . . . . . . . . . -55.96 106.71 0.67 Allowed Glycine 0 CA--C 1.52 0.401 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.685 -178.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.36 -34.54 90.24 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.28 -168.44 48.41 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 55' ' ' SER . . . . . . . . . . . . . 90.7 p -74.2 161.16 30.23 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.009 0.433 . . . . 0.0 110.812 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 56' ' ' LEU . . . . . . . . . . . . . 54.8 tp -89.67 131.97 35.39 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.221 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 57' ' ' ARG . . . . . . . . . . . . . 18.1 ttm-85 -62.73 138.33 58.49 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 120.466 -0.494 . . . . 0.0 111.056 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.49 17.53 75.62 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 111.51 -0.636 . . . . 0.0 111.51 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 59' ' ' SER . . . . . . . . . . . . . 92.3 p . . . . . 0 C--N 1.323 -0.574 0 CA-C-O 117.978 -1.01 . . . . 0.0 110.999 179.903 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' L' L ' 1' ' ' MET . . . . . . . . . . . . . 6.3 ttp . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 124.806 2.241 . . . . 0.0 106.839 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' L' L ' 2' ' ' SER . . . . . . . . . . . . . 8.8 m -58.88 136.63 57.9 Favored 'General case' 0 C--N 1.319 -0.756 0 O-C-N 118.606 -2.559 . . . . 0.0 109.909 178.452 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.09 163.23 10.95 Favored Glycine 0 CA--C 1.537 1.418 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.52 9.94 82.56 Favored Glycine 0 CA--C 1.533 1.184 0 C-N-CA 121.576 -0.345 . . . . 0.0 113.484 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.72 67.43 2.73 Favored Glycine 0 N--CA 1.471 1.005 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 6' ' ' VAL . . . . . . . . . . . . . 16.8 m -109.42 4.73 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -178.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 7' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -81.98 -72.62 0.43 Allowed 'General case' 0 C--O 1.207 -1.148 0 CA-C-O 121.68 0.753 . . . . 0.0 110.462 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 8' ' ' THR . . . . . . . . . . . . . 9.6 m -32.43 -34.35 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -178.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 9' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -76.65 -21.92 54.77 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 113.359 0.874 . . . . 0.0 113.359 -177.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 10' ' ' ILE . . . . . 0.423 ' O ' ' N ' ' L' ' 14' ' ' ALA . 94.4 mt -62.85 -43.21 98.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 -178.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 11' ' ' LEU . . . . . . . . . . . . . 46.0 tp -60.01 -42.42 94.27 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 12' ' ' ALA . . . . . . . . . . . . . . . -62.65 -37.62 87.07 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 177.413 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 13' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' L' ' 16' ' ' ARG . . . -68.48 -76.24 0.09 Allowed 'General case' 0 C--O 1.206 -1.192 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.769 179.04 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 14' ' ' ALA . . . . . 0.423 ' N ' ' O ' ' L' ' 10' ' ' ILE . . . -32.29 -48.1 0.17 Allowed 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 112.114 0.412 . . . . 0.0 112.114 179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.95 -45.5 82.66 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 16' ' ' ARG . . . . . 0.47 ' N ' ' O ' ' L' ' 13' ' ' ALA . 65.3 ttt-85 -68.83 -44.04 74.29 Favored 'General case' 0 C--O 1.224 -0.272 0 CA-C-O 120.739 0.304 . . . . 0.0 111.361 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 17' ' ' ILE . . . . . . . . . . . . . 95.2 mt -64.51 -45.69 94.91 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.813 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -177.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 18' ' ' PHE . . . . . 0.584 ' O ' HG12 ' L' ' 22' ' ' VAL . 49.3 t80 -48.47 -19.69 0.35 Allowed 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.564 -0.71 . . . . 0.0 110.873 -178.536 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 19' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -65.31 -38.45 90.23 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 120.82 0.343 . . . . 0.0 110.788 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 20' ' ' VAL . . . . . . . . . . . . . 88.6 t -64.75 -46.8 91.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 112.778 0.659 . . . . 0.0 112.778 -177.452 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 21' ' ' MET . . . . . . . . . . . . . 97.0 mmm -66.22 -61.46 2.01 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.725 0.774 . . . . 0.0 110.447 -179.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 22' ' ' VAL . . . . . 0.584 HG12 ' O ' ' L' ' 18' ' ' PHE . 11.6 p -54.53 -34.83 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 CA-C-N 115.238 -0.892 . . . . 0.0 112.118 -177.237 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 23' ' ' GLU . . . . . 0.417 ' N ' HG13 ' L' ' 22' ' ' VAL . 81.9 tt0 -69.07 -29.28 67.37 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -178.396 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 24' ' ' GLY . . . . . . . . . . . . . . . -98.86 -8.67 53.91 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 25' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 -67.1 -43.05 83.49 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -178.503 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 26' ' ' TRP . . . . . 0.416 ' O ' ' N ' ' L' ' 28' ' ' THR . 99.7 m95 -68.25 -47.49 67.61 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 116.429 2.011 . . . . 0.0 116.429 -175.424 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 27' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -36.68 -24.45 0.01 OUTLIER 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 115.878 1.807 . . . . 0.0 115.878 -176.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 28' ' ' THR . . . . . 0.416 ' N ' ' O ' ' L' ' 26' ' ' TRP . 77.5 m -63.58 -44.29 94.5 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 114.299 1.222 . . . . 0.0 114.299 -178.37 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 29' ' ' VAL . . . . . 0.665 HG22 HBC1 ' L' ' 101' ' ' BCL . 60.7 t -55.13 -72.36 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 N-CA-C 114.325 1.231 . . . . 0.0 114.325 -176.008 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 30' ' ' GLY . . . . . . . . . . . . . . . 0.32 -73.6 0.0 OUTLIER Glycine 0 CA--C 1.539 1.538 0 N-CA-C 116.577 1.391 . . . . 0.0 116.577 -177.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 31' ' ' MET . . . . . . . . . . . . . 62.8 mtp -64.59 -36.96 85.92 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 113.904 1.075 . . . . 0.0 113.904 -176.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 tp -32.9 -67.32 0.12 Allowed 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 114.295 1.221 . . . . 0.0 114.295 -175.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 33' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -69.18 -43.09 74.93 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 114.541 1.311 . . . . 0.0 114.541 -178.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 34' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -63.61 -36.32 83.42 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 118.462 2.764 . . . . 0.0 118.462 -173.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 35' ' ' SER . . . . . . . . . . . . . 27.1 t -61.92 -35.36 78.15 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 119.563 1.074 . . . . 0.0 113.448 -175.325 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 36' ' ' LEU . . . . . 0.511 ' O ' ' N ' ' L' ' 38' ' ' LYS . 48.6 tp -52.98 -41.76 64.89 Favored 'General case' 0 CA--C 1.551 0.983 0 N-CA-C 115.893 1.812 . . . . 0.0 115.893 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -39.7 -12.54 0.01 OUTLIER Glycine 0 CA--C 1.543 1.784 0 N-CA-C 116.202 1.241 . . . . 0.0 116.202 -176.053 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 38' ' ' LYS . . . . . 0.511 ' N ' ' O ' ' L' ' 36' ' ' LEU . 55.3 mttm -96.2 -7.47 35.61 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-N 119.645 1.722 . . . . 0.0 114.301 -176.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 39' ' ' GLY . . . . . . . . . . . . . . . -90.4 -30.3 12.48 Favored Glycine 0 CA--C 1.538 1.518 0 C-N-CA 120.543 -0.837 . . . . 0.0 114.644 -177.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 40' ' ' THR . . . . . . . . . . . . . 18.6 p -76.25 -17.02 59.68 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -176.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 41' ' ' MET . . . . . . . . . . . . . 91.0 mmm -64.92 -36.78 85.49 Favored 'General case' 0 CA--C 1.554 1.133 0 N-CA-C 116.114 1.894 . . . . 0.0 116.114 -176.162 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 42' ' ' ARG . . . . . . . . . . . . . 82.8 mmt-85 -73.2 -7.98 53.79 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 116.368 1.988 . . . . 0.0 116.368 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 43' ' ' ILE . . . . . . . . . . . . . 24.2 mm -105.08 -32.47 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 44' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -64.9 -40.3 94.87 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 113.989 -1.459 . . . . 0.0 110.225 177.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 45' ' ' ARG . . . . . 0.441 ' O ' ' O ' ' L' ' 48' ' ' TYR . 29.4 ttp180 -69.89 -47.54 62.13 Favored 'General case' 0 C--O 1.216 -0.707 0 N-CA-C 116.349 1.981 . . . . 0.0 116.349 -177.251 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 46' ' ' ASN . . . . . 0.544 ' OD1' ' CE3' ' N' ' 26' ' ' TRP . 7.3 t-20 -70.56 -49.93 42.79 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 120.177 1.353 . . . . 0.0 114.605 -177.462 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 47' ' ' ALA . . . . . . . . . . . . . . . -63.56 -34.38 77.68 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.104 -0.638 . . . . 0.0 111.924 -176.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 48' ' ' TYR . . . . . 0.441 ' O ' ' O ' ' L' ' 45' ' ' ARG . 80.8 m-85 -109.84 146.24 35.39 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.15 -19.7 0.02 OUTLIER Glycine 0 N--CA 1.46 0.289 0 C-N-CA 119.794 -1.194 . . . . 0.0 111.207 -178.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 50' ' ' SER . . . . . . . . . . . . . 47.2 m -102.74 94.11 5.44 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.281 0.562 . . . . 0.0 110.52 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 51' ' ' MET . . . . . . . . . . . . . 62.9 mtm -66.44 -36.49 82.92 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.429 178.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 52' ' ' GLY . . . . . . . . . . . . . . . -52.27 108.53 0.68 Allowed Glycine 0 CA--C 1.526 0.76 0 CA-C-N 115.097 -0.956 . . . . 0.0 112.086 -178.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.84 -34.7 90.63 Favored Glycine 0 CA--C 1.53 0.984 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.4 -170.34 50.47 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 55' ' ' SER . . . . . . . . . . . . . 88.1 p -74.86 161.65 29.36 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.969 0.414 . . . . 0.0 110.905 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 56' ' ' LEU . . . . . . . . . . . . . 58.0 tp -89.92 130.49 36.13 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.519 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 57' ' ' ARG . . . . . . . . . . . . . 15.6 ttm-85 -61.84 137.72 58.27 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.153 -0.619 . . . . 0.0 110.262 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.93 16.97 73.63 Favored Glycine 0 CA--C 1.522 0.511 0 C-N-CA 121.208 -0.52 . . . . 0.0 111.973 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 59' ' ' SER . . . . . . . . . . . . . 89.7 p . . . . . 0 C--N 1.325 -0.488 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.755 179.932 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' M' M ' 1' ' ' MET . . . . . 0.519 ' SD ' ' OBD' ' A' ' 101' ' ' BCL . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 124.117 1.913 . . . . 0.0 106.851 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 2' ' ' SER . . . . . . . . . . . . . 12.3 m -82.48 132.24 35.21 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.21 171.29 21.01 Favored Glycine 0 CA--C 1.535 1.282 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.71 9.14 86.73 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.989 -0.444 . . . . 0.0 111.989 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.08 66.76 2.72 Favored Glycine 0 N--CA 1.468 0.782 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 6' ' ' VAL . . . . . . . . . . . . . 16.3 m -107.24 2.44 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -178.383 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 7' ' ' PHE . . . . . 0.558 ' CD2' ' CD2' ' J' ' 7' ' ' PHE . 0.1 OUTLIER -84.35 -58.2 2.84 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 122.357 1.075 . . . . 0.0 112.173 -178.066 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' M' M ' 8' ' ' THR . . . . . . . . . . . . . 25.3 m -47.14 -22.64 0.39 Allowed 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 113.006 -1.906 . . . . 0.0 111.857 -174.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 9' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -86.2 -19.72 29.6 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -63.39 -42.62 96.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 11' ' ' LEU . . . . . 0.442 HD11 HD13 ' A' ' 36' ' ' LEU . 58.7 tp -60.57 -42.5 96.75 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 115.058 -0.974 . . . . 0.0 108.786 179.231 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 12' ' ' ALA . . . . . 0.433 ' CB ' ' OG ' ' A' ' 35' ' ' SER . . . -61.17 -37.83 84.33 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 177.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 13' ' ' ALA . . . . . 0.675 ' O ' ' N ' ' M' ' 15' ' ' GLY . . . -73.26 -141.5 0.01 OUTLIER 'General case' 0 C--O 1.173 -2.954 0 N-CA-C 102.314 -3.217 . . . . 0.0 102.314 171.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 14' ' ' ALA . . . . . . . . . . . . . . . 42.14 -74.95 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.19 0 CA-C-N 122.372 2.351 . . . . 0.0 111.94 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 15' ' ' GLY . . . . . 0.675 ' N ' ' O ' ' M' ' 13' ' ' ALA . . . -62.74 -47.98 84.83 Favored Glycine 0 CA--C 1.548 2.134 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 176.431 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 16' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -64.57 -43.28 94.4 Favored 'General case' 0 N--CA 1.484 1.23 0 N-CA-C 106.327 -1.731 . . . . 0.0 106.327 178.545 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 17' ' ' ILE . . . . . 0.912 HG22 ' H ' ' M' ' 18' ' ' PHE . 84.3 mt -69.92 -162.95 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.201 -1.479 0 N-CA-C 101.25 -3.611 . . . . 0.0 101.25 175.226 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 18' ' ' PHE . . . . . 0.912 ' H ' HG22 ' M' ' 17' ' ' ILE . 24.5 t80 64.31 -34.08 0.15 Allowed 'General case' 1 C--N 1.241 -4.134 0 O-C-N 120.142 -1.599 . . . . 0.0 109.524 -176.59 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' M' M ' 19' ' ' GLU . . . . . 0.557 ' N ' ' O ' ' M' ' 17' ' ' ILE . 69.6 mt-10 -62.43 -37.17 84.83 Favored 'General case' 0 C--N 1.377 1.77 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 20' ' ' VAL . . . . . . . . . . . . . 89.8 t -67.45 -46.61 83.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.066 0 CA-C-N 114.921 -1.036 . . . . 0.0 112.172 -178.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 21' ' ' MET . . . . . 0.4 ' CE ' ' O1A' ' M' ' 101' ' ' BCL . 98.3 mmm -67.61 -48.11 67.74 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 22' ' ' VAL . . . . . 0.547 HG12 ' O ' ' M' ' 18' ' ' PHE . 12.2 p -66.09 -37.06 78.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.92 0.867 . . . . 0.0 112.29 -178.339 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 23' ' ' GLU . . . . . 0.475 ' N ' HG13 ' M' ' 22' ' ' VAL . 85.6 tt0 -68.03 -36.5 80.03 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.826 -177.724 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 24' ' ' GLY . . . . . . . . . . . . . . . -92.82 -7.5 62.77 Favored Glycine 0 N--CA 1.474 1.178 0 N-CA-C 110.026 -1.229 . . . . 0.0 110.026 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 25' ' ' HIS . . . . . . . . . . . . . 10.8 t-80 -68.2 -46.45 70.59 Favored 'General case' 0 CA--C 1.559 1.301 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 -179.033 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 26' ' ' TRP . . . . . 0.735 ' CE3' ' ND2' ' A' ' 46' ' ' ASN . 97.6 m95 -66.94 -42.61 85.0 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 117.35 2.352 . . . . 0.0 117.35 -176.392 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 27' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -39.93 -21.88 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.16 0 N-CA-C 114.982 1.475 . . . . 0.0 114.982 -176.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 28' ' ' THR . . . . . . . . . . . . . 86.3 m -63.87 -42.97 97.4 Favored 'General case' 0 CA--C 1.554 1.123 0 N-CA-C 114.588 1.329 . . . . 0.0 114.588 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 29' ' ' VAL . . . . . 0.607 HG22 HBC1 ' M' ' 101' ' ' BCL . 57.7 t -61.97 -46.25 96.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 N-CA-C 116.424 2.009 . . . . 0.0 116.424 -174.529 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 30' ' ' GLY . . . . . . . . . . . . . . . -28.81 -66.89 0.09 OUTLIER Glycine 0 CA--C 1.541 1.695 0 N-CA-C 115.742 1.057 . . . . 0.0 115.742 -174.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 31' ' ' MET . . . . . . . . . . . . . 21.5 mtp -64.81 -38.74 91.99 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -175.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 32' ' ' LEU . . . . . . . . . . . . . 10.8 tp -34.61 -66.79 0.16 Allowed 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 114.31 1.226 . . . . 0.0 114.31 -175.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 33' ' ' PHE . . . . . . . . . . . . . 24.1 t80 -69.04 -43.51 74.57 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -177.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 34' ' ' ASP . . . . . . . . . . . . . 34.8 t70 -63.23 -39.66 95.26 Favored 'General case' 0 CA--C 1.559 1.325 0 N-CA-C 117.979 2.585 . . . . 0.0 117.979 -174.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 35' ' ' SER . . . . . . . . . . . . . 6.4 t -60.53 -25.03 65.82 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 114.412 1.264 . . . . 0.0 114.412 -175.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 36' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' M' ' 38' ' ' LYS . 48.2 tp -62.72 -41.72 99.3 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 116.458 2.022 . . . . 0.0 116.458 -177.116 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -45.16 -5.88 0.01 OUTLIER Glycine 0 CA--C 1.539 1.565 0 N-CA-C 116.026 1.17 . . . . 0.0 116.026 -174.491 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 38' ' ' LYS . . . . . 0.459 ' N ' ' O ' ' M' ' 36' ' ' LEU . 62.6 mttm -100.4 -9.56 22.08 Favored 'General case' 0 N--CA 1.495 1.812 0 CA-C-N 119.696 1.748 . . . . 0.0 113.195 -176.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 39' ' ' GLY . . . . . . . . . . . . . . . -91.19 -24.84 25.78 Favored Glycine 0 N--CA 1.483 1.809 0 O-C-N 121.494 -0.754 . . . . 0.0 113.977 -177.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -77.56 -19.03 56.34 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -177.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 41' ' ' MET . . . . . . . . . . . . . 90.4 mmm -65.25 -38.78 91.41 Favored 'General case' 0 CA--C 1.559 1.308 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -176.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 42' ' ' ARG . . . . . . . . . . . . . 88.4 mmt-85 -66.68 -21.66 66.09 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 -174.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 43' ' ' ILE . . . . . . . . . . . . . 29.4 mm -90.44 -34.71 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.077 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 44' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -64.08 -40.68 96.77 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 114.819 -1.082 . . . . 0.0 111.602 179.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 45' ' ' ARG . . . . . . . . . . . . . 17.0 ttp180 -65.01 -44.61 88.64 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 116.492 2.034 . . . . 0.0 116.492 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 46' ' ' ASN . . . . . . . . . . . . . 47.9 t30 -74.43 -51.88 13.67 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 115.23 1.567 . . . . 0.0 115.23 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 47' ' ' ALA . . . . . . . . . . . . . . . -64.49 -34.52 78.41 Favored 'General case' 0 C--O 1.22 -0.454 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.838 -178.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 48' ' ' TYR . . . . . . . . . . . . . 78.5 m-85 -110.67 134.86 52.07 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 49' ' ' GLY . . . . . . . . . . . . . . . -160.65 -12.91 0.03 OUTLIER Glycine 0 CA--C 1.52 0.374 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.445 -178.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 50' ' ' SER . . . . . . . . . . . . . 58.7 m -107.91 94.82 5.28 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-O 121.033 0.444 . . . . 0.0 110.715 -179.502 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 51' ' ' MET . . . . . . . . . . . . . 65.4 mtm -66.2 -37.26 85.17 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.231 178.091 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 52' ' ' GLY . . . . . . . . . . . . . . . -51.43 109.8 0.88 Allowed Glycine 0 CA--C 1.524 0.654 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.404 -178.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.02 -34.19 89.26 Favored Glycine 0 CA--C 1.535 1.323 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.057 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.02 -169.75 52.21 Favored Glycine 0 N--CA 1.476 1.303 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 55' ' ' SER . . . . . . . . . . . . . 86.4 p -76.16 162.71 27.76 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.068 0.461 . . . . 0.0 111.259 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 56' ' ' LEU . . . . . . . . . . . . . 60.6 tp -89.96 128.41 36.23 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.32 179.324 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 57' ' ' ARG . . . . . . . . . . . . . 13.1 ttm-85 -61.43 138.92 58.28 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.912 -179.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.97 15.56 77.07 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 59' ' ' SER . . . . . . . . . . . . . 90.1 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.864 -1.065 . . . . 0.0 110.698 179.842 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' N' N ' 1' ' ' MET . . . . . . . . . . . . 0.261 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 124.866 2.27 . . . . 0.0 107.15 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 2' ' ' SER . . . . . . . . . . . . . 10.8 m -82.08 130.08 34.98 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 120.329 -1.482 . . . . 0.0 109.576 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 3' ' ' GLY . . . . . . . . . . . . . . . 70.76 177.21 23.47 Favored Glycine 0 N--CA 1.468 0.801 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.41 10.89 85.98 Favored Glycine 0 CA--C 1.521 0.437 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.66 63.5 3.26 Favored Glycine 0 N--CA 1.469 0.848 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 6' ' ' VAL . . . . . . . . . . . . . 22.3 m -105.9 -0.81 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -178.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 7' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -81.34 -47.04 13.81 Favored 'General case' 0 N--CA 1.484 1.273 0 CA-C-N 119.142 0.883 . . . . 0.0 111.889 -178.174 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 8' ' ' THR . . . . . . . . . . . . . 25.6 m -59.55 -28.21 66.91 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 114.608 -1.178 . . . . 0.0 112.777 -174.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 9' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -78.7 -19.63 52.0 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 10' ' ' ILE . . . . . 0.426 ' O ' ' HB3' ' N' ' 13' ' ' ALA . 92.7 mt -64.17 -42.79 96.64 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 119.774 -0.77 . . . . 0.0 109.237 -178.844 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 11' ' ' LEU . . . . . . . . . . . . . 48.1 tp -60.04 -43.28 95.47 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.0 -35.36 74.88 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 178.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 13' ' ' ALA . . . . . 0.544 ' O ' ' N ' ' N' ' 16' ' ' ARG . . . -71.91 -78.83 0.08 Allowed 'General case' 0 C--O 1.193 -1.872 0 CA-C-O 118.339 -0.838 . . . . 0.0 109.5 178.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 14' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' N' ' 13' ' ' ALA . . . -25.49 -49.55 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.332 0 O-C-N 123.806 0.691 . . . . 0.0 112.777 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.15 -47.58 52.2 Favored Glycine 0 CA--C 1.536 1.395 0 N-CA-C 111.509 -0.637 . . . . 0.0 111.509 177.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 16' ' ' ARG . . . . . 0.544 ' N ' ' O ' ' N' ' 13' ' ' ALA . 66.7 ttt-85 -69.69 -41.19 75.77 Favored 'General case' 0 C--O 1.2 -1.508 0 CA-C-O 121.504 0.669 . . . . 0.0 109.601 179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -68.54 -50.66 54.19 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.954 0 O-C-N 119.981 -1.699 . . . . 0.0 110.996 -177.413 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 18' ' ' PHE . . . . . 0.44 ' O ' HG12 ' N' ' 22' ' ' VAL . 39.6 t80 -49.03 -21.26 0.66 Allowed 'General case' 0 C--N 1.309 -1.178 0 O-C-N 120.983 -1.073 . . . . 0.0 110.558 -176.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 19' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -58.1 -37.24 74.15 Favored 'General case' 0 CA--C 1.547 0.849 0 CA-C-O 121.733 0.778 . . . . 0.0 109.909 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 20' ' ' VAL . . . . . . . . . . . . . 87.0 t -68.73 -48.71 69.87 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 21' ' ' MET . . . . . . . . . . . . . 97.7 mmm -64.2 -44.31 92.34 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.578 0.704 . . . . 0.0 112.782 -177.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 22' ' ' VAL . . . . . 0.498 HG13 ' N ' ' N' ' 23' ' ' GLU . 13.5 p -68.49 -35.41 70.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.055 -0.975 . . . . 0.0 112.324 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 23' ' ' GLU . . . . . 0.498 ' N ' HG13 ' N' ' 22' ' ' VAL . 84.5 tt0 -66.84 -42.49 85.65 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 120.166 -0.613 . . . . 0.0 112.306 -176.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.25 -12.13 74.09 Favored Glycine 0 CA--C 1.533 1.188 0 N-CA-C 111.675 -0.57 . . . . 0.0 111.675 -179.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 25' ' ' HIS . . . . . . . . . . . . . 5.5 t-80 -63.65 -47.8 79.84 Favored 'General case' 0 CA--C 1.555 1.162 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -178.447 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 26' ' ' TRP . . . . . 0.544 ' CE3' ' OD1' ' L' ' 46' ' ' ASN . 98.7 m95 -65.12 -40.46 94.53 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 117.888 2.551 . . . . 0.0 117.888 -177.43 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 27' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -42.26 -24.73 0.06 Allowed 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 115.254 1.576 . . . . 0.0 115.254 -176.141 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 28' ' ' THR . . . . . . . . . . . . . 77.3 m -61.99 -42.62 99.34 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -177.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 29' ' ' VAL . . . . . . . . . . . . . 79.2 t -61.49 -47.11 94.89 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.178 0 N-CA-C 116.54 2.052 . . . . 0.0 116.54 -173.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 30' ' ' GLY . . . . . . . . . . . . . . . -29.79 -63.49 0.15 Allowed Glycine 0 CA--C 1.544 1.872 0 N-CA-C 116.479 1.352 . . . . 0.0 116.479 -176.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 31' ' ' MET . . . . . . . . . . . . . 78.6 mmm -64.3 -37.47 87.62 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 114.009 1.115 . . . . 0.0 114.009 -176.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 32' ' ' LEU . . . . . . . . . . . . . 13.7 tp -41.19 -64.79 0.5 Allowed 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 -174.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 33' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -69.69 -44.66 69.99 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -177.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 34' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -61.34 -45.55 93.96 Favored 'General case' 0 CA--C 1.557 1.242 0 N-CA-C 118.516 2.784 . . . . 0.0 118.516 -173.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 35' ' ' SER . . . . . . . . . . . . . 5.1 t -56.32 -25.48 49.0 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 114.163 1.172 . . . . 0.0 114.163 -175.367 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 36' ' ' LEU . . . . . 0.472 ' O ' ' N ' ' N' ' 38' ' ' LYS . 46.6 tp -62.19 -41.7 98.59 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 115.831 1.789 . . . . 0.0 115.831 -176.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -42.25 -11.59 0.01 OUTLIER Glycine 0 CA--C 1.546 1.983 0 N-CA-C 116.016 1.166 . . . . 0.0 116.016 -174.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 38' ' ' LYS . . . . . 0.472 ' N ' ' O ' ' N' ' 36' ' ' LEU . 31.9 mttm -95.47 -16.13 22.45 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-N 120.168 1.984 . . . . 0.0 114.8 -176.326 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 39' ' ' GLY . . . . . . . . . . . . . . . -86.16 -22.79 47.17 Favored Glycine 0 N--CA 1.476 1.331 0 C-N-CA 120.527 -0.844 . . . . 0.0 113.654 -177.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 40' ' ' THR . . . . . . . . . . . . . 26.2 p -76.27 -22.45 55.07 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 113.523 0.935 . . . . 0.0 113.523 -177.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 41' ' ' MET . . . . . . . . . . . . . 89.6 mmm -62.48 -41.57 98.88 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 117.192 2.293 . . . . 0.0 117.192 -176.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 42' ' ' ARG . . . . . . . . . . . . . 89.0 mmt-85 -61.91 -37.12 83.45 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 115.653 1.723 . . . . 0.0 115.653 -174.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 43' ' ' ILE . . . . . . . . . . . . . 31.7 mm -74.92 -33.23 29.31 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 119.117 0.871 . . . . 0.0 109.066 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 44' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -63.68 -40.36 96.62 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.49 -1.232 . . . . 0.0 111.554 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 45' ' ' ARG . . . . . . . . . . . . . 4.3 ttp180 -64.82 -44.02 91.22 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 115.742 1.756 . . . . 0.0 115.742 -177.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 46' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -74.98 -55.67 5.52 Favored 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 115.911 1.819 . . . . 0.0 115.911 -175.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 47' ' ' ALA . . . . . . . . . . . . . . . -63.61 -36.36 83.57 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.279 -0.568 . . . . 0.0 112.012 -176.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 48' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -108.41 113.53 26.66 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 49' ' ' GLY . . . . . . . . . . . . . . . -138.65 -9.46 1.0 Allowed Glycine 0 N--CA 1.48 1.577 0 N-CA-C 111.654 -0.578 . . . . 0.0 111.654 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 50' ' ' SER . . . . . . . . . . . . . 58.4 m -110.87 102.8 11.28 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 117.279 0.54 . . . . 0.0 111.599 -179.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 51' ' ' MET . . . . . . . . . . . . . 67.1 mtm -73.64 -36.44 65.42 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.583 0.706 . . . . 0.0 110.111 177.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 52' ' ' GLY . . . . . . . . . . . . . . . -51.35 108.84 0.65 Allowed Glycine 0 CA--C 1.52 0.406 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.044 -178.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.29 -34.71 90.69 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.97 -174.24 51.06 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 55' ' ' SER . . . . . . . . . . . . . 87.3 p -74.73 161.95 29.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.017 0.437 . . . . 0.0 110.386 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 56' ' ' LEU . . . . . . . . . . . . . 57.8 tp -88.75 129.22 35.6 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.816 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 57' ' ' ARG . . . . . 0.403 HH21 ' HG3' ' N' ' 57' ' ' ARG . 11.6 ttm-85 -62.05 137.9 58.31 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.065 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 58' ' ' GLY . . . . . . . . . . . . . . . 81.49 16.03 74.64 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.68 -0.568 . . . . 0.0 111.68 179.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 59' ' ' SER . . . . . . . . . . . . . 89.2 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.628 179.924 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 101' ' ' BCL . . . . . 0.788 HBB2 HMB1 ' A' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 101' ' ' BCL . . . . . 0.771 HBB2 HMB1 ' B' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 101' ' ' BCL . . . . . 0.875 HBB2 HMB1 ' C' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 101' ' ' BCL . . . . . 0.863 HBB2 HMB1 ' D' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 101' ' ' BCL . . . . . 0.878 HBB2 HMB1 ' E' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 101' ' ' BCL . . . . . 0.898 HBB2 HMB1 ' F' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 101' ' ' BCL . . . . . 0.891 HBB2 HMB1 ' G' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 101' ' ' BCL . . . . . 0.917 HBB2 HMB1 ' H' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 101' ' ' BCL . . . . . 0.844 HBB2 HMB1 ' I' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 101' ' ' BCL . . . . . 0.622 HBB2 HMB1 ' J' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 101' ' ' BCL . . . . . 0.861 HBB2 HMB1 ' K' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 101' ' ' BCL . . . . . 0.869 HBB2 HMB1 ' L' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 101' ' ' BCL . . . . . 0.83 HBB2 HMB1 ' M' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 101' ' ' BCL . . . . . 0.854 HBB2 HMB1 ' N' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.163 0 CA-C-O 124.188 1.947 . . . . 0.0 109.349 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.3 m -74.79 133.41 41.94 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 120.352 -1.468 . . . . 0.0 110.972 -177.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.71 179.32 8.71 Favored Glycine 0 CA--C 1.533 1.169 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.36 13.69 82.62 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 111.705 -0.558 . . . . 0.0 111.705 178.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.57 54.19 3.44 Favored Glycine 0 N--CA 1.47 0.93 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 30.0 m -88.02 -10.83 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 113.999 1.111 . . . . 0.0 113.999 -179.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -71.54 -56.58 5.62 Favored 'General case' 0 CA--C 1.552 1.052 0 N-CA-C 115.51 1.671 . . . . 0.0 115.51 -175.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.8 m -51.98 -42.41 62.91 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.752 -174.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -62.05 -25.04 67.45 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 63.5 mt -62.92 -43.05 98.72 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.093 0 C-N-CA 118.428 -1.309 . . . . 0.0 110.16 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 32.1 tp -58.02 -42.92 86.32 Favored 'General case' 0 CA--C 1.49 -1.353 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.743 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -58.99 -35.42 73.19 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -74.61 -49.03 23.15 Favored 'General case' 0 C--O 1.196 -1.738 0 CA-C-N 114.415 -1.266 . . . . 0.0 113.827 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.08 -40.25 76.57 Favored 'General case' 0 C--N 1.318 -0.768 0 O-C-N 121.366 -0.834 . . . . 0.0 110.218 -178.167 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.83 -48.58 33.37 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.578 -0.82 . . . . 0.0 111.257 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 70.4 ttt-85 -68.45 -42.67 78.46 Favored 'General case' 0 CA--C 1.554 1.116 0 CA-C-N 115.006 -0.597 . . . . 0.0 112.119 -177.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 93.3 mt -67.06 -44.45 88.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 O-C-N 120.893 -1.13 . . . . 0.0 110.339 -177.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.509 ' O ' HG12 ' A' ' 22' ' ' VAL . 22.8 t80 -57.43 -18.82 19.99 Favored 'General case' 0 N--CA 1.442 -0.869 0 C-N-CA 118.793 -1.163 . . . . 0.0 109.359 -176.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -62.41 -30.49 71.25 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 124.71 1.256 . . . . 0.0 108.186 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 66.8 t -74.59 -49.23 31.52 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 98.1 mmm -63.83 -43.5 96.0 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-O 121.659 0.742 . . . . 0.0 111.833 -176.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.509 HG12 ' O ' ' A' ' 18' ' ' PHE . 13.2 p -67.15 -39.48 83.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 114.418 -1.265 . . . . 0.0 113.002 -178.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.481 ' N ' HG13 ' A' ' 22' ' ' VAL . 83.9 tt0 -64.12 -45.89 86.57 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -177.02 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.78 -28.7 70.36 Favored Glycine 0 CA--C 1.546 2.026 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.839 179.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -61.48 -38.25 86.61 Favored 'General case' 0 CA--C 1.571 1.783 0 N-CA-C 115.869 1.803 . . . . 0.0 115.869 -174.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.569 ' CE3' ' OD1' ' E' ' 46' ' ' ASN . 99.3 m95 -74.18 -32.53 63.12 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 117.716 2.487 . . . . 0.0 117.716 -177.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -49.47 -33.42 14.25 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 114.334 1.235 . . . . 0.0 114.334 -174.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 m -55.07 -40.43 70.34 Favored 'General case' 0 CA--C 1.564 1.484 0 N-CA-C 114.448 1.277 . . . . 0.0 114.448 -176.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.507 ' CG2' HBC1 ' A' ' 101' ' ' BCL . 55.2 t -60.88 -41.88 90.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 117.841 2.534 . . . . 0.0 117.841 -174.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -50.15 -45.35 43.17 Favored Glycine 0 CA--C 1.541 1.677 0 C-N-CA 120.549 -0.834 . . . . 0.0 115.128 -171.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 64.3 mmm -68.35 -33.11 73.68 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 119.13 1.465 . . . . 0.0 113.127 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 11.2 tp -51.35 -59.18 4.51 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 117.994 2.59 . . . . 0.0 117.994 -171.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 30.5 t80 -72.71 -43.05 63.5 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 120.478 1.49 . . . . 0.0 112.635 -179.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -59.68 -50.34 74.23 Favored 'General case' 0 CA--C 1.556 1.208 0 N-CA-C 118.375 2.731 . . . . 0.0 118.375 -173.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.433 ' OG ' ' CB ' ' M' ' 12' ' ' ALA . 4.8 t -53.1 -26.55 16.81 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -173.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.442 HD13 HD11 ' M' ' 11' ' ' LEU . 42.0 tp -63.5 -31.4 72.55 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 117.111 2.263 . . . . 0.0 117.111 -176.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -51.24 -29.22 21.63 Favored Glycine 0 CA--C 1.544 1.851 0 C-N-CA 118.161 -1.971 . . . . 0.0 114.246 -170.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 16.4 mttt -67.0 -38.48 86.09 Favored 'General case' 0 CA--C 1.555 1.17 0 N-CA-C 116.596 2.073 . . . . 0.0 116.596 -178.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -62.67 -33.65 87.34 Favored Glycine 0 CA--C 1.545 1.908 0 N-CA-C 116.125 1.21 . . . . 0.0 116.125 -174.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.1 p -71.47 -23.42 61.82 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 113.715 1.005 . . . . 0.0 113.715 -176.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . . . . . . . . . 91.4 mmm -60.99 -41.57 96.73 Favored 'General case' 0 CA--C 1.553 1.079 0 N-CA-C 118.615 2.82 . . . . 0.0 118.615 -174.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 88.4 mmt-85 -63.88 -41.78 97.66 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-N 120.09 1.313 . . . . 0.0 114.119 -174.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 33.0 mm -63.86 -42.2 95.05 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.569 0 N-CA-C 108.193 -1.039 . . . . 0.0 108.193 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 -58.41 -39.62 80.21 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.53 178.077 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.8 ttp180 -63.33 -44.49 94.78 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 115.675 1.731 . . . . 0.0 115.675 -177.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.584 ' OD1' ' CE3' ' M' ' 26' ' ' TRP . 0.7 OUTLIER -73.47 -64.1 1.06 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 117.119 2.266 . . . . 0.0 117.119 -175.831 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -57.23 -34.63 68.77 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -174.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -99.08 34.37 2.14 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 118.695 2.85 . . . . 0.0 118.695 -174.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -69.85 -12.08 67.23 Favored Glycine 0 CA--C 1.564 3.124 0 N-CA-C 117.915 1.926 . . . . 0.0 117.915 -175.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 53.5 m -106.34 116.61 32.23 Favored 'General case' 0 N--CA 1.501 2.09 0 CA-C-N 120.916 2.358 . . . . 0.0 111.809 -178.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 68.2 mtm -86.75 -33.39 19.98 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 121.387 0.613 . . . . 0.0 110.417 178.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -55.06 107.22 0.68 Allowed Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.47 -34.56 90.27 Favored Glycine 0 N--CA 1.448 -0.545 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.57 -170.59 46.47 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.5 p -74.51 161.11 30.08 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-O 121.12 0.486 . . . . 0.0 111.244 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 59.0 tp -88.53 128.31 35.55 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.688 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 45.2 ttt85 -60.42 135.28 57.7 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.581 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.63 15.53 77.7 Favored Glycine 0 CA--C 1.526 0.749 0 C-N-CA 121.059 -0.591 . . . . 0.0 111.635 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 88.7 p . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.863 -1.065 . . . . 0.0 111.018 179.78 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.159 0 CA-C-O 123.649 1.69 . . . . 0.0 109.181 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 10.2 m -68.32 135.11 51.36 Favored 'General case' 0 C--N 1.326 -0.435 0 O-C-N 119.805 -1.809 . . . . 0.0 109.869 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . 70.19 172.12 10.36 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.44 16.68 80.48 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 121.444 -0.408 . . . . 0.0 113.017 178.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.11 53.49 3.57 Favored Glycine 0 N--CA 1.469 0.894 0 N-CA-C 110.546 -1.022 . . . . 0.0 110.546 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' B' ' 7' ' ' PHE . 30.9 m -84.76 -14.53 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 113.168 0.803 . . . . 0.0 113.168 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' PHE . . . . . 0.634 ' O ' ' N ' ' B' ' 9' ' ' ASP . 0.3 OUTLIER -66.67 -140.01 0.0 OUTLIER 'General case' 0 C--O 1.188 -2.183 0 N-CA-C 105.258 -2.127 . . . . 0.0 105.258 175.843 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' THR . . . . . . . . . . . . . 15.2 m 41.43 -66.16 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 176.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' ASP . . . . . 0.634 ' N ' ' O ' ' B' ' 7' ' ' PHE . 11.9 t70 -56.08 -26.6 50.12 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 123.944 0.897 . . . . 0.0 111.247 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' ILE . . . . . 0.4 ' O ' ' HB3' ' B' ' 13' ' ' ALA . 46.2 mt -63.66 -42.87 97.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 C-N-CA 117.885 -1.526 . . . . 0.0 108.873 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' LEU . . . . . . . . . . . . . 25.5 tp -58.78 -42.88 90.05 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.031 -0.668 . . . . 0.0 109.277 178.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' ALA . . . . . 0.451 ' CB ' ' OG ' ' H' ' 35' ' ' SER . . . -58.5 -35.21 71.88 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 178.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' ALA . . . . . 0.536 ' O ' ' N ' ' B' ' 16' ' ' ARG . . . -73.91 -75.95 0.14 Allowed 'General case' 0 C--O 1.209 -1.051 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.973 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' ALA . . . . . . . . . . . . . . . -30.95 -32.53 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 113.396 0.888 . . . . 0.0 113.396 -179.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' B' ' 13' ' ' ALA . . . -81.17 -49.02 5.74 Favored Glycine 0 CA--C 1.52 0.351 0 N-CA-C 109.176 -1.569 . . . . 0.0 109.176 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' ARG . . . . . 0.536 ' N ' ' O ' ' B' ' 13' ' ' ALA . 74.5 ttt-85 -67.99 -43.31 79.2 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 113.98 -1.11 . . . . 0.0 111.042 -179.003 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 88.4 mt -63.72 -43.49 98.04 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.899 0 C-N-CA 120.337 -0.545 . . . . 0.0 110.014 -177.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' PHE . . . . . 0.482 ' O ' HG12 ' B' ' 22' ' ' VAL . 6.8 t80 -57.5 -20.14 29.24 Favored 'General case' 0 CA--C 1.484 -1.559 0 C-N-CA 118.789 -1.164 . . . . 0.0 110.826 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -61.4 -33.96 74.57 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 119.009 -1.076 . . . . 0.0 110.203 178.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.38 -48.49 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.22 0 C-N-CA 119.808 -0.757 . . . . 0.0 112.892 -178.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' MET . . . . . . . . . . . . . 97.6 mmm -64.63 -44.27 91.03 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-O 121.42 0.629 . . . . 0.0 112.384 -176.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' VAL . . . . . 0.526 HG13 ' N ' ' B' ' 23' ' ' GLU . 14.3 p -67.35 -38.77 81.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.155 0 CA-C-N 115.434 -0.803 . . . . 0.0 112.915 -178.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' GLU . . . . . 0.526 ' N ' HG13 ' B' ' 22' ' ' VAL . 83.1 tt0 -64.35 -42.53 96.19 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -176.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' GLY . . . . . . . . . . . . . . . -91.03 13.83 65.13 Favored Glycine 0 N--CA 1.472 1.074 0 N-CA-C 112.605 -0.198 . . . . 0.0 112.605 -178.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . . . . . . . . . 2.6 t-80 -100.36 -15.87 17.83 Favored 'General case' 0 CA--C 1.564 1.495 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -176.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' TRP . . . . . 0.594 ' CZ3' ' OD1' ' H' ' 46' ' ' ASN . 97.0 m95 -94.42 -33.65 13.05 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 -178.055 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -50.16 -24.25 2.67 Favored 'General case' 0 N--CA 1.482 1.16 0 N-CA-C 115.773 1.768 . . . . 0.0 115.773 -176.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' THR . . . . . . . . . . . . . 81.3 m -61.82 -41.51 97.87 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -178.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' VAL . . . . . 0.667 ' CG2' HBC1 ' B' ' 101' ' ' BCL . 68.7 t -61.27 -45.58 98.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 116.215 1.932 . . . . 0.0 116.215 -174.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' GLY . . . . . . . . . . . . . . . -27.73 -61.42 0.11 Allowed Glycine 0 CA--C 1.549 2.162 0 N-CA-C 115.255 0.862 . . . . 0.0 115.255 -176.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' MET . . . . . . . . . . . . . 4.2 mtp -67.73 -33.25 74.5 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 115.558 1.688 . . . . 0.0 115.558 -176.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' LEU . . . . . . . . . . . . . 2.0 tp -41.78 -75.14 0.03 OUTLIER 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 114.862 1.43 . . . . 0.0 114.862 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -62.84 -44.96 94.73 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 119.346 -0.942 . . . . 0.0 113.519 -176.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -52.26 -70.73 0.08 Allowed 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 115.916 1.821 . . . . 0.0 115.916 -176.244 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' SER . . . . . . . . . . . . . 1.5 t -32.0 -33.23 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 117.059 2.244 . . . . 0.0 117.059 -174.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 47.4 tp -62.15 -44.34 96.83 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 116.434 2.013 . . . . 0.0 116.434 -175.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -29.49 -38.51 0.02 OUTLIER Glycine 0 CA--C 1.549 2.187 0 N-CA-C 115.857 1.103 . . . . 0.0 115.857 -173.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -66.1 -39.36 89.92 Favored 'General case' 0 CA--C 1.548 0.868 0 N-CA-C 115.607 1.706 . . . . 0.0 115.607 -174.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . -62.29 -32.64 83.47 Favored Glycine 0 N--CA 1.481 1.683 0 N-CA-C 117.047 1.579 . . . . 0.0 117.047 -174.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' THR . . . . . . . . . . . . . 7.2 p -76.0 -14.01 60.23 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 118.628 1.214 . . . . 0.0 112.941 -177.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' MET . . . . . . . . . . . . . 91.9 mmm -64.92 -41.13 95.81 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 117.347 2.351 . . . . 0.0 117.347 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' ARG . . . . . 0.509 ' NH1' ' OE2' ' C' ' 23' ' ' GLU . 89.3 mmt-85 -64.83 -42.08 95.23 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 118.989 -1.085 . . . . 0.0 113.634 -174.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 26.3 mm -63.38 -42.66 97.13 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.913 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -60.52 -36.24 77.92 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.207 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' ARG . . . . . . . . . . . . . 2.0 ttp180 -62.58 -45.78 91.35 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' ASN . . . . . 0.575 ' OD1' ' CD2' ' J' ' 26' ' ' TRP . 0.4 OUTLIER -76.32 -69.84 0.48 Allowed 'General case' 0 N--CA 1.484 1.247 0 N-CA-C 116.658 2.096 . . . . 0.0 116.658 -175.336 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.09 -40.34 31.62 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 120.401 -0.519 . . . . 0.0 111.591 -174.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -104.68 114.97 29.53 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.08 -22.01 0.53 Allowed Glycine 0 N--CA 1.482 1.76 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' SER . . . . . . . . . . . . . 36.1 m -99.95 107.21 19.13 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 117.195 0.498 . . . . 0.0 111.314 -179.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' MET . . . . . . . . . . . . . 64.8 mtm -75.2 -34.49 61.5 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.838 177.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -52.39 107.06 0.44 Allowed Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 -178.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.02 -33.45 87.29 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.43 -171.07 47.32 Favored Glycine 0 N--CA 1.46 0.281 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' SER . . . . . . . . . . . . . 87.9 p -75.33 163.24 27.67 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.079 0.466 . . . . 0.0 111.631 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' LEU . . . . . . . . . . . . . 54.1 tp -88.03 130.55 34.95 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.626 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 39.3 ttt180 -63.61 132.4 51.05 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.13 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.89 16.05 76.0 Favored Glycine 0 CA--C 1.536 1.387 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' SER . . . . . . . . . . . . . 78.4 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.424 179.789 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.148 0 CA-C-O 124.162 1.934 . . . . 0.0 109.191 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 2' ' ' SER . . . . . . . . . . . . . 7.2 m -52.12 136.22 30.15 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 114.403 -1.272 . . . . 0.0 109.915 179.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.36 164.2 13.49 Favored Glycine 0 N--CA 1.438 -1.221 0 CA-C-N 115.098 -0.956 . . . . 0.0 110.894 -179.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.07 16.35 80.8 Favored Glycine 0 CA--C 1.532 1.107 0 C-N-CA 121.445 -0.407 . . . . 0.0 113.595 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.69 69.33 2.24 Favored Glycine 0 N--CA 1.473 1.162 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 6' ' ' VAL . . . . . . . . . . . . . 18.6 m -103.12 -6.16 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 7' ' ' PHE . . . . . 0.567 ' O ' ' N ' ' C' ' 9' ' ' ASP . 0.8 OUTLIER -71.63 -98.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 CA-C-O 117.058 -1.448 . . . . 0.0 109.278 -179.899 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 8' ' ' THR . . . . . . . . . . . . . 31.8 m -7.15 -49.63 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.008 0 N-CA-C 116.067 1.877 . . . . 0.0 116.067 -179.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 9' ' ' ASP . . . . . 0.567 ' N ' ' O ' ' C' ' 7' ' ' PHE . 14.7 t70 -61.69 -27.05 68.42 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 117.872 0.305 . . . . 0.0 111.611 -179.238 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 10' ' ' ILE . . . . . . . . . . . . . 21.4 mt -65.12 -43.66 95.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 O-C-N 120.663 -1.273 . . . . 0.0 108.457 179.151 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 11' ' ' LEU . . . . . 0.437 ' O ' ' O ' ' C' ' 13' ' ' ALA . 41.3 tp -61.01 -40.03 92.0 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.4 -39.86 88.86 Favored 'General case' 0 C--O 1.234 0.238 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 177.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 13' ' ' ALA . . . . . 0.508 ' O ' ' N ' ' C' ' 15' ' ' GLY . . . -79.71 -158.78 0.18 Allowed 'General case' 0 C--O 1.175 -2.862 0 N-CA-C 101.643 -3.466 . . . . 0.0 101.643 174.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 14' ' ' ALA . . . . . . . . . . . . . . . 60.2 -38.85 0.09 Allowed 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 122.067 2.212 . . . . 0.0 113.135 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 15' ' ' GLY . . . . . 0.508 ' N ' ' O ' ' C' ' 13' ' ' ALA . . . -95.6 -48.01 2.42 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 106.314 -2.714 . . . . 0.0 106.314 178.202 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 16' ' ' ARG . . . . . . . . . . . . . 76.6 ttt-85 -65.35 -43.57 90.45 Favored 'General case' 0 C--N 1.353 0.752 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 76.6 mt -63.77 -42.95 97.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.657 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 18' ' ' PHE . . . . . 0.45 ' O ' HG12 ' C' ' 22' ' ' VAL . 6.6 t80 -56.79 -19.0 14.79 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.911 -0.715 . . . . 0.0 111.721 -177.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 19' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -65.66 -36.9 85.0 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-O 121.479 0.657 . . . . 0.0 110.655 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 20' ' ' VAL . . . . . . . . . . . . . 91.2 t -66.41 -47.78 82.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 C-N-CA 119.918 -0.713 . . . . 0.0 110.891 -178.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 21' ' ' MET . . . . . . . . . . . . . 97.0 mmm -66.64 -45.63 78.4 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 -177.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 22' ' ' VAL . . . . . 0.451 HG13 ' N ' ' C' ' 23' ' ' GLU . 14.7 p -67.08 -37.56 79.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.886 -178.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 23' ' ' GLU . . . . . 0.509 ' OE2' ' NH1' ' B' ' 42' ' ' ARG . 88.8 tt0 -61.78 -44.7 96.35 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 -178.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 24' ' ' GLY . . . . . . . . . . . . . . . -92.67 22.97 30.6 Favored Glycine 0 CA--C 1.547 2.048 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 25' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -107.92 -9.86 15.63 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 112.635 0.606 . . . . 0.0 112.635 -178.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -99.99 -36.21 9.45 Favored 'General case' 0 CA--C 1.56 1.338 0 N-CA-C 114.01 1.115 . . . . 0.0 114.01 -178.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -49.41 -24.5 2.0 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 114.296 1.221 . . . . 0.0 114.296 -176.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' THR . . . . . . . . . . . . . 98.9 m -62.24 -42.8 99.64 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 113.286 0.847 . . . . 0.0 113.286 -178.268 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 88.1 t -60.83 -45.53 97.87 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 N-CA-C 115.61 1.707 . . . . 0.0 115.61 -175.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . -23.12 -69.08 0.02 OUTLIER Glycine 0 CA--C 1.55 2.275 0 N-CA-C 116.197 1.239 . . . . 0.0 116.197 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' MET . . . . . . . . . . . . . 39.6 mtp -65.4 -36.49 84.12 Favored 'General case' 0 N--CA 1.485 1.317 0 N-CA-C 115.073 1.509 . . . . 0.0 115.073 -176.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -33.35 -77.15 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -175.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -61.83 -47.48 84.9 Favored 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 118.9 -1.12 . . . . 0.0 113.74 -176.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -46.73 -73.7 0.04 OUTLIER 'General case' 0 CA--C 1.561 1.379 0 N-CA-C 116.199 1.925 . . . . 0.0 116.199 -177.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' SER . . . . . . . . . . . . . 2.7 t -30.44 -33.78 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 117.202 2.297 . . . . 0.0 117.202 -174.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 43.8 tp -63.12 -42.21 99.49 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 115.269 1.581 . . . . 0.0 115.269 -176.358 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -29.26 -43.36 0.05 OUTLIER Glycine 0 CA--C 1.545 1.925 0 N-CA-C 115.946 1.139 . . . . 0.0 115.946 -175.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 32.1 mttm -65.65 -40.53 92.56 Favored 'General case' 0 CA--C 1.559 1.306 0 N-CA-C 115.087 1.514 . . . . 0.0 115.087 -174.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . -58.68 -40.53 94.92 Favored Glycine 0 N--CA 1.484 1.889 0 N-CA-C 117.603 1.801 . . . . 0.0 117.603 -173.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' THR . . . . . . . . . . . . . 25.3 p -71.28 -15.58 62.43 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 118.481 1.14 . . . . 0.0 112.548 -176.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 41' ' ' MET . . . . . . . . . . . . . 81.9 mmm -63.32 -39.84 95.68 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 115.923 1.823 . . . . 0.0 115.923 -174.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 42' ' ' ARG . . . . . . . . . . . . . 89.1 mmt-85 -63.28 -41.66 99.02 Favored 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 119.617 -0.833 . . . . 0.0 113.131 -175.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 21.3 mm -63.11 -43.85 99.15 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 44' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -63.61 -26.07 68.52 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.622 -178.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 45' ' ' ARG . . . . . 0.709 ' NH1' HH12 ' H' ' 45' ' ' ARG . 1.0 OUTLIER -70.27 -44.19 68.93 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 118.701 -1.2 . . . . 0.0 112.76 179.945 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 46' ' ' ASN . . . . . 0.561 ' OD1' ' CD2' ' G' ' 26' ' ' TRP . 1.5 t-20 -75.42 -77.23 0.13 Allowed 'General case' 0 N--CA 1.466 0.359 0 N-CA-C 115.817 1.784 . . . . 0.0 115.817 -173.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 47' ' ' ALA . . . . . . . . . . . . . . . -43.01 -45.86 5.29 Favored 'General case' 0 CA--C 1.518 -0.261 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.889 -176.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 48' ' ' TYR . . . . . . . . . . . . . 69.4 m-85 -96.21 131.48 42.64 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 49' ' ' GLY . . . . . . . . . . . . . . . -152.44 -25.45 0.05 OUTLIER Glycine 0 N--CA 1.466 0.697 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 -178.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 50' ' ' SER . . . . . . . . . . . . . 58.6 m -103.1 97.99 8.0 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 51' ' ' MET . . . . . . . . . . . . . 67.2 mtm -65.42 -38.02 88.67 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 108.733 -0.839 . . . . 0.0 108.733 176.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . -46.79 107.76 0.23 Allowed Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.89 -33.91 88.49 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.71 -173.55 49.35 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 55' ' ' SER . . . . . . . . . . . . . 93.2 p -74.04 163.24 28.14 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.896 0.379 . . . . 0.0 110.681 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 56' ' ' LEU . . . . . . . . . . . . . 50.3 tp -87.37 133.15 33.76 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.177 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 57' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -67.49 132.3 47.33 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.147 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 58' ' ' GLY . . . . . . . . . . . . . . . 83.78 15.09 71.29 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 59' ' ' SER . . . . . . . . . . . . . 71.9 p . . . . . 0 C--N 1.325 -0.49 0 CA-C-O 117.942 -1.027 . . . . 0.0 110.718 -179.954 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 1' ' ' MET . . . . . . . . . . . . . 7.2 ttp . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 2' ' ' SER . . . . . . . . . . . . . 6.1 m -46.67 138.67 5.85 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.662 178.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.41 163.28 8.08 Favored Glycine 0 CA--C 1.535 1.288 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 -178.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 4' ' ' GLY . . . . . . . . . . . . . . . 78.37 15.71 80.55 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 121.006 -0.616 . . . . 0.0 113.522 178.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.46 74.7 1.92 Allowed Glycine 0 N--CA 1.473 1.155 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 6' ' ' VAL . . . . . . . . . . . . . 26.8 m -111.13 2.38 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.287 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 7' ' ' PHE . . . . . 0.445 ' O ' ' N ' ' D' ' 9' ' ' ASP . 7.0 m-85 -79.69 -82.2 0.11 Allowed 'General case' 0 C--O 1.21 -0.984 0 CA-C-N 118.664 0.666 . . . . 0.0 111.38 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 8' ' ' THR . . . . . . . . . . . . . 87.8 m -25.65 -40.47 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 9' ' ' ASP . . . . . 0.445 ' N ' ' O ' ' D' ' 7' ' ' PHE . 25.5 t70 -64.35 -32.33 73.9 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -179.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 10' ' ' ILE . . . . . 0.48 ' O ' ' N ' ' D' ' 14' ' ' ALA . 38.1 mt -62.45 -43.4 98.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 O-C-N 121.548 -0.72 . . . . 0.0 109.539 -178.597 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 11' ' ' LEU . . . . . . . . . . . . . 40.5 tp -59.84 -40.94 90.22 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 12' ' ' ALA . . . . . . . . . . . . . . . -62.35 -35.5 79.31 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 176.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 13' ' ' ALA . . . . . . . . . . . . . . . -90.9 -5.78 55.03 Favored 'General case' 0 C--O 1.199 -1.583 0 N-CA-C 114.847 1.425 . . . . 0.0 114.847 -178.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 14' ' ' ALA . . . . . 0.48 ' N ' ' O ' ' D' ' 10' ' ' ILE . . . -94.45 -12.9 26.84 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.055 -1.653 . . . . 0.0 107.727 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 15' ' ' GLY . . . . . . . . . . . . . . . -100.28 -48.9 1.5 Allowed Glycine 0 CA--C 1.525 0.68 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 16' ' ' ARG . . . . . . . . . . . . . 77.1 ttt-85 -63.71 -43.33 96.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.267 -0.467 . . . . 0.0 110.933 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 17' ' ' ILE . . . . . . . . . . . . . 17.9 mt -64.11 -42.98 97.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.229 -177.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 18' ' ' PHE . . . . . 0.471 ' O ' HG12 ' D' ' 22' ' ' VAL . 9.0 t80 -55.92 -19.34 11.74 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.162 -178.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 19' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -66.33 -36.86 83.99 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.001 0.429 . . . . 0.0 111.036 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 20' ' ' VAL . . . . . . . . . . . . . 96.8 t -66.66 -49.34 75.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-O 120.916 0.389 . . . . 0.0 111.99 -178.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 21' ' ' MET . . . . . . . . . . . . . 94.8 mmm -65.13 -43.89 90.45 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 22' ' ' VAL . . . . . 0.471 HG12 ' O ' ' D' ' 18' ' ' PHE . 12.9 p -68.94 -33.85 61.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.201 -177.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 23' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -65.43 -40.33 93.16 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 111.972 0.36 . . . . 0.0 111.972 -178.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 24' ' ' GLY . . . . . . . . . . . . . . . -96.41 21.5 45.19 Favored Glycine 0 CA--C 1.539 1.561 0 N-CA-C 111.946 -0.462 . . . . 0.0 111.946 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 25' ' ' HIS . . . . . . . . . . . . . 4.4 t-80 -103.57 -6.41 21.73 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.082 0.553 . . . . 0.0 111.526 -178.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 26' ' ' TRP . . . . . . . . . . . . . 98.5 m95 -105.44 -35.22 7.56 Favored 'General case' 0 N--CA 1.485 1.306 0 N-CA-C 114.163 1.171 . . . . 0.0 114.163 -178.168 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 27' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -51.26 -25.4 5.61 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 114.014 1.116 . . . . 0.0 114.014 -176.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 28' ' ' THR . . . . . . . . . . . . . 31.8 m -61.17 -43.35 99.02 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 29' ' ' VAL . . . . . 0.662 HG21 HBC1 ' D' ' 101' ' ' BCL . 92.1 t -62.14 -46.02 97.41 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.821 0 N-CA-C 115.653 1.723 . . . . 0.0 115.653 -174.276 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 30' ' ' GLY . . . . . . . . . . . . . . . -22.34 -70.08 0.01 OUTLIER Glycine 0 CA--C 1.54 1.652 0 N-CA-C 115.736 1.054 . . . . 0.0 115.736 -177.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 31' ' ' MET . . . . . . . . . . . . . 85.2 mtp -65.98 -36.64 83.86 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 115.058 1.503 . . . . 0.0 115.058 -176.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -30.0 -77.41 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -176.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 33' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -61.73 -46.26 90.4 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.771 -0.771 . . . . 0.0 113.011 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 34' ' ' ASP . . . . . 0.498 ' O ' ' N ' ' D' ' 36' ' ' LEU . 31.9 t70 -49.3 -82.04 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.176 0 N-CA-C 116.676 2.102 . . . . 0.0 116.676 -177.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 35' ' ' SER . . . . . 0.417 ' OG ' ' HB1' ' F' ' 12' ' ' ALA . 8.2 t -22.23 -36.31 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 -176.04 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . 0.498 ' N ' ' O ' ' D' ' 34' ' ' ASP . 43.0 tp -61.01 -42.33 98.25 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.141 1.163 . . . . 0.0 114.141 -176.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -27.34 -44.54 0.03 OUTLIER Glycine 0 CA--C 1.552 2.366 0 N-CA-C 115.959 1.143 . . . . 0.0 115.959 -176.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 38' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -65.02 -41.48 95.26 Favored 'General case' 0 CA--C 1.557 1.249 0 N-CA-C 115.69 1.737 . . . . 0.0 115.69 -175.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 39' ' ' GLY . . . . . . . . . . . . . . . -56.19 -41.19 85.9 Favored Glycine 0 N--CA 1.479 1.551 0 N-CA-C 117.09 1.596 . . . . 0.0 117.09 -173.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 40' ' ' THR . . . . . . . . . . . . . 35.7 p -70.46 -16.37 62.92 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 114.037 1.125 . . . . 0.0 114.037 -176.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 41' ' ' MET . . . . . . . . . . . . . 65.8 mmm -63.79 -40.08 95.81 Favored 'General case' 0 CA--C 1.55 0.976 0 N-CA-C 116.42 2.007 . . . . 0.0 116.42 -174.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 42' ' ' ARG . . . . . . . . . . . . . 88.6 mmt-85 -62.94 -42.06 99.69 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 119.131 -1.028 . . . . 0.0 113.102 -175.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 20.2 mm -61.05 -43.19 95.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 44' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -64.85 -27.99 69.25 Favored 'General case' 0 CA--C 1.561 1.398 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.914 -178.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 45' ' ' ARG . . . . . 0.874 HH12 HH12 ' E' ' 45' ' ' ARG . 0.8 OUTLIER -71.11 -39.26 72.19 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 119.118 0.872 . . . . 0.0 112.275 179.75 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 46' ' ' ASN . . . . . 0.542 ' OD1' ' CE3' ' F' ' 26' ' ' TRP . 8.6 t-20 -80.16 -74.04 0.33 Allowed 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -172.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 47' ' ' ALA . . . . . . . . . . . . . . . -48.77 -41.39 32.26 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.064 -175.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 48' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -97.47 135.53 39.2 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 178.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 49' ' ' GLY . . . . . . . . . . . . . . . -156.97 -26.59 0.03 OUTLIER Glycine 0 N--CA 1.465 0.571 0 N-CA-C 111.673 -0.571 . . . . 0.0 111.673 -178.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 50' ' ' SER . . . . . . . . . . . . . 58.5 m -102.71 95.76 6.42 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -178.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 51' ' ' MET . . . . . . . . . . . . . 67.9 mtm -63.62 -38.96 93.1 Favored 'General case' 0 CA--C 1.533 0.31 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 177.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . . . . . . . . . . . -43.49 107.23 0.11 Allowed Glycine 0 CA--C 1.531 1.049 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.981 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.27 -34.49 90.05 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.29 -173.42 51.73 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 55' ' ' SER . . . . . . . . . . . . . 87.4 p -75.36 163.65 27.23 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.912 0.387 . . . . 0.0 111.655 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 56' ' ' LEU . . . . . 0.406 ' O ' ' OXT' ' D' ' 59' ' ' SER . 50.5 tp -87.75 130.55 34.8 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.901 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 57' ' ' ARG . . . . . . . . . . . . . 65.0 ttt180 -66.58 134.07 51.61 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.817 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.08 14.51 76.89 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.871 -0.891 . . . . 0.0 110.871 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 59' ' ' SER . . . . . 0.406 ' OXT' ' O ' ' D' ' 56' ' ' LEU . 71.8 p . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.865 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 1' ' ' MET . . . . . . . . . . . . . 67.1 ttp . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 2' ' ' SER . . . . . . . . . . . . . 6.6 m -48.99 137.34 13.1 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.131 0.491 . . . . 0.0 110.164 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.08 165.95 16.4 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 4' ' ' GLY . . . . . . . . . . . . . . . 76.78 14.92 82.05 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.804 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.65 75.3 1.66 Allowed Glycine 0 N--CA 1.475 1.27 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 6' ' ' VAL . . . . . . . . . . . . . 17.9 m -112.27 1.87 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 113.337 0.866 . . . . 0.0 113.337 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 7' ' ' PHE . . . . . 0.464 ' O ' ' N ' ' E' ' 9' ' ' ASP . 7.8 m-85 -79.03 -83.08 0.09 Allowed 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.783 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 8' ' ' THR . . . . . . . . . . . . . 97.8 m -23.52 -42.23 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.842 1.053 . . . . 0.0 113.842 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 9' ' ' ASP . . . . . 0.464 ' N ' ' O ' ' E' ' 7' ' ' PHE . 25.7 t70 -62.74 -39.32 93.72 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 113.308 0.855 . . . . 0.0 113.308 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 10' ' ' ILE . . . . . 0.416 ' N ' ' O ' ' E' ' 7' ' ' PHE . 57.3 mt -53.77 -42.79 53.62 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.837 0 O-C-N 121.871 -0.518 . . . . 0.0 110.239 -178.423 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 11' ' ' LEU . . . . . . . . . . . . . 40.5 tp -61.08 -41.2 96.19 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 119.843 -0.743 . . . . 0.0 110.332 178.116 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.87 -38.35 87.94 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 13' ' ' ALA . . . . . 0.405 ' O ' ' CG1' ' E' ' 17' ' ' ILE . . . -74.85 -41.8 59.18 Favored 'General case' 0 CA--C 1.553 1.084 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.09 -23.09 66.3 Favored 'General case' 0 CA--C 1.512 -0.499 0 O-C-N 121.354 -0.841 . . . . 0.0 110.699 -178.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 15' ' ' GLY . . . . . . . . . . . . . . . -90.18 -45.82 4.31 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 16' ' ' ARG . . . . . . . . . . . . . 77.2 ttt-85 -69.64 -42.92 73.65 Favored 'General case' 0 CA--C 1.542 0.669 0 CA-C-N 115.465 -0.368 . . . . 0.0 111.561 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 17' ' ' ILE . . . . . 0.405 ' CG1' ' O ' ' E' ' 13' ' ' ALA . 1.1 mm -62.3 -44.38 99.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 CA-C-O 120.975 0.417 . . . . 0.0 111.432 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 18' ' ' PHE . . . . . 0.493 ' O ' HG12 ' E' ' 22' ' ' VAL . 14.9 t80 -57.97 -19.11 28.14 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.333 -178.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 19' ' ' GLU . . . . . . . . . . . . . 89.8 mt-10 -65.77 -37.04 85.25 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.216 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 20' ' ' VAL . . . . . . . . . . . . . 95.6 t -66.96 -48.47 79.41 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.8 -178.491 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 21' ' ' MET . . . . . . . . . . . . . 94.9 mmm -64.93 -43.16 93.67 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 22' ' ' VAL . . . . . 0.493 HG12 ' O ' ' E' ' 18' ' ' PHE . 12.0 p -70.35 -30.67 44.05 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -177.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 23' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -68.05 -41.28 82.28 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 113.14 0.793 . . . . 0.0 113.14 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 24' ' ' GLY . . . . . . . . . . . . . . . -95.66 16.94 60.23 Favored Glycine 0 N--CA 1.479 1.511 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 25' ' ' HIS . . . . . 0.416 ' O ' ' CG ' ' E' ' 25' ' ' HIS . 6.5 t-80 -97.3 -3.95 39.59 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 123.309 0.644 . . . . 0.0 111.827 -178.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 26' ' ' TRP . . . . . . . . . . . . . 98.4 m95 -107.69 -39.34 5.62 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 113.591 0.96 . . . . 0.0 113.591 -177.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 27' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -45.48 -30.15 1.33 Allowed 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -177.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 28' ' ' THR . . . . . . . . . . . . . 71.7 m -61.67 -43.05 99.6 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 113.78 1.03 . . . . 0.0 113.78 -177.629 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 29' ' ' VAL . . . . . 0.607 HG21 HBC1 ' E' ' 101' ' ' BCL . 86.0 t -60.78 -45.48 97.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -175.216 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 30' ' ' GLY . . . . . . . . . . . . . . . -25.05 -70.33 0.03 OUTLIER Glycine 0 CA--C 1.543 1.819 0 N-CA-C 115.87 1.108 . . . . 0.0 115.87 -176.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 31' ' ' MET . . . . . . . . . . . . . 95.3 mtp -65.67 -36.83 84.78 Favored 'General case' 0 CA--C 1.544 0.716 0 N-CA-C 115.062 1.504 . . . . 0.0 115.062 -176.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -29.86 -75.9 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -177.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 33' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -62.59 -46.57 87.69 Favored 'General case' 0 CA--C 1.552 1.027 0 N-CA-C 113.991 1.108 . . . . 0.0 113.991 -178.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 34' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -58.72 -53.26 60.37 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 117.729 2.492 . . . . 0.0 117.729 -174.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 35' ' ' SER . . . . . . . . . . . . . 33.8 t -45.2 -43.09 9.88 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 114.936 1.458 . . . . 0.0 114.936 -174.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 36' ' ' LEU . . . . . 0.524 ' O ' ' N ' ' E' ' 38' ' ' LYS . 38.2 tp -48.63 -54.78 13.33 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 114.921 1.452 . . . . 0.0 114.921 -177.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -10.59 -49.98 0.01 OUTLIER Glycine 0 CA--C 1.551 2.291 0 N-CA-C 116.616 1.406 . . . . 0.0 116.616 -177.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 38' ' ' LYS . . . . . 0.524 ' N ' ' O ' ' E' ' 36' ' ' LEU . 62.6 mttm -64.12 -42.62 96.77 Favored 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 116.063 1.875 . . . . 0.0 116.063 -175.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 39' ' ' GLY . . . . . . . . . . . . . . . -56.86 -30.75 60.34 Favored Glycine 0 N--CA 1.484 1.895 0 N-CA-C 116.741 1.457 . . . . 0.0 116.741 -174.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 40' ' ' THR . . . . . . . . . . . . . 29.9 p -79.85 -15.21 57.83 Favored 'General case' 0 CA--C 1.55 0.971 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -176.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 41' ' ' MET . . . . . . . . . . . . . 69.3 mmm -64.59 -39.49 93.82 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 114.996 1.48 . . . . 0.0 114.996 -176.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 42' ' ' ARG . . . . . . . . . . . . . 87.7 mmt-85 -63.98 -35.09 79.56 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 43' ' ' ILE . . . . . . . . . . . . . 18.2 mm -71.98 -29.38 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 44' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -73.62 -29.68 62.51 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 113.934 -1.485 . . . . 0.0 112.009 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 45' ' ' ARG . . . . . 0.874 HH12 HH12 ' D' ' 45' ' ' ARG . 13.1 ttm-85 -78.89 -18.27 54.18 Favored 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -177.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 46' ' ' ASN . . . . . 0.569 ' OD1' ' CE3' ' A' ' 26' ' ' TRP . 26.0 t-20 -95.76 -87.6 0.28 Allowed 'General case' 0 N--CA 1.473 0.711 0 O-C-N 121.112 -0.992 . . . . 0.0 112.013 -177.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 47' ' ' ALA . . . . . . . . . . . . . . . -36.69 -36.31 0.11 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.638 -177.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 48' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -104.71 138.68 40.65 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 178.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 49' ' ' GLY . . . . . . . . . . . . . . . -164.19 -24.18 0.02 OUTLIER Glycine 0 N--CA 1.468 0.826 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.353 -178.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 50' ' ' SER . . . . . . . . . . . . . 53.7 m -103.15 93.61 5.09 Favored 'General case' 0 N--CA 1.478 0.932 0 O-C-N 122.366 -0.49 . . . . 0.0 111.943 -178.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 51' ' ' MET . . . . . . . . . . . . . 68.9 mtm -63.51 -40.39 96.93 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.997 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 52' ' ' GLY . . . . . . . . . . . . . . . -44.44 109.72 0.3 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.434 -0.666 . . . . 0.0 111.434 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.3 -34.19 89.24 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 110.356 -1.097 . . . . 0.0 110.356 178.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 54' ' ' GLY . . . . . . . . . . . . . . . 85.08 -174.35 49.32 Favored Glycine 0 CA--C 1.529 0.967 0 N-CA-C 112.077 -0.409 . . . . 0.0 112.077 179.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 55' ' ' SER . . . . . . . . . . . . . 85.8 p -73.19 159.56 33.29 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 120.86 0.362 . . . . 0.0 110.665 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 56' ' ' LEU . . . . . 0.404 ' O ' ' OXT' ' E' ' 59' ' ' SER . 51.4 tp -84.99 131.4 34.48 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.622 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 57' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -66.81 135.19 53.56 Favored 'General case' 0 CA--C 1.508 -0.651 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.48 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.28 16.31 76.56 Favored Glycine 0 CA--C 1.532 1.122 0 CA-C-N 115.184 -0.917 . . . . 0.0 110.824 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 59' ' ' SER . . . . . 0.404 ' OXT' ' O ' ' E' ' 56' ' ' LEU . 65.9 p . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.735 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 1' ' ' MET . . . . . . . . . . . . . 61.5 ttp . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 2' ' ' SER . . . . . . . . . . . . . 6.6 m -53.16 134.71 38.77 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 121.45 -0.781 . . . . 0.0 110.287 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . 76.09 166.98 23.17 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 4' ' ' GLY . . . . . . . . . . . . . . . 78.01 13.89 82.89 Favored Glycine 0 CA--C 1.531 1.075 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 179.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 5' ' ' GLY . . . . . . . . . . . . . . . -87.64 72.44 2.49 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 179.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 6' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' F' ' 7' ' ' PHE . 16.8 m -110.42 -6.99 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 112.52 0.563 . . . . 0.0 112.52 -179.177 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 7' ' ' PHE . . . . . 0.658 ' O ' ' N ' ' F' ' 9' ' ' ASP . 2.3 m-85 -71.68 -121.24 0.0 OUTLIER 'General case' 0 C--O 1.188 -2.162 0 N-CA-C 103.044 -2.946 . . . . 0.0 103.044 174.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 8' ' ' THR . . . . . 0.422 ' O ' ' O ' ' F' ' 9' ' ' ASP . 60.2 m 22.51 -58.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 125.822 1.649 . . . . 0.0 115.327 176.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 9' ' ' ASP . . . . . 0.658 ' N ' ' O ' ' F' ' 7' ' ' PHE . 19.7 t70 -50.8 -86.7 0.0 OUTLIER 'General case' 0 C--O 1.153 -3.999 0 CA-C-O 116.24 -1.838 . . . . 0.0 107.862 174.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 10' ' ' ILE . . . . . 0.485 ' O ' ' N ' ' F' ' 13' ' ' ALA . 58.0 mt 0.01 -64.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.51 2.531 0 CA-C-N 120.028 1.286 . . . . 0.0 113.453 177.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 11' ' ' LEU . . . . . 0.493 ' N ' ' O ' ' F' ' 9' ' ' ASP . 27.2 tp -48.81 -43.18 38.07 Favored 'General case' 0 N--CA 1.478 0.94 0 O-C-N 122.086 -0.384 . . . . 0.0 111.058 177.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 12' ' ' ALA . . . . . 0.489 ' N ' ' O ' ' F' ' 9' ' ' ASP . . . -60.71 -39.98 90.56 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 177.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 13' ' ' ALA . . . . . 0.485 ' N ' ' O ' ' F' ' 10' ' ' ILE . . . -72.66 -46.66 52.82 Favored 'General case' 0 C--O 1.214 -0.791 0 CA-C-N 115.02 -0.991 . . . . 0.0 112.522 179.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.06 -35.25 69.12 Favored 'General case' 0 C--N 1.32 -0.694 0 O-C-N 120.734 -1.229 . . . . 0.0 108.96 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.29 -48.22 19.96 Favored Glycine 0 CA--C 1.533 1.175 0 N-CA-C 111.236 -0.745 . . . . 0.0 111.236 178.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 16' ' ' ARG . . . . . . . . . . . . . 72.2 ttt-85 -70.16 -44.74 68.19 Favored 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 113.45 0.908 . . . . 0.0 113.45 -177.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mm -62.57 -44.14 99.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.268 -177.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 18' ' ' PHE . . . . . 0.519 ' O ' HG12 ' F' ' 22' ' ' VAL . 37.6 t80 -57.9 -18.58 23.81 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.393 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 19' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -67.59 -36.61 81.21 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.188 0.518 . . . . 0.0 110.065 -179.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 20' ' ' VAL . . . . . . . . . . . . . 86.8 t -66.29 -48.51 80.84 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.904 -178.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 21' ' ' MET . . . . . . . . . . . . . 97.8 mmm -65.86 -44.24 86.04 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -178.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 22' ' ' VAL . . . . . 0.519 HG12 ' O ' ' F' ' 18' ' ' PHE . 14.2 p -69.78 -27.6 33.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 O-C-N 123.317 0.386 . . . . 0.0 111.438 -178.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 23' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -70.79 -41.44 71.65 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 113.43 0.9 . . . . 0.0 113.43 -177.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 24' ' ' GLY . . . . . . . . . . . . . . . -95.27 10.36 69.53 Favored Glycine 0 N--CA 1.479 1.538 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 25' ' ' HIS . . . . . . . . . . . . . 6.4 t-80 -87.1 -8.38 57.08 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 114.794 -0.703 . . . . 0.0 111.579 -178.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 26' ' ' TRP . . . . . 0.552 ' O ' ' N ' ' F' ' 28' ' ' THR . 97.7 m95 -101.74 -60.76 1.48 Allowed 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -176.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 27' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -21.94 -34.92 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 115.073 1.508 . . . . 0.0 115.073 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 28' ' ' THR . . . . . 0.552 ' N ' ' O ' ' F' ' 26' ' ' TRP . 19.3 m -60.51 -44.61 95.84 Favored 'General case' 0 CA--C 1.558 1.277 0 N-CA-C 114.735 1.383 . . . . 0.0 114.735 -178.606 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 29' ' ' VAL . . . . . . . . . . . . . 92.9 t -60.66 -45.06 98.13 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 114.219 1.192 . . . . 0.0 114.219 -175.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 30' ' ' GLY . . . . . . . . . . . . . . . -25.88 -69.82 0.04 OUTLIER Glycine 0 CA--C 1.543 1.832 0 N-CA-C 116.144 1.217 . . . . 0.0 116.144 -176.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 31' ' ' MET . . . . . . . . . . . . . 94.6 mtp -67.59 -30.81 70.51 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 114.203 1.186 . . . . 0.0 114.203 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 tp -37.91 -67.54 0.19 Allowed 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 112.711 0.634 . . . . 0.0 112.711 -176.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 33' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -68.35 -43.84 76.58 Favored 'General case' 0 CA--C 1.556 1.179 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -178.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 34' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -61.31 -44.26 97.5 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 116.924 2.194 . . . . 0.0 116.924 -174.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 35' ' ' SER . . . . . . . . . . . . . 14.5 t -54.57 -44.44 72.94 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 114.652 1.352 . . . . 0.0 114.652 -174.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 36' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' F' ' 38' ' ' LYS . 30.9 tp -44.45 -65.76 0.48 Allowed 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 114.604 1.335 . . . . 0.0 114.604 -178.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 2.77 -58.19 0.0 OUTLIER Glycine 0 CA--C 1.549 2.214 0 N-CA-C 117.17 1.628 . . . . 0.0 117.17 -178.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 38' ' ' LYS . . . . . 0.545 ' N ' ' O ' ' F' ' 36' ' ' LEU . 65.4 mttm -61.13 -41.68 97.17 Favored 'General case' 0 CA--C 1.554 1.121 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -174.344 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 39' ' ' GLY . . . . . . . . . . . . . . . -56.95 -22.97 44.05 Favored Glycine 0 CA--C 1.542 1.78 0 N-CA-C 117.154 1.622 . . . . 0.0 117.154 -175.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 40' ' ' THR . . . . . . . . . . . . . 6.2 p -87.96 -13.43 41.79 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-N 119.272 1.536 . . . . 0.0 112.27 -177.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 41' ' ' MET . . . . . . . . . . . . . 53.9 mmm -65.68 -37.51 86.69 Favored 'General case' 0 CA--C 1.554 1.105 0 N-CA-C 115.386 1.624 . . . . 0.0 115.386 -177.112 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 42' ' ' ARG . . . . . . . . . . . . . 88.8 mmt-85 -65.49 -31.49 72.58 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 114.661 1.356 . . . . 0.0 114.661 -175.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 43' ' ' ILE . . . . . . . . . . . . . 31.3 mm -76.0 -35.02 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 44' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -64.47 -39.49 93.91 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-N 113.9 -1.5 . . . . 0.0 112.124 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 45' ' ' ARG . . . . . . . . . . . . . 8.8 ttm-85 -70.36 -18.59 63.07 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 114.164 1.172 . . . . 0.0 114.164 -177.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 46' ' ' ASN . . . . . 0.558 ' O ' ' N ' ' F' ' 48' ' ' TYR . 17.3 t-20 -93.36 -100.02 0.14 Allowed 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 118.724 0.693 . . . . 0.0 109.954 -178.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 47' ' ' ALA . . . . . . . . . . . . . . . -22.63 -37.02 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 -179.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 48' ' ' TYR . . . . . 0.558 ' N ' ' O ' ' F' ' 46' ' ' ASN . 78.4 m-85 -107.28 143.78 35.03 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.198 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.28 -20.81 0.02 OUTLIER Glycine 0 CA--C 1.526 0.738 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.958 -178.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 50' ' ' SER . . . . . . . . . . . . . 53.4 m -105.42 91.39 3.75 Favored 'General case' 0 N--CA 1.48 1.032 0 O-C-N 122.306 -0.526 . . . . 0.0 111.402 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 51' ' ' MET . . . . . . . . . . . . . 68.8 mtm -63.11 -39.82 95.82 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.149 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 52' ' ' GLY . . . . . . . . . . . . . . . -41.67 111.28 0.28 Allowed Glycine 0 CA--C 1.531 1.079 0 C-N-CA 121.212 -0.518 . . . . 0.0 111.971 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.15 -35.39 91.92 Favored Glycine 0 CA--C 1.529 0.953 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 178.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.3 -176.71 52.87 Favored Glycine 0 N--CA 1.462 0.379 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -72.52 157.71 37.08 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 56' ' ' LEU . . . . . . . . . . . . . 51.5 tp -84.44 131.23 34.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.042 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 57' ' ' ARG . . . . . . . . . . . . . 42.5 ttt180 -64.83 135.18 55.48 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.936 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.44 17.32 73.88 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 59' ' ' SER . . . . . . . . . . . . . 77.5 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.72 -179.946 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 1' ' ' MET . . . . . 0.501 ' SD ' ' OBD' ' C' ' 101' ' ' BCL . 54.1 ttp . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 2' ' ' SER . . . . . . . . . . . . . 7.1 m -56.59 134.46 54.43 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 120.803 -1.185 . . . . 0.0 109.695 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . 76.24 165.95 21.22 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.55 13.95 80.78 Favored Glycine 0 N--CA 1.461 0.302 0 C-N-CA 121.347 -0.454 . . . . 0.0 113.007 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.5 76.23 1.78 Allowed Glycine 0 CA--C 1.528 0.88 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 6' ' ' VAL . . . . . . . . . . . . . 16.3 m -116.44 6.93 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 N-CA-C 112.33 0.493 . . . . 0.0 112.33 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 7' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -86.37 -63.0 1.39 Allowed 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 8' ' ' THR . . . . . 0.473 ' O ' ' O ' ' G' ' 9' ' ' ASP . 89.7 m -38.61 -38.23 0.38 Allowed 'General case' 0 CA--C 1.505 -0.764 0 CA-C-N 114.529 -1.214 . . . . 0.0 112.658 -178.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 9' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' G' ' 11' ' ' LEU . 25.1 t70 -67.25 -115.68 0.0 OUTLIER 'General case' 0 C--O 1.168 -3.228 0 N-CA-C 103.732 -2.692 . . . . 0.0 103.732 176.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 10' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' G' ' 13' ' ' ALA . 43.7 mt 34.66 -70.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 CA-C-N 121.156 1.798 . . . . 0.0 112.505 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 11' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' G' ' 9' ' ' ASP . 38.1 tp -49.82 -42.24 46.67 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 119.629 1.104 . . . . 0.0 110.386 175.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.74 -37.79 85.52 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 13' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' G' ' 10' ' ' ILE . . . -73.73 -50.58 20.04 Favored 'General case' 0 C--O 1.205 -1.284 0 CA-C-N 115.12 -0.945 . . . . 0.0 112.776 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 14' ' ' ALA . . . . . . . . . . . . . . . -55.03 -39.19 68.88 Favored 'General case' 0 C--O 1.22 -0.488 0 O-C-N 120.755 -1.216 . . . . 0.0 108.638 -179.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.6 -44.6 70.83 Favored Glycine 0 CA--C 1.537 1.436 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 178.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 16' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -73.95 -49.15 25.94 Favored 'General case' 0 C--O 1.218 -0.577 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -178.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 17' ' ' ILE . . . . . . . . . . . . . 2.1 mm -55.99 -46.15 80.48 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.083 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 18' ' ' PHE . . . . . 0.499 ' O ' HG12 ' G' ' 22' ' ' VAL . 53.5 t80 -55.62 -22.81 24.26 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.907 -177.173 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 19' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -63.97 -36.5 84.18 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.486 0.66 . . . . 0.0 109.946 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 20' ' ' VAL . . . . . . . . . . . . . 86.2 t -66.94 -47.92 81.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 C-N-CA 120.068 -0.653 . . . . 0.0 111.933 -178.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 21' ' ' MET . . . . . . . . . . . . . 87.6 mmm -65.83 -43.95 87.03 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -177.043 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 22' ' ' VAL . . . . . 0.499 HG12 ' O ' ' G' ' 18' ' ' PHE . 12.7 p -70.81 -29.15 36.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.727 -0.669 . . . . 0.0 112.373 -177.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 23' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -69.95 -38.43 76.12 Favored 'General case' 0 CA--C 1.539 0.537 0 N-CA-C 112.031 0.382 . . . . 0.0 112.031 -177.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 24' ' ' GLY . . . . . . . . . . . . . . . -95.38 2.73 65.54 Favored Glycine 0 N--CA 1.473 1.155 0 N-CA-C 111.141 -0.783 . . . . 0.0 111.141 -179.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 25' ' ' HIS . . . . . . . . . . . . . 17.7 t-80 -75.23 -27.72 59.61 Favored 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 123.227 0.611 . . . . 0.0 110.538 179.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 26' ' ' TRP . . . . . 0.567 ' O ' ' N ' ' G' ' 28' ' ' THR . 97.4 m95 -80.6 -120.85 0.02 OUTLIER 'General case' 0 C--O 1.194 -1.819 0 CA-C-O 115.867 -2.016 . . . . 0.0 106.63 178.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 27' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 45.1 -52.37 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.349 0 N-CA-C 116.646 2.091 . . . . 0.0 116.646 177.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 28' ' ' THR . . . . . 0.567 ' N ' ' O ' ' G' ' 26' ' ' TRP . 19.9 m -57.14 -42.89 81.82 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -178.593 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 29' ' ' VAL . . . . . . . . . . . . . 92.1 t -60.6 -45.11 97.84 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -176.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 30' ' ' GLY . . . . . . . . . . . . . . . -27.04 -69.37 0.05 OUTLIER Glycine 0 CA--C 1.542 1.78 0 N-CA-C 115.702 1.041 . . . . 0.0 115.702 -176.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 31' ' ' MET . . . . . . . . . . . . . 99.0 mtp -74.83 -7.95 54.97 Favored 'General case' 0 CA--C 1.55 0.947 0 N-CA-C 115.48 1.659 . . . . 0.0 115.48 -176.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 32' ' ' LEU . . . . . . . . . . . . . 17.9 tp -59.95 -50.87 72.04 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 119.663 1.12 . . . . 0.0 113.306 -177.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 33' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -80.72 -41.6 23.34 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 179.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 34' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -63.65 -38.69 92.06 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 116.766 2.136 . . . . 0.0 116.766 -175.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 35' ' ' SER . . . . . . . . . . . . . 12.9 t -59.48 -42.5 92.23 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 113.718 1.007 . . . . 0.0 113.718 -175.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 36' ' ' LEU . . . . . 0.553 ' O ' ' N ' ' G' ' 38' ' ' LYS . 21.6 tp -44.2 -72.65 0.06 Allowed 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 112.794 0.664 . . . . 0.0 112.794 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 10.51 -61.44 0.0 OUTLIER Glycine 0 CA--C 1.55 2.263 0 N-CA-C 117.259 1.664 . . . . 0.0 117.259 -178.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 38' ' ' LYS . . . . . 0.553 ' N ' ' O ' ' G' ' 36' ' ' LEU . 65.1 mttm -60.51 -41.25 93.96 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -174.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 39' ' ' GLY . . . . . . . . . . . . . . . -59.03 -13.98 22.28 Favored Glycine 0 CA--C 1.542 1.729 0 N-CA-C 116.744 1.458 . . . . 0.0 116.744 -175.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 40' ' ' THR . . . . . . . . . . . . . 20.4 p -96.24 -13.68 23.24 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 119.584 1.692 . . . . 0.0 111.835 -178.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 41' ' ' MET . . . . . . . . . . . . . 84.3 mmm -65.77 -37.13 85.48 Favored 'General case' 0 CA--C 1.55 0.972 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 -177.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 42' ' ' ARG . . . . . . . . . . . . . 88.9 mmt-85 -65.36 -31.36 72.43 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 115.141 1.534 . . . . 0.0 115.141 -175.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 43' ' ' ILE . . . . . . . . . . . . . 31.0 mm -78.25 -36.15 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 44' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -63.91 -39.97 95.4 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-N 114.541 -1.208 . . . . 0.0 110.633 178.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 45' ' ' ARG . . . . . . . . . . . . . 2.8 ttm-85 -61.54 -39.06 89.71 Favored 'General case' 0 N--CA 1.464 0.242 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.799 -177.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 46' ' ' ASN . . . . . 0.455 ' O ' ' N ' ' G' ' 48' ' ' TYR . 12.6 t-20 -86.94 -168.49 2.26 Favored 'General case' 0 C--O 1.196 -1.761 0 N-CA-C 103.761 -2.681 . . . . 0.0 103.761 177.189 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 47' ' ' ALA . . . . . 0.42 ' H ' ' CG ' ' G' ' 46' ' ' ASN . . . 53.05 -39.82 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 114.967 1.469 . . . . 0.0 114.967 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 48' ' ' TYR . . . . . 0.455 ' N ' ' O ' ' G' ' 46' ' ' ASN . 71.5 m-85 -119.68 141.17 49.61 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 49' ' ' GLY . . . . . 0.424 ' H ' ' H ' ' G' ' 50' ' ' SER . . . -171.31 -16.46 0.02 OUTLIER Glycine 0 C--N 1.313 -0.709 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -178.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 50' ' ' SER . . . . . 0.424 ' H ' ' H ' ' G' ' 49' ' ' GLY . 56.4 m -107.01 90.97 3.46 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-O 121.206 0.527 . . . . 0.0 111.492 -179.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 51' ' ' MET . . . . . . . . . . . . . 67.8 mtm -63.35 -38.82 92.65 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.757 178.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 52' ' ' GLY . . . . . . . . . . . . . . . -43.12 113.14 0.61 Allowed Glycine 0 CA--C 1.533 1.187 0 CA-C-N 116.386 -0.37 . . . . 0.0 112.44 -178.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.95 -34.52 90.16 Favored Glycine 0 N--CA 1.469 0.875 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 54' ' ' GLY . . . . . . . . . . . . . . . 78.53 -172.77 55.28 Favored Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 -179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 55' ' ' SER . . . . . . . . . . . . . 87.0 p -75.58 161.95 28.7 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.916 0.389 . . . . 0.0 111.319 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 56' ' ' LEU . . . . . 0.418 ' O ' ' OXT' ' G' ' 59' ' ' SER . 54.7 tp -89.37 130.34 35.75 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.398 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 57' ' ' ARG . . . . . . . . . . . . . 25.4 ttt85 -64.48 135.62 56.25 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.612 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.13 18.07 75.33 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 59' ' ' SER . . . . . 0.418 ' OXT' ' O ' ' G' ' 56' ' ' LEU . 82.2 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.906 -1.045 . . . . 0.0 111.062 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 1' ' ' MET . . . . . . . . . . . . . 45.0 ttp . . . . . 0 N--CA 1.487 1.406 0 CA-C-O 122.424 1.107 . . . . 0.0 108.222 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 2' ' ' SER . . . . . . . . . . . . . 8.4 m -69.74 134.64 48.84 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 120.024 -1.673 . . . . 0.0 109.054 179.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.87 170.67 22.25 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.65 12.78 83.25 Favored Glycine 0 CA--C 1.528 0.85 0 C-N-CA 121.119 -0.562 . . . . 0.0 111.979 178.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.66 76.65 1.55 Allowed Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 6' ' ' VAL . . . . . . . . . . . . . 16.3 m -120.76 18.23 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.156 0 C-N-CA 122.85 0.46 . . . . 0.0 112.048 -179.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 7' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -97.11 -42.3 7.92 Favored 'General case' 0 N--CA 1.483 1.214 0 CA-C-O 121.681 0.753 . . . . 0.0 110.127 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 8' ' ' THR . . . . . . . . . . . . . 17.5 m -59.04 -43.8 91.7 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.569 -1.196 . . . . 0.0 111.154 -177.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 9' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -63.46 -40.16 96.39 Favored 'General case' 0 CA--C 1.554 1.103 0 N-CA-C 113.722 1.008 . . . . 0.0 113.722 -178.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 10' ' ' ILE . . . . . . . . . . . . . 68.5 mt -48.2 -43.69 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 O-C-N 120.632 -1.293 . . . . 0.0 111.685 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 11' ' ' LEU . . . . . . . . . . . . . 41.1 tp -60.22 -42.05 94.36 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.204 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.75 -39.0 87.09 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.112 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 13' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' H' ' 17' ' ' ILE . . . -71.53 -47.75 53.15 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 112.661 0.615 . . . . 0.0 112.661 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.22 -40.56 86.2 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 -179.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.2 -40.59 94.93 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 109.766 -1.333 . . . . 0.0 109.766 177.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 16' ' ' ARG . . . . . . . . . . . . . 72.4 ttt-85 -74.33 -76.95 0.12 Allowed 'General case' 0 C--O 1.212 -0.892 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.166 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 17' ' ' ILE . . . . . 0.403 ' N ' ' O ' ' H' ' 13' ' ' ALA . 1.1 mm -29.18 -48.42 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 N-CA-C 113.611 0.967 . . . . 0.0 113.611 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 18' ' ' PHE . . . . . 0.491 ' O ' HG12 ' H' ' 22' ' ' VAL . 56.4 t80 -53.76 -21.17 6.72 Favored 'General case' 0 C--O 1.224 -0.28 0 C-N-CA 120.782 -0.367 . . . . 0.0 111.984 -176.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 19' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -65.97 -38.31 88.22 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.831 0.824 . . . . 0.0 110.028 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 20' ' ' VAL . . . . . . . . . . . . . 98.4 t -66.46 -47.73 82.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.923 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 21' ' ' MET . . . . . . . . . . . . . 89.5 mmm -65.99 -44.26 85.37 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -178.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 22' ' ' VAL . . . . . 0.491 HG12 ' O ' ' H' ' 18' ' ' PHE . 12.1 p -70.01 -31.82 49.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 -178.152 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 23' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -69.04 -35.48 76.65 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -177.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 24' ' ' GLY . . . . . . . . . . . . . . . -97.41 2.41 60.91 Favored Glycine 0 N--CA 1.478 1.464 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 25' ' ' HIS . . . . . . . . . . . . . 12.4 t-80 -79.67 -20.53 46.41 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.073 -0.564 . . . . 0.0 112.258 -178.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 26' ' ' TRP . . . . . 0.563 ' O ' ' N ' ' H' ' 28' ' ' THR . 97.2 m95 -86.64 -68.59 0.73 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 114.147 1.166 . . . . 0.0 114.147 -175.565 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 27' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -13.01 -37.04 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 117.224 2.305 . . . . 0.0 117.224 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 28' ' ' THR . . . . . 0.563 ' N ' ' O ' ' H' ' 26' ' ' TRP . 37.5 m -58.7 -42.8 89.48 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 114.576 1.325 . . . . 0.0 114.576 -178.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 29' ' ' VAL . . . . . 0.612 HG22 HBC1 ' H' ' 101' ' ' BCL . 57.8 t -60.99 -45.69 98.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -176.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 30' ' ' GLY . . . . . . . . . . . . . . . -25.52 -67.39 0.05 OUTLIER Glycine 0 CA--C 1.541 1.693 0 N-CA-C 115.339 0.895 . . . . 0.0 115.339 -177.197 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 31' ' ' MET . . . . . . . . . . . . . 98.8 mtp -76.74 -6.36 51.87 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 115.493 1.664 . . . . 0.0 115.493 -176.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 32' ' ' LEU . . . . . . . . . . . . . 34.0 tp -61.64 -44.6 96.67 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 114.743 1.386 . . . . 0.0 114.743 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 33' ' ' PHE . . . . . . . . . . . . . 45.8 t80 -91.29 -37.98 12.94 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 120.828 -1.17 . . . . 0.0 111.931 -179.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 34' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -63.48 -39.08 93.49 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 116.044 1.868 . . . . 0.0 116.044 -176.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 35' ' ' SER . . . . . 0.451 ' OG ' ' CB ' ' B' ' 12' ' ' ALA . 6.9 t -58.93 -44.74 91.41 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 -175.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 36' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' H' ' 38' ' ' LYS . 12.9 tp -40.82 -72.87 0.06 Allowed 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 -178.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 10.63 -60.74 0.0 OUTLIER Glycine 0 CA--C 1.543 1.803 0 N-CA-C 117.795 1.878 . . . . 0.0 117.795 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 38' ' ' LYS . . . . . 0.538 ' N ' ' O ' ' H' ' 36' ' ' LEU . 64.9 mttm -61.84 -39.52 92.14 Favored 'General case' 0 CA--C 1.55 0.959 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -174.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 39' ' ' GLY . . . . . . . . . . . . . . . -58.31 -22.23 50.07 Favored Glycine 0 CA--C 1.542 1.78 0 N-CA-C 116.513 1.365 . . . . 0.0 116.513 -175.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 40' ' ' THR . . . . . . . . . . . . . 5.5 p -90.24 -15.05 32.11 Favored 'General case' 0 N--CA 1.485 1.309 0 CA-C-N 119.054 1.427 . . . . 0.0 113.123 -177.406 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 41' ' ' MET . . . . . . . . . . . . . 82.8 mmm -64.96 -39.51 93.59 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 115.623 1.712 . . . . 0.0 115.623 -175.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 42' ' ' ARG . . . . . . . . . . . . . 88.3 mmt-85 -62.48 -36.32 82.13 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -174.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 43' ' ' ILE . . . . . . . . . . . . . 25.5 mm -72.13 -37.92 61.32 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.83 0 CA-C-O 122.052 0.929 . . . . 0.0 108.999 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 44' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 -62.02 -39.93 93.96 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 114.376 -1.284 . . . . 0.0 110.25 178.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 45' ' ' ARG . . . . . 0.709 HH12 ' NH1' ' C' ' 45' ' ' ARG . 0.0 OUTLIER -60.18 -43.32 95.97 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 112.702 0.63 . . . . 0.0 112.702 -177.219 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' H' H ' 46' ' ' ASN . . . . . 0.594 ' OD1' ' CZ3' ' B' ' 26' ' ' TRP . 25.0 t-20 -74.0 -89.83 0.02 OUTLIER 'General case' 0 C--O 1.216 -0.667 0 C-N-CA 119.832 -0.747 . . . . 0.0 112.724 -177.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 47' ' ' ALA . . . . . . . . . . . . . . . -33.85 -21.21 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 115.2 1.556 . . . . 0.0 115.2 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 48' ' ' TYR . . . . . 0.52 ' N ' ' O ' ' H' ' 46' ' ' ASN . 76.1 m-85 -123.45 142.3 51.13 Favored 'General case' 0 N--CA 1.487 1.379 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.33 -20.33 0.02 OUTLIER Glycine 0 CA--C 1.522 0.497 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.883 -178.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 50' ' ' SER . . . . . . . . . . . . . 49.6 m -102.49 91.82 4.4 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-O 121.321 0.581 . . . . 0.0 111.38 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 51' ' ' MET . . . . . . . . . . . . . 68.3 mtm -64.3 -38.17 90.1 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.483 178.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 52' ' ' GLY . . . . . . . . . . . . . . . -47.81 109.53 0.48 Allowed Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.695 -0.562 . . . . 0.0 111.695 -179.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.85 -33.49 87.38 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.15 -171.32 53.43 Favored Glycine 0 CA--C 1.535 1.305 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 55' ' ' SER . . . . . . . . . . . . . 87.2 p -74.38 160.58 30.84 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.085 0.469 . . . . 0.0 110.891 -179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 56' ' ' LEU . . . . . . . . . . . . . 53.5 tp -87.15 131.5 34.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.809 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 57' ' ' ARG . . . . . 0.407 ' HG3' HH21 ' H' ' 57' ' ' ARG . 11.9 ttm-85 -63.97 135.95 56.92 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.703 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.35 19.13 72.42 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 121.459 -0.401 . . . . 0.0 112.457 178.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 59' ' ' SER . . . . . . . . . . . . . 77.5 p . . . . . 0 C--N 1.325 -0.484 0 CA-C-O 118.162 -0.923 . . . . 0.0 109.974 179.754 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 1' ' ' MET . . . . . . . . . . . . . 14.7 ttp . . . . . 0 N--CA 1.488 1.459 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 2' ' ' SER . . . . . . . . . . . . . 10.7 m -78.21 131.39 37.12 Favored 'General case' 0 N--CA 1.463 0.223 0 O-C-N 120.793 -1.192 . . . . 0.0 108.507 178.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.0 175.83 29.71 Favored Glycine 0 CA--C 1.519 0.291 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 4' ' ' GLY . . . . . . . . . . . . . . . 78.26 9.76 86.73 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.58 72.07 1.97 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 110.107 -1.197 . . . . 0.0 110.107 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 6' ' ' VAL . . . . . . . . . . . . . 16.0 m -117.78 21.66 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 122.807 0.443 . . . . 0.0 111.262 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 7' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -97.89 -43.3 7.16 Favored 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 121.761 0.791 . . . . 0.0 111.191 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 8' ' ' THR . . . . . . . . . . . . . 18.8 m -59.75 -42.68 93.74 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 114.356 -1.293 . . . . 0.0 111.861 -177.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 9' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -65.84 -23.05 66.6 Favored 'General case' 0 CA--C 1.552 1.042 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -179.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 10' ' ' ILE . . . . . . . . . . . . . 61.6 mt -62.09 -44.44 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 CA-C-N 119.405 1.002 . . . . 0.0 110.357 -178.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 11' ' ' LEU . . . . . . . . . . . . . 30.7 tp -60.63 -42.99 98.02 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 177.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.08 -40.21 88.75 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 13' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' I' ' 17' ' ' ILE . . . -70.25 -48.65 55.97 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 115.235 -0.893 . . . . 0.0 112.313 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.56 -43.1 89.23 Favored 'General case' 0 CA--C 1.512 -0.491 0 CA-C-O 121.314 0.578 . . . . 0.0 109.566 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.75 -37.06 93.06 Favored Glycine 0 C--O 1.221 -0.676 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 177.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 16' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -78.98 -69.1 0.6 Allowed 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 120.226 -0.59 . . . . 0.0 110.49 -179.272 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 17' ' ' ILE . . . . . 0.494 ' N ' ' O ' ' I' ' 13' ' ' ALA . 18.8 mt -40.43 -43.08 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.575 0 N-CA-C 112.53 0.567 . . . . 0.0 112.53 -178.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 18' ' ' PHE . . . . . 0.491 ' O ' HG12 ' I' ' 22' ' ' VAL . 61.9 t80 -51.01 -20.23 1.3 Allowed 'General case' 0 CA--C 1.492 -1.27 0 C-N-CA 119.385 -0.926 . . . . 0.0 111.329 -176.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 19' ' ' GLU . . . . . 0.413 ' N ' ' C ' ' I' ' 17' ' ' ILE . 93.8 mt-10 -66.34 -37.68 85.9 Favored 'General case' 0 C--N 1.319 -0.752 0 O-C-N 125.189 1.555 . . . . 0.0 111.933 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 20' ' ' VAL . . . . . . . . . . . . . 92.7 t -66.55 -46.67 85.69 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 C-N-CA 119.966 -0.694 . . . . 0.0 111.939 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 21' ' ' MET . . . . . . . . . . . . . 89.9 mmm -65.52 -45.83 81.98 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.088 0.773 . . . . 0.0 113.088 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 22' ' ' VAL . . . . . 0.491 HG12 ' O ' ' I' ' 18' ' ' PHE . 14.8 p -70.26 -28.71 36.57 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.998 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.804 -178.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 23' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -76.38 -17.59 59.3 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 24' ' ' GLY . . . . . . . . . . . . . . . -111.2 -4.58 27.23 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 25' ' ' HIS . . . . . . . . . . . . . 19.5 t-80 -67.83 -37.3 81.75 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-N 113.135 -1.532 . . . . 0.0 112.052 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 26' ' ' TRP . . . . . 0.569 ' O ' ' N ' ' I' ' 28' ' ' THR . 96.7 m95 -74.64 -67.52 0.62 Allowed 'General case' 0 C--O 1.216 -0.676 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 -174.031 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 27' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -17.59 -31.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 117.336 2.347 . . . . 0.0 117.336 -177.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 28' ' ' THR . . . . . 0.569 ' N ' ' O ' ' I' ' 26' ' ' TRP . 99.4 m -61.0 -43.67 98.55 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 113.86 1.059 . . . . 0.0 113.86 -178.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 29' ' ' VAL . . . . . . . . . . . . . 84.9 t -60.97 -45.24 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 115.24 1.57 . . . . 0.0 115.24 -175.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 30' ' ' GLY . . . . . . . . . . . . . . . -29.05 -64.48 0.11 Allowed Glycine 0 CA--C 1.534 1.254 0 N-CA-C 115.534 0.974 . . . . 0.0 115.534 -175.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 31' ' ' MET . . . . . . . . . . . . . 98.8 mtp -77.25 -6.19 52.18 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 115.034 1.494 . . . . 0.0 115.034 -176.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 32' ' ' LEU . . . . . . . . . . . . . 26.7 tp -60.36 -48.3 82.34 Favored 'General case' 0 CA--C 1.544 0.742 0 N-CA-C 114.094 1.146 . . . . 0.0 114.094 -177.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 33' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -89.18 -38.21 14.45 Favored 'General case' 0 N--CA 1.479 0.981 0 O-C-N 121.814 -0.554 . . . . 0.0 112.34 -177.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 34' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -62.14 -44.04 97.5 Favored 'General case' 0 CA--C 1.546 0.791 0 N-CA-C 115.539 1.681 . . . . 0.0 115.539 -176.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 35' ' ' SER . . . . . . . . . . . . . 21.3 t -49.25 -59.1 3.97 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 -176.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 36' ' ' LEU . . . . . 0.561 ' O ' ' N ' ' I' ' 38' ' ' LYS . 27.8 tp -26.06 -75.41 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 6.22 -58.11 0.0 OUTLIER Glycine 0 CA--C 1.543 1.782 0 N-CA-C 117.254 1.661 . . . . 0.0 117.254 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 38' ' ' LYS . . . . . 0.561 ' N ' ' O ' ' I' ' 36' ' ' LEU . 63.5 mttm -61.84 -37.49 84.65 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 114.444 1.275 . . . . 0.0 114.444 -175.152 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 39' ' ' GLY . . . . . . . . . . . . . . . -60.45 -27.08 65.22 Favored Glycine 0 CA--C 1.553 2.44 0 N-CA-C 116.816 1.486 . . . . 0.0 116.816 -175.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 40' ' ' THR . . . . . . . . . . . . . 1.9 p -86.66 -13.92 44.12 Favored 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 119.009 1.404 . . . . 0.0 112.41 -176.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 41' ' ' MET . . . . . . . . . . . . . 87.8 mmm -66.34 -39.45 89.21 Favored 'General case' 0 CA--C 1.553 1.071 0 N-CA-C 115.665 1.728 . . . . 0.0 115.665 -176.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 42' ' ' ARG . . . . . . . . . . . . . 87.6 mmt-85 -61.39 -34.56 75.55 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 -175.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 43' ' ' ILE . . . . . . . . . . . . . 33.3 mm -79.1 -36.66 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 CA-C-N 118.608 0.64 . . . . 0.0 110.0 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 44' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -61.71 -40.34 94.68 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.151 178.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.04 -47.78 84.43 Favored 'General case' 0 CA--C 1.55 0.955 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -179.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 46' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -73.43 -54.58 7.95 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 115.814 1.783 . . . . 0.0 115.814 -174.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 47' ' ' ALA . . . . . . . . . . . . . . . -70.37 -9.57 56.62 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -176.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 48' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -128.99 144.62 51.24 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.56 -29.42 0.02 OUTLIER Glycine 0 CA--C 1.532 1.15 0 C-N-CA 119.947 -1.121 . . . . 0.0 112.834 -177.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 50' ' ' SER . . . . . . . . . . . . . 35.3 m -97.07 94.05 6.94 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-O 121.3 0.571 . . . . 0.0 110.222 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 51' ' ' MET . . . . . . . . . . . . . 66.3 mtm -64.78 -35.27 80.55 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.439 -0.8 . . . . 0.0 109.958 178.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 52' ' ' GLY . . . . . . . . . . . . . . . -51.75 107.36 0.44 Allowed Glycine 0 CA--C 1.521 0.465 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.023 -179.28 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.94 -34.54 90.21 Favored Glycine 0 C--O 1.231 -0.064 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.31 -170.27 48.71 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.972 -0.451 . . . . 0.0 111.972 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 55' ' ' SER . . . . . . . . . . . . . 86.8 p -73.6 160.48 31.56 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.897 0.38 . . . . 0.0 110.263 -179.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 56' ' ' LEU . . . . . . . . . . . . . 54.4 tp -89.22 133.24 34.51 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.823 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 57' ' ' ARG . . . . . . . . . . . . . 13.9 ttm-85 -63.95 136.43 57.33 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 120.184 -0.607 . . . . 0.0 110.757 -179.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.06 18.83 73.87 Favored Glycine 0 N--CA 1.468 0.783 0 N-CA-C 112.167 -0.373 . . . . 0.0 112.167 178.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 59' ' ' SER . . . . . . . . . . . . . 88.0 p . . . . . 0 C--N 1.323 -0.584 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.541 179.769 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' J' J ' 1' ' ' MET . . . . . 0.506 ' SD ' ' OBD' ' B' ' 101' ' ' BCL . 0.0 OUTLIER . . . . . 0 N--CA 1.483 1.179 0 CA-C-O 124.917 2.294 . . . . 0.0 106.704 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 2' ' ' SER . . . . . . . . . . . . . 13.0 m -77.64 131.23 37.67 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 119.883 -1.761 . . . . 0.0 108.981 179.178 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 3' ' ' GLY . . . . . . . . . . . . . . . 71.43 179.6 31.3 Favored Glycine 0 C--O 1.23 -0.123 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 4' ' ' GLY . . . . . 0.457 ' O ' ' CZ ' ' J' ' 7' ' ' PHE . . . 78.69 7.06 88.35 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.71 67.34 2.46 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 6' ' ' VAL . . . . . . . . . . . . . 15.4 m -112.31 20.44 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 123.143 0.577 . . . . 0.0 111.256 -179.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 7' ' ' PHE . . . . . 0.558 ' CD2' ' CD2' ' M' ' 7' ' ' PHE . 0.9 OUTLIER -95.13 -54.88 3.27 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 122.405 1.098 . . . . 0.0 111.697 -178.68 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 8' ' ' THR . . . . . . . . . . . . . 4.7 m -49.31 -43.28 43.36 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 113.145 -1.843 . . . . 0.0 111.045 -175.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 9' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -66.37 -22.26 66.25 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 113.426 0.899 . . . . 0.0 113.426 -179.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 10' ' ' ILE . . . . . . . . . . . . . 63.0 mt -62.57 -43.31 98.33 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.818 0 C-N-CA 119.121 -1.032 . . . . 0.0 110.219 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 11' ' ' LEU . . . . . . . . . . . . . 24.0 tp -60.45 -43.37 96.92 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.87 -40.82 94.41 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.94 -48.68 65.26 Favored 'General case' 0 C--O 1.214 -0.813 0 CA-C-N 114.653 -1.158 . . . . 0.0 112.92 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 14' ' ' ALA . . . . . . . . . . . . . . . -60.95 -42.1 97.57 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.95 -41.82 95.13 Favored Glycine 0 C--O 1.217 -0.967 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.969 178.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 16' ' ' ARG . . . . . . . . . . . . . 76.0 ttt-85 -76.41 -49.35 16.95 Favored 'General case' 0 C--O 1.215 -0.73 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.852 -178.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 17' ' ' ILE . . . . . 0.432 ' C ' ' N ' ' J' ' 19' ' ' GLU . 92.6 mt -60.55 -43.13 93.83 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.057 -176.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 18' ' ' PHE . . . . . 0.538 ' O ' HG12 ' J' ' 22' ' ' VAL . 64.0 t80 -48.56 -19.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.026 -178.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 19' ' ' GLU . . . . . 0.432 ' N ' ' C ' ' J' ' 17' ' ' ILE . 96.1 mt-10 -67.72 -37.07 81.73 Favored 'General case' 0 C--O 1.221 -0.425 0 O-C-N 124.09 0.868 . . . . 0.0 111.43 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 20' ' ' VAL . . . . . . . . . . . . . 80.6 t -65.47 -45.77 91.88 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 C-N-CA 120.111 -0.636 . . . . 0.0 111.235 -178.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 21' ' ' MET . . . . . 0.443 ' CE ' ' O1A' ' J' ' 101' ' ' BCL . 97.4 mmm -63.63 -54.01 42.54 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 113.404 0.891 . . . . 0.0 113.404 -179.086 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 22' ' ' VAL . . . . . 0.538 HG12 ' O ' ' J' ' 18' ' ' PHE . 13.2 p -63.89 -30.11 49.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 114.919 -1.037 . . . . 0.0 112.689 -178.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 23' ' ' GLU . . . . . . . . . . . . . 64.8 tt0 -82.37 4.81 22.47 Favored 'General case' 0 N--CA 1.48 1.028 0 CA-C-O 122.06 0.934 . . . . 0.0 111.45 -177.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 24' ' ' GLY . . . . . . . . . . . . . . . -128.76 -11.55 2.91 Favored Glycine 0 N--CA 1.483 1.769 0 N-CA-C 107.984 -2.046 . . . . 0.0 107.984 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 25' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' J' ' 26' ' ' TRP . 22.8 t-80 -64.08 -47.41 80.18 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 112.498 -1.851 . . . . 0.0 110.441 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 26' ' ' TRP . . . . . 0.575 ' CD2' ' OD1' ' B' ' 46' ' ' ASN . 94.3 m95 -64.38 -128.66 0.0 OUTLIER 'General case' 0 C--O 1.197 -1.672 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 27' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 50.46 -45.87 0.01 OUTLIER 'General case' 0 CA--C 1.574 1.891 0 N-CA-C 115.908 1.818 . . . . 0.0 115.908 178.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 28' ' ' THR . . . . . 0.53 ' N ' ' O ' ' J' ' 26' ' ' TRP . 93.2 m -59.91 -44.05 94.51 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 119.375 0.989 . . . . 0.0 112.46 -178.115 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 29' ' ' VAL . . . . . . . . . . . . . 95.0 t -55.43 -68.16 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.474 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -177.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 30' ' ' GLY . . . . . . . . . . . . . . . -5.67 -73.19 0.01 OUTLIER Glycine 0 CA--C 1.546 1.984 0 N-CA-C 116.419 1.327 . . . . 0.0 116.419 -178.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 31' ' ' MET . . . . . . . . . . . . . 92.4 mtp -68.82 -24.53 64.4 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 114.538 1.31 . . . . 0.0 114.538 -176.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 32' ' ' LEU . . . . . . . . . . . . . 15.4 tp -43.37 -63.84 0.75 Allowed 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -176.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 33' ' ' PHE . . . . . . . . . . . . . 36.2 t80 -73.65 -42.84 60.83 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 114.711 1.374 . . . . 0.0 114.711 -177.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 34' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -58.23 -46.93 85.03 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 115.818 1.785 . . . . 0.0 115.818 -175.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 35' ' ' SER . . . . . . . . . . . . . 32.9 t -45.52 -67.06 0.32 Allowed 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -177.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 36' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' J' ' 38' ' ' LYS . 37.4 tp -17.91 -67.31 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 114.876 1.435 . . . . 0.0 114.876 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -7.71 -48.72 0.0 OUTLIER Glycine 0 CA--C 1.546 2.0 0 N-CA-C 116.985 1.554 . . . . 0.0 116.985 -176.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 38' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' J' ' 36' ' ' LEU . 64.6 mttm -68.44 -25.27 64.93 Favored 'General case' 0 CA--C 1.556 1.197 0 N-CA-C 114.035 1.124 . . . . 0.0 114.035 -175.332 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 39' ' ' GLY . . . . . . . . . . . . . . . -67.17 -35.0 87.8 Favored Glycine 0 CA--C 1.547 2.076 0 N-CA-C 116.607 1.403 . . . . 0.0 116.607 -176.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 40' ' ' THR . . . . . . . . . . . . . 2.8 p -81.54 -13.62 57.85 Favored 'General case' 0 N--CA 1.482 1.167 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -175.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 41' ' ' MET . . . . . . . . . . . . . 88.8 mmm -66.77 -39.87 88.0 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -176.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 42' ' ' ARG . . . . . . . . . . . . . 84.0 mmt-85 -61.55 -32.18 72.24 Favored 'General case' 0 CA--C 1.543 0.69 0 N-CA-C 115.168 1.544 . . . . 0.0 115.168 -175.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 43' ' ' ILE . . . . . . . . . . . . . 30.8 mm -84.47 -36.71 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 O-C-N 121.519 -0.738 . . . . 0.0 109.407 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 44' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -61.93 -41.21 97.69 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.72 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 45' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' J' ' 48' ' ' TYR . 8.0 ttp180 -60.95 -56.61 19.08 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 113.978 1.103 . . . . 0.0 113.978 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 46' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -64.97 -48.61 73.41 Favored 'General case' 0 CA--C 1.551 1.005 0 N-CA-C 115.948 1.833 . . . . 0.0 115.948 -175.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 47' ' ' ALA . . . . . . . . . . . . . . . -72.3 -15.17 61.89 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-N 118.839 0.745 . . . . 0.0 112.764 -176.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 48' ' ' TYR . . . . . 0.479 ' O ' ' O ' ' J' ' 45' ' ' ARG . 79.6 m-85 -124.0 151.31 43.85 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.24 -29.37 0.04 OUTLIER Glycine 0 C--N 1.319 -0.4 0 C-N-CA 119.134 -1.508 . . . . 0.0 111.776 -177.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 50' ' ' SER . . . . . . . . . . . . . 26.2 m -94.88 99.23 11.31 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.162 0.506 . . . . 0.0 110.631 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 51' ' ' MET . . . . . . . . . . . . . 69.3 mtm -70.52 -32.51 70.0 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.593 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 52' ' ' GLY . . . . . . . . . . . . . . . -58.04 105.79 0.69 Allowed Glycine 0 CA--C 1.525 0.702 0 CA-C-N 114.988 -1.005 . . . . 0.0 111.454 -178.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.24 -33.46 87.31 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 178.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.16 -165.51 45.23 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -75.35 162.12 28.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.026 0.441 . . . . 0.0 111.463 -179.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 56' ' ' LEU . . . . . . . . . . . . . 54.6 tp -90.16 131.43 36.01 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.505 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 57' ' ' ARG . . . . . . . . . . . . . 17.6 ttm-85 -61.99 136.23 57.87 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 120.379 -0.528 . . . . 0.0 110.702 -179.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.83 19.29 73.37 Favored Glycine 0 CA--C 1.527 0.791 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.037 178.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 59' ' ' SER . . . . . . . . . . . . . 93.5 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.681 179.851 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' K' K ' 1' ' ' MET . . . . . 0.418 ' O ' ' HG2' ' K' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.74 0 CA-C-O 124.548 2.118 . . . . 0.0 107.037 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 2' ' ' SER . . . . . . . . . . . . . 6.6 m -47.65 132.66 14.02 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 119.433 -2.042 . . . . 0.0 111.513 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.01 169.86 25.39 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.9 8.23 86.95 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.877 -0.489 . . . . 0.0 111.877 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 5' ' ' GLY . . . . . . . . . . . . . . . -88.93 66.63 3.07 Favored Glycine 0 N--CA 1.468 0.822 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 6' ' ' VAL . . . . . . . . . . . . . 16.2 m -107.91 3.1 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 123.066 0.546 . . . . 0.0 111.761 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 7' ' ' PHE . . . . . 0.619 ' O ' ' N ' ' K' ' 9' ' ' ASP . 0.2 OUTLIER -78.54 -126.24 0.01 OUTLIER 'General case' 0 C--O 1.197 -1.662 0 N-CA-C 101.117 -3.66 . . . . 0.0 101.117 175.149 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' K' K ' 8' ' ' THR . . . . . . . . . . . . . 1.8 m 28.98 -63.37 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 115.444 1.646 . . . . 0.0 115.444 176.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 9' ' ' ASP . . . . . 0.619 ' N ' ' O ' ' K' ' 7' ' ' PHE . 28.0 t70 -61.2 -23.67 65.77 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 10' ' ' ILE . . . . . . . . . . . . . 93.4 mt -62.34 -42.82 96.96 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.912 0 N-CA-C 106.895 -1.521 . . . . 0.0 106.895 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 11' ' ' LEU . . . . . . . . . . . . . 39.9 tp -60.17 -42.14 94.32 Favored 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 12' ' ' ALA . . . . . . . . . . . . . . . -62.7 -38.13 89.21 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.4 -0.818 . . . . 0.0 108.834 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 13' ' ' ALA . . . . . . . . . . . . . . . -70.29 -50.89 34.77 Favored 'General case' 0 C--O 1.208 -1.113 0 CA-C-N 114.948 -1.024 . . . . 0.0 113.041 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.9 -45.29 86.67 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.362 -0.606 . . . . 0.0 109.362 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 15' ' ' GLY . . . . . . . . . . . . . . . -64.2 -47.17 87.68 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 120.455 -0.879 . . . . 0.0 111.108 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 16' ' ' ARG . . . . . . . . . . . . . 73.4 ttt-85 -69.24 -44.17 72.53 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-O 120.7 0.286 . . . . 0.0 111.1 -178.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 17' ' ' ILE . . . . . . . . . . . . . 94.3 mt -64.0 -43.52 97.63 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.74 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -177.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 18' ' ' PHE . . . . . 0.555 ' O ' HG12 ' K' ' 22' ' ' VAL . 52.9 t80 -50.19 -20.45 1.03 Allowed 'General case' 0 C--N 1.311 -1.08 0 C-N-CA 120.024 -0.67 . . . . 0.0 110.437 -178.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 19' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -66.14 -38.72 88.82 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.516 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 20' ' ' VAL . . . . . . . . . . . . . 79.0 t -64.26 -47.9 87.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 C-N-CA 119.786 -0.765 . . . . 0.0 112.574 -177.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 21' ' ' MET . . . . . . . . . . . . . 96.7 mmm -64.0 -53.18 54.14 Favored 'General case' 0 C--O 1.211 -0.962 0 N-CA-C 112.581 0.585 . . . . 0.0 112.581 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 22' ' ' VAL . . . . . 0.555 HG12 ' O ' ' K' ' 18' ' ' PHE . 12.6 p -63.63 -28.32 44.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.89 -177.057 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 23' ' ' GLU . . . . . . . . . . . . . 68.6 tt0 -84.99 1.05 49.25 Favored 'General case' 0 N--CA 1.48 1.035 0 CA-C-O 121.54 0.686 . . . . 0.0 111.361 -177.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.24 -11.99 4.95 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.451 -1.86 . . . . 0.0 108.451 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 25' ' ' HIS . . . . . . . . . . . . . 19.8 t-80 -66.48 -44.59 82.24 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 113.359 -1.421 . . . . 0.0 113.195 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 26' ' ' TRP . . . . . 0.578 ' O ' ' N ' ' K' ' 28' ' ' THR . 99.2 m95 -64.14 -69.02 0.3 Allowed 'General case' 0 C--O 1.216 -0.67 0 N-CA-C 115.51 1.67 . . . . 0.0 115.51 -175.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 27' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -16.12 -33.63 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 117.39 2.367 . . . . 0.0 117.39 -178.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 28' ' ' THR . . . . . 0.578 ' N ' ' O ' ' K' ' 26' ' ' TRP . 34.2 m -60.27 -45.08 94.54 Favored 'General case' 0 CA--C 1.544 0.739 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 29' ' ' VAL . . . . . 0.424 HG22 HBC1 ' K' ' 101' ' ' BCL . 83.2 t -53.71 -74.55 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.547 0.943 . . . . 0.0 113.547 -176.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 30' ' ' GLY . . . . . . . . . . . . . . . 2.59 -74.8 0.0 OUTLIER Glycine 0 CA--C 1.54 1.647 0 N-CA-C 116.615 1.406 . . . . 0.0 116.615 -178.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 31' ' ' MET . . . . . . . . . . . . . 74.6 mtp -63.85 -36.4 83.8 Favored 'General case' 0 CA--C 1.543 0.71 0 N-CA-C 113.382 0.882 . . . . 0.0 113.382 -176.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 32' ' ' LEU . . . . . . . . . . . . . 8.2 tp -32.27 -68.2 0.1 Allowed 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 -176.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 33' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -68.86 -44.13 73.97 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -178.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 34' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -59.78 -45.99 90.59 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 117.385 2.365 . . . . 0.0 117.385 -173.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 35' ' ' SER . . . . . . . . . . . . . 34.1 t -51.52 -52.59 45.58 Favored 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 119.267 0.94 . . . . 0.0 113.398 -175.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 36' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' K' ' 38' ' ' LYS . 40.0 tp -30.67 -54.4 0.2 Allowed 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -178.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -26.31 -27.31 0.0 OUTLIER Glycine 0 CA--C 1.55 2.271 0 N-CA-C 117.188 1.635 . . . . 0.0 117.188 -175.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 38' ' ' LYS . . . . . 0.531 ' N ' ' O ' ' K' ' 36' ' ' LEU . 56.2 mttm -85.88 -9.05 57.61 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 119.366 1.583 . . . . 0.0 114.776 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 39' ' ' GLY . . . . . . . . . . . . . . . -86.24 -31.86 18.5 Favored Glycine 0 N--CA 1.494 2.519 0 CA-C-N 119.143 0.883 . . . . 0.0 115.237 -177.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 40' ' ' THR . . . . . . . . . . . . . 6.4 p -77.96 -14.61 59.47 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 114.074 1.139 . . . . 0.0 114.074 -176.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 41' ' ' MET . . . . . . . . . . . . . 90.1 mmm -65.94 -38.8 89.57 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 115.371 1.619 . . . . 0.0 115.371 -176.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 42' ' ' ARG . . . . . . . . . . . . . 83.8 mmt-85 -70.36 -15.32 62.85 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 115.719 1.748 . . . . 0.0 115.719 -174.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 43' ' ' ILE . . . . . . . . . . . . . 23.7 mm -98.1 -33.04 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 44' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -63.85 -40.32 96.3 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 114.609 -1.178 . . . . 0.0 109.273 177.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 45' ' ' ARG . . . . . 0.515 ' O ' ' O ' ' K' ' 48' ' ' TYR . 14.0 ttp180 -61.96 -88.86 0.01 OUTLIER 'General case' 0 C--O 1.192 -1.95 0 C-N-CA 119.302 -0.959 . . . . 0.0 109.99 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 46' ' ' ASN . . . . . 0.557 ' OD1' ' CZ3' ' I' ' 26' ' ' TRP . 10.7 t-20 -30.02 -63.54 0.13 Allowed 'General case' 0 CA--C 1.564 1.484 0 N-CA-C 118.506 2.78 . . . . 0.0 118.506 -178.233 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 47' ' ' ALA . . . . . . . . . . . . . . . -59.49 -27.57 66.25 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 119.582 1.083 . . . . 0.0 112.269 -175.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 48' ' ' TYR . . . . . 0.515 ' O ' ' O ' ' K' ' 45' ' ' ARG . 82.9 m-85 -114.5 153.19 30.45 Favored 'General case' 0 C--O 1.202 -1.405 0 CA-C-O 121.416 0.627 . . . . 0.0 109.671 179.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 49' ' ' GLY . . . . . . . . . . . . . . . -175.94 -24.38 0.03 OUTLIER Glycine 0 C--N 1.312 -0.776 0 O-C-N 120.056 -1.653 . . . . 0.0 110.899 -179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 50' ' ' SER . . . . . . . . . . . . . 31.8 m -97.5 97.46 9.1 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 121.021 0.439 . . . . 0.0 111.407 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 51' ' ' MET . . . . . . . . . . . . . 68.9 mtm -69.28 -34.36 74.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.245 -0.889 . . . . 0.0 109.95 178.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 52' ' ' GLY . . . . . . . . . . . . . . . -55.96 106.71 0.67 Allowed Glycine 0 CA--C 1.52 0.401 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.685 -178.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.36 -34.54 90.24 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.28 -168.44 48.41 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 55' ' ' SER . . . . . . . . . . . . . 90.7 p -74.2 161.16 30.23 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.009 0.433 . . . . 0.0 110.812 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 56' ' ' LEU . . . . . . . . . . . . . 54.8 tp -89.67 131.97 35.39 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.221 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 57' ' ' ARG . . . . . . . . . . . . . 18.1 ttm-85 -62.73 138.33 58.49 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 120.466 -0.494 . . . . 0.0 111.056 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.49 17.53 75.62 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 111.51 -0.636 . . . . 0.0 111.51 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 59' ' ' SER . . . . . . . . . . . . . 92.3 p . . . . . 0 C--N 1.323 -0.574 0 CA-C-O 117.978 -1.01 . . . . 0.0 110.999 179.903 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' L' L ' 1' ' ' MET . . . . . . . . . . . . . 6.3 ttp . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 124.806 2.241 . . . . 0.0 106.839 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' L' L ' 2' ' ' SER . . . . . . . . . . . . . 8.8 m -58.88 136.63 57.9 Favored 'General case' 0 C--N 1.319 -0.756 0 O-C-N 118.606 -2.559 . . . . 0.0 109.909 178.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 3' ' ' GLY . . . . . . . . . . . . . . . 75.09 163.23 10.95 Favored Glycine 0 CA--C 1.537 1.418 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.52 9.94 82.56 Favored Glycine 0 CA--C 1.533 1.184 0 C-N-CA 121.576 -0.345 . . . . 0.0 113.484 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.72 67.43 2.73 Favored Glycine 0 N--CA 1.471 1.005 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 6' ' ' VAL . . . . . . . . . . . . . 16.8 m -109.42 4.73 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -178.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 7' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -81.98 -72.62 0.43 Allowed 'General case' 0 C--O 1.207 -1.148 0 CA-C-O 121.68 0.753 . . . . 0.0 110.462 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 8' ' ' THR . . . . . . . . . . . . . 9.6 m -32.43 -34.35 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -178.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 9' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -76.65 -21.92 54.77 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 113.359 0.874 . . . . 0.0 113.359 -177.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 10' ' ' ILE . . . . . 0.423 ' O ' ' N ' ' L' ' 14' ' ' ALA . 94.4 mt -62.85 -43.21 98.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 -178.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 11' ' ' LEU . . . . . . . . . . . . . 46.0 tp -60.01 -42.42 94.27 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 12' ' ' ALA . . . . . . . . . . . . . . . -62.65 -37.62 87.07 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 177.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 13' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' L' ' 16' ' ' ARG . . . -68.48 -76.24 0.09 Allowed 'General case' 0 C--O 1.206 -1.192 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.769 179.04 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 14' ' ' ALA . . . . . 0.423 ' N ' ' O ' ' L' ' 10' ' ' ILE . . . -32.29 -48.1 0.17 Allowed 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 112.114 0.412 . . . . 0.0 112.114 179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.95 -45.5 82.66 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 16' ' ' ARG . . . . . 0.47 ' N ' ' O ' ' L' ' 13' ' ' ALA . 65.3 ttt-85 -68.83 -44.04 74.29 Favored 'General case' 0 C--O 1.224 -0.272 0 CA-C-O 120.739 0.304 . . . . 0.0 111.361 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 17' ' ' ILE . . . . . . . . . . . . . 95.2 mt -64.51 -45.69 94.91 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.813 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -177.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 18' ' ' PHE . . . . . 0.584 ' O ' HG12 ' L' ' 22' ' ' VAL . 49.3 t80 -48.47 -19.69 0.35 Allowed 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.564 -0.71 . . . . 0.0 110.873 -178.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 19' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -65.31 -38.45 90.23 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 120.82 0.343 . . . . 0.0 110.788 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 20' ' ' VAL . . . . . . . . . . . . . 88.6 t -64.75 -46.8 91.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 112.778 0.659 . . . . 0.0 112.778 -177.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 21' ' ' MET . . . . . . . . . . . . . 97.0 mmm -66.22 -61.46 2.01 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.725 0.774 . . . . 0.0 110.447 -179.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 22' ' ' VAL . . . . . 0.584 HG12 ' O ' ' L' ' 18' ' ' PHE . 11.6 p -54.53 -34.83 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 CA-C-N 115.238 -0.892 . . . . 0.0 112.118 -177.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 23' ' ' GLU . . . . . 0.417 ' N ' HG13 ' L' ' 22' ' ' VAL . 81.9 tt0 -69.07 -29.28 67.37 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -178.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 24' ' ' GLY . . . . . . . . . . . . . . . -98.86 -8.67 53.91 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 25' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 -67.1 -43.05 83.49 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -178.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 26' ' ' TRP . . . . . 0.416 ' O ' ' N ' ' L' ' 28' ' ' THR . 99.7 m95 -68.25 -47.49 67.61 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 116.429 2.011 . . . . 0.0 116.429 -175.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 27' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -36.68 -24.45 0.01 OUTLIER 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 115.878 1.807 . . . . 0.0 115.878 -176.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 28' ' ' THR . . . . . 0.416 ' N ' ' O ' ' L' ' 26' ' ' TRP . 77.5 m -63.58 -44.29 94.5 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 114.299 1.222 . . . . 0.0 114.299 -178.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 29' ' ' VAL . . . . . 0.665 HG22 HBC1 ' L' ' 101' ' ' BCL . 60.7 t -55.13 -72.36 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 N-CA-C 114.325 1.231 . . . . 0.0 114.325 -176.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 30' ' ' GLY . . . . . . . . . . . . . . . 0.32 -73.6 0.0 OUTLIER Glycine 0 CA--C 1.539 1.538 0 N-CA-C 116.577 1.391 . . . . 0.0 116.577 -177.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 31' ' ' MET . . . . . . . . . . . . . 62.8 mtp -64.59 -36.96 85.92 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 113.904 1.075 . . . . 0.0 113.904 -176.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 tp -32.9 -67.32 0.12 Allowed 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 114.295 1.221 . . . . 0.0 114.295 -175.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 33' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -69.18 -43.09 74.93 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 114.541 1.311 . . . . 0.0 114.541 -178.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 34' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -63.61 -36.32 83.42 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 118.462 2.764 . . . . 0.0 118.462 -173.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 35' ' ' SER . . . . . . . . . . . . . 27.1 t -61.92 -35.36 78.15 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 119.563 1.074 . . . . 0.0 113.448 -175.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 36' ' ' LEU . . . . . 0.511 ' O ' ' N ' ' L' ' 38' ' ' LYS . 48.6 tp -52.98 -41.76 64.89 Favored 'General case' 0 CA--C 1.551 0.983 0 N-CA-C 115.893 1.812 . . . . 0.0 115.893 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -39.7 -12.54 0.01 OUTLIER Glycine 0 CA--C 1.543 1.784 0 N-CA-C 116.202 1.241 . . . . 0.0 116.202 -176.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 38' ' ' LYS . . . . . 0.511 ' N ' ' O ' ' L' ' 36' ' ' LEU . 55.3 mttm -96.2 -7.47 35.61 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-N 119.645 1.722 . . . . 0.0 114.301 -176.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 39' ' ' GLY . . . . . . . . . . . . . . . -90.4 -30.3 12.48 Favored Glycine 0 CA--C 1.538 1.518 0 C-N-CA 120.543 -0.837 . . . . 0.0 114.644 -177.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 40' ' ' THR . . . . . . . . . . . . . 18.6 p -76.25 -17.02 59.68 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -176.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 41' ' ' MET . . . . . . . . . . . . . 91.0 mmm -64.92 -36.78 85.49 Favored 'General case' 0 CA--C 1.554 1.133 0 N-CA-C 116.114 1.894 . . . . 0.0 116.114 -176.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 42' ' ' ARG . . . . . . . . . . . . . 82.8 mmt-85 -73.2 -7.98 53.79 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 116.368 1.988 . . . . 0.0 116.368 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 43' ' ' ILE . . . . . . . . . . . . . 24.2 mm -105.08 -32.47 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 44' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -64.9 -40.3 94.87 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 113.989 -1.459 . . . . 0.0 110.225 177.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 45' ' ' ARG . . . . . 0.441 ' O ' ' O ' ' L' ' 48' ' ' TYR . 29.4 ttp180 -69.89 -47.54 62.13 Favored 'General case' 0 C--O 1.216 -0.707 0 N-CA-C 116.349 1.981 . . . . 0.0 116.349 -177.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 46' ' ' ASN . . . . . 0.544 ' OD1' ' CE3' ' N' ' 26' ' ' TRP . 7.3 t-20 -70.56 -49.93 42.79 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 120.177 1.353 . . . . 0.0 114.605 -177.462 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 47' ' ' ALA . . . . . . . . . . . . . . . -63.56 -34.38 77.68 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.104 -0.638 . . . . 0.0 111.924 -176.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 48' ' ' TYR . . . . . 0.441 ' O ' ' O ' ' L' ' 45' ' ' ARG . 80.8 m-85 -109.84 146.24 35.39 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.15 -19.7 0.02 OUTLIER Glycine 0 N--CA 1.46 0.289 0 C-N-CA 119.794 -1.194 . . . . 0.0 111.207 -178.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 50' ' ' SER . . . . . . . . . . . . . 47.2 m -102.74 94.11 5.44 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.281 0.562 . . . . 0.0 110.52 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 51' ' ' MET . . . . . . . . . . . . . 62.9 mtm -66.44 -36.49 82.92 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.429 178.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 52' ' ' GLY . . . . . . . . . . . . . . . -52.27 108.53 0.68 Allowed Glycine 0 CA--C 1.526 0.76 0 CA-C-N 115.097 -0.956 . . . . 0.0 112.086 -178.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.84 -34.7 90.63 Favored Glycine 0 CA--C 1.53 0.984 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.4 -170.34 50.47 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 55' ' ' SER . . . . . . . . . . . . . 88.1 p -74.86 161.65 29.36 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.969 0.414 . . . . 0.0 110.905 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 56' ' ' LEU . . . . . . . . . . . . . 58.0 tp -89.92 130.49 36.13 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.519 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 57' ' ' ARG . . . . . . . . . . . . . 15.6 ttm-85 -61.84 137.72 58.27 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.153 -0.619 . . . . 0.0 110.262 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.93 16.97 73.63 Favored Glycine 0 CA--C 1.522 0.511 0 C-N-CA 121.208 -0.52 . . . . 0.0 111.973 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 59' ' ' SER . . . . . . . . . . . . . 89.7 p . . . . . 0 C--N 1.325 -0.488 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.755 179.932 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' M' M ' 1' ' ' MET . . . . . 0.519 ' SD ' ' OBD' ' A' ' 101' ' ' BCL . 0.7 OUTLIER . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 124.117 1.913 . . . . 0.0 106.851 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 2' ' ' SER . . . . . . . . . . . . . 12.3 m -82.48 132.24 35.21 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 3' ' ' GLY . . . . . . . . . . . . . . . 73.21 171.29 21.01 Favored Glycine 0 CA--C 1.535 1.282 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.71 9.14 86.73 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.989 -0.444 . . . . 0.0 111.989 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 5' ' ' GLY . . . . . . . . . . . . . . . -90.08 66.76 2.72 Favored Glycine 0 N--CA 1.468 0.782 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 6' ' ' VAL . . . . . . . . . . . . . 16.3 m -107.24 2.44 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -178.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 7' ' ' PHE . . . . . 0.558 ' CD2' ' CD2' ' J' ' 7' ' ' PHE . 0.1 OUTLIER -84.35 -58.2 2.84 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 122.357 1.075 . . . . 0.0 112.173 -178.066 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' M' M ' 8' ' ' THR . . . . . . . . . . . . . 25.3 m -47.14 -22.64 0.39 Allowed 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 113.006 -1.906 . . . . 0.0 111.857 -174.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 9' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -86.2 -19.72 29.6 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -63.39 -42.62 96.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 11' ' ' LEU . . . . . 0.442 HD11 HD13 ' A' ' 36' ' ' LEU . 58.7 tp -60.57 -42.5 96.75 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 115.058 -0.974 . . . . 0.0 108.786 179.231 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 12' ' ' ALA . . . . . 0.433 ' CB ' ' OG ' ' A' ' 35' ' ' SER . . . -61.17 -37.83 84.33 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 177.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 13' ' ' ALA . . . . . 0.675 ' O ' ' N ' ' M' ' 15' ' ' GLY . . . -73.26 -141.5 0.01 OUTLIER 'General case' 0 C--O 1.173 -2.954 0 N-CA-C 102.314 -3.217 . . . . 0.0 102.314 171.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 14' ' ' ALA . . . . . . . . . . . . . . . 42.14 -74.95 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.19 0 CA-C-N 122.372 2.351 . . . . 0.0 111.94 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 15' ' ' GLY . . . . . 0.675 ' N ' ' O ' ' M' ' 13' ' ' ALA . . . -62.74 -47.98 84.83 Favored Glycine 0 CA--C 1.548 2.134 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 176.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 16' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -64.57 -43.28 94.4 Favored 'General case' 0 N--CA 1.484 1.23 0 N-CA-C 106.327 -1.731 . . . . 0.0 106.327 178.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 17' ' ' ILE . . . . . 0.912 HG22 ' H ' ' M' ' 18' ' ' PHE . 84.3 mt -69.92 -162.95 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.201 -1.479 0 N-CA-C 101.25 -3.611 . . . . 0.0 101.25 175.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 18' ' ' PHE . . . . . 0.912 ' H ' HG22 ' M' ' 17' ' ' ILE . 24.5 t80 64.31 -34.08 0.15 Allowed 'General case' 1 C--N 1.241 -4.134 0 O-C-N 120.142 -1.599 . . . . 0.0 109.524 -176.59 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' M' M ' 19' ' ' GLU . . . . . 0.557 ' N ' ' O ' ' M' ' 17' ' ' ILE . 69.6 mt-10 -62.43 -37.17 84.83 Favored 'General case' 0 C--N 1.377 1.77 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 20' ' ' VAL . . . . . . . . . . . . . 89.8 t -67.45 -46.61 83.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.066 0 CA-C-N 114.921 -1.036 . . . . 0.0 112.172 -178.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 21' ' ' MET . . . . . 0.4 ' CE ' ' O1A' ' M' ' 101' ' ' BCL . 98.3 mmm -67.61 -48.11 67.74 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 22' ' ' VAL . . . . . 0.547 HG12 ' O ' ' M' ' 18' ' ' PHE . 12.2 p -66.09 -37.06 78.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.92 0.867 . . . . 0.0 112.29 -178.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 23' ' ' GLU . . . . . 0.475 ' N ' HG13 ' M' ' 22' ' ' VAL . 85.6 tt0 -68.03 -36.5 80.03 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.826 -177.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 24' ' ' GLY . . . . . . . . . . . . . . . -92.82 -7.5 62.77 Favored Glycine 0 N--CA 1.474 1.178 0 N-CA-C 110.026 -1.229 . . . . 0.0 110.026 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 25' ' ' HIS . . . . . . . . . . . . . 10.8 t-80 -68.2 -46.45 70.59 Favored 'General case' 0 CA--C 1.559 1.301 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 -179.033 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 26' ' ' TRP . . . . . 0.584 ' CE3' ' OD1' ' A' ' 46' ' ' ASN . 97.6 m95 -66.94 -42.61 85.0 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 117.35 2.352 . . . . 0.0 117.35 -176.392 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 27' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -39.93 -21.88 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.16 0 N-CA-C 114.982 1.475 . . . . 0.0 114.982 -176.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 28' ' ' THR . . . . . . . . . . . . . 86.3 m -63.87 -42.97 97.4 Favored 'General case' 0 CA--C 1.554 1.123 0 N-CA-C 114.588 1.329 . . . . 0.0 114.588 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 29' ' ' VAL . . . . . 0.607 HG22 HBC1 ' M' ' 101' ' ' BCL . 57.7 t -61.97 -46.25 96.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 N-CA-C 116.424 2.009 . . . . 0.0 116.424 -174.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 30' ' ' GLY . . . . . . . . . . . . . . . -28.81 -66.89 0.09 OUTLIER Glycine 0 CA--C 1.541 1.695 0 N-CA-C 115.742 1.057 . . . . 0.0 115.742 -174.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 31' ' ' MET . . . . . . . . . . . . . 21.5 mtp -64.81 -38.74 91.99 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 114.514 1.301 . . . . 0.0 114.514 -175.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 32' ' ' LEU . . . . . . . . . . . . . 10.8 tp -34.61 -66.79 0.16 Allowed 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 114.31 1.226 . . . . 0.0 114.31 -175.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 33' ' ' PHE . . . . . . . . . . . . . 24.1 t80 -69.04 -43.51 74.57 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 -177.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 34' ' ' ASP . . . . . . . . . . . . . 34.8 t70 -63.23 -39.66 95.26 Favored 'General case' 0 CA--C 1.559 1.325 0 N-CA-C 117.979 2.585 . . . . 0.0 117.979 -174.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 35' ' ' SER . . . . . . . . . . . . . 6.4 t -60.53 -25.03 65.82 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 114.412 1.264 . . . . 0.0 114.412 -175.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 36' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' M' ' 38' ' ' LYS . 48.2 tp -62.72 -41.72 99.3 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 116.458 2.022 . . . . 0.0 116.458 -177.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . -45.16 -5.88 0.01 OUTLIER Glycine 0 CA--C 1.539 1.565 0 N-CA-C 116.026 1.17 . . . . 0.0 116.026 -174.491 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 38' ' ' LYS . . . . . 0.459 ' N ' ' O ' ' M' ' 36' ' ' LEU . 62.6 mttm -100.4 -9.56 22.08 Favored 'General case' 0 N--CA 1.495 1.812 0 CA-C-N 119.696 1.748 . . . . 0.0 113.195 -176.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 39' ' ' GLY . . . . . . . . . . . . . . . -91.19 -24.84 25.78 Favored Glycine 0 N--CA 1.483 1.809 0 O-C-N 121.494 -0.754 . . . . 0.0 113.977 -177.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -77.56 -19.03 56.34 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -177.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 41' ' ' MET . . . . . . . . . . . . . 90.4 mmm -65.25 -38.78 91.41 Favored 'General case' 0 CA--C 1.559 1.308 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -176.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 42' ' ' ARG . . . . . . . . . . . . . 88.4 mmt-85 -66.68 -21.66 66.09 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 -174.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 43' ' ' ILE . . . . . . . . . . . . . 29.4 mm -90.44 -34.71 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.077 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 44' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -64.08 -40.68 96.77 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 114.819 -1.082 . . . . 0.0 111.602 179.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 45' ' ' ARG . . . . . . . . . . . . . 17.0 ttp180 -65.01 -44.61 88.64 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 116.492 2.034 . . . . 0.0 116.492 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 46' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -74.43 -51.88 13.67 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 115.23 1.567 . . . . 0.0 115.23 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 47' ' ' ALA . . . . . . . . . . . . . . . -64.49 -34.52 78.41 Favored 'General case' 0 C--O 1.22 -0.454 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.838 -178.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 48' ' ' TYR . . . . . . . . . . . . . 78.5 m-85 -110.67 134.86 52.07 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 49' ' ' GLY . . . . . . . . . . . . . . . -160.65 -12.91 0.03 OUTLIER Glycine 0 CA--C 1.52 0.374 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.445 -178.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 50' ' ' SER . . . . . . . . . . . . . 58.7 m -107.91 94.82 5.28 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-O 121.033 0.444 . . . . 0.0 110.715 -179.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 51' ' ' MET . . . . . . . . . . . . . 65.4 mtm -66.2 -37.26 85.17 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.231 178.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 52' ' ' GLY . . . . . . . . . . . . . . . -51.43 109.8 0.88 Allowed Glycine 0 CA--C 1.524 0.654 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.404 -178.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.02 -34.19 89.26 Favored Glycine 0 CA--C 1.535 1.323 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.057 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.02 -169.75 52.21 Favored Glycine 0 N--CA 1.476 1.303 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 55' ' ' SER . . . . . . . . . . . . . 86.4 p -76.16 162.71 27.76 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.068 0.461 . . . . 0.0 111.259 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 56' ' ' LEU . . . . . . . . . . . . . 60.6 tp -89.96 128.41 36.23 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.32 179.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 57' ' ' ARG . . . . . . . . . . . . . 13.1 ttm-85 -61.43 138.92 58.28 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.912 -179.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.97 15.56 77.07 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 59' ' ' SER . . . . . . . . . . . . . 90.1 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.864 -1.065 . . . . 0.0 110.698 179.842 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' N' N ' 1' ' ' MET . . . . . . . . . . . . 0.261 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 124.866 2.27 . . . . 0.0 107.15 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 2' ' ' SER . . . . . . . . . . . . . 10.8 m -82.08 130.08 34.98 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 120.329 -1.482 . . . . 0.0 109.576 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 3' ' ' GLY . . . . . . . . . . . . . . . 70.76 177.21 23.47 Favored Glycine 0 N--CA 1.468 0.801 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.41 10.89 85.98 Favored Glycine 0 CA--C 1.521 0.437 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 5' ' ' GLY . . . . . . . . . . . . . . . -89.66 63.5 3.26 Favored Glycine 0 N--CA 1.469 0.848 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 6' ' ' VAL . . . . . . . . . . . . . 22.3 m -105.9 -0.81 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -178.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 7' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -81.34 -47.04 13.81 Favored 'General case' 0 N--CA 1.484 1.273 0 CA-C-N 119.142 0.883 . . . . 0.0 111.889 -178.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 8' ' ' THR . . . . . . . . . . . . . 25.6 m -59.55 -28.21 66.91 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 114.608 -1.178 . . . . 0.0 112.777 -174.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 9' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -78.7 -19.63 52.0 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 10' ' ' ILE . . . . . 0.426 ' O ' ' HB3' ' N' ' 13' ' ' ALA . 92.7 mt -64.17 -42.79 96.64 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 119.774 -0.77 . . . . 0.0 109.237 -178.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 11' ' ' LEU . . . . . . . . . . . . . 48.1 tp -60.04 -43.28 95.47 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.0 -35.36 74.88 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 178.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 13' ' ' ALA . . . . . 0.544 ' O ' ' N ' ' N' ' 16' ' ' ARG . . . -71.91 -78.83 0.08 Allowed 'General case' 0 C--O 1.193 -1.872 0 CA-C-O 118.339 -0.838 . . . . 0.0 109.5 178.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 14' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' N' ' 13' ' ' ALA . . . -25.49 -49.55 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.332 0 O-C-N 123.806 0.691 . . . . 0.0 112.777 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.15 -47.58 52.2 Favored Glycine 0 CA--C 1.536 1.395 0 N-CA-C 111.509 -0.637 . . . . 0.0 111.509 177.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 16' ' ' ARG . . . . . 0.544 ' N ' ' O ' ' N' ' 13' ' ' ALA . 66.7 ttt-85 -69.69 -41.19 75.77 Favored 'General case' 0 C--O 1.2 -1.508 0 CA-C-O 121.504 0.669 . . . . 0.0 109.601 179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -68.54 -50.66 54.19 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.954 0 O-C-N 119.981 -1.699 . . . . 0.0 110.996 -177.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 18' ' ' PHE . . . . . 0.44 ' O ' HG12 ' N' ' 22' ' ' VAL . 39.6 t80 -49.03 -21.26 0.66 Allowed 'General case' 0 C--N 1.309 -1.178 0 O-C-N 120.983 -1.073 . . . . 0.0 110.558 -176.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 19' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -58.1 -37.24 74.15 Favored 'General case' 0 CA--C 1.547 0.849 0 CA-C-O 121.733 0.778 . . . . 0.0 109.909 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 20' ' ' VAL . . . . . . . . . . . . . 87.0 t -68.73 -48.71 69.87 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 21' ' ' MET . . . . . . . . . . . . . 97.7 mmm -64.2 -44.31 92.34 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.578 0.704 . . . . 0.0 112.782 -177.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 22' ' ' VAL . . . . . 0.498 HG13 ' N ' ' N' ' 23' ' ' GLU . 13.5 p -68.49 -35.41 70.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.055 -0.975 . . . . 0.0 112.324 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 23' ' ' GLU . . . . . 0.498 ' N ' HG13 ' N' ' 22' ' ' VAL . 84.5 tt0 -66.84 -42.49 85.65 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 120.166 -0.613 . . . . 0.0 112.306 -176.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.25 -12.13 74.09 Favored Glycine 0 CA--C 1.533 1.188 0 N-CA-C 111.675 -0.57 . . . . 0.0 111.675 -179.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 25' ' ' HIS . . . . . . . . . . . . . 5.5 t-80 -63.65 -47.8 79.84 Favored 'General case' 0 CA--C 1.555 1.162 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -178.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 26' ' ' TRP . . . . . 0.544 ' CE3' ' OD1' ' L' ' 46' ' ' ASN . 98.7 m95 -65.12 -40.46 94.53 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 117.888 2.551 . . . . 0.0 117.888 -177.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 27' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -42.26 -24.73 0.06 Allowed 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 115.254 1.576 . . . . 0.0 115.254 -176.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 28' ' ' THR . . . . . . . . . . . . . 77.3 m -61.99 -42.62 99.34 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -177.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 29' ' ' VAL . . . . . . . . . . . . . 79.2 t -61.49 -47.11 94.89 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.178 0 N-CA-C 116.54 2.052 . . . . 0.0 116.54 -173.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 30' ' ' GLY . . . . . . . . . . . . . . . -29.79 -63.49 0.15 Allowed Glycine 0 CA--C 1.544 1.872 0 N-CA-C 116.479 1.352 . . . . 0.0 116.479 -176.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 31' ' ' MET . . . . . . . . . . . . . 78.6 mmm -64.3 -37.47 87.62 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 114.009 1.115 . . . . 0.0 114.009 -176.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 32' ' ' LEU . . . . . . . . . . . . . 13.7 tp -41.19 -64.79 0.5 Allowed 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 -174.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 33' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -69.69 -44.66 69.99 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -177.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 34' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -61.34 -45.55 93.96 Favored 'General case' 0 CA--C 1.557 1.242 0 N-CA-C 118.516 2.784 . . . . 0.0 118.516 -173.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 35' ' ' SER . . . . . . . . . . . . . 5.1 t -56.32 -25.48 49.0 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 114.163 1.172 . . . . 0.0 114.163 -175.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 36' ' ' LEU . . . . . 0.472 ' O ' ' N ' ' N' ' 38' ' ' LYS . 46.6 tp -62.19 -41.7 98.59 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 115.831 1.789 . . . . 0.0 115.831 -176.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . -42.25 -11.59 0.01 OUTLIER Glycine 0 CA--C 1.546 1.983 0 N-CA-C 116.016 1.166 . . . . 0.0 116.016 -174.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 38' ' ' LYS . . . . . 0.472 ' N ' ' O ' ' N' ' 36' ' ' LEU . 31.9 mttm -95.47 -16.13 22.45 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-N 120.168 1.984 . . . . 0.0 114.8 -176.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 39' ' ' GLY . . . . . . . . . . . . . . . -86.16 -22.79 47.17 Favored Glycine 0 N--CA 1.476 1.331 0 C-N-CA 120.527 -0.844 . . . . 0.0 113.654 -177.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 40' ' ' THR . . . . . . . . . . . . . 26.2 p -76.27 -22.45 55.07 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 113.523 0.935 . . . . 0.0 113.523 -177.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 41' ' ' MET . . . . . . . . . . . . . 89.6 mmm -62.48 -41.57 98.88 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 117.192 2.293 . . . . 0.0 117.192 -176.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 42' ' ' ARG . . . . . . . . . . . . . 89.0 mmt-85 -61.91 -37.12 83.45 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 115.653 1.723 . . . . 0.0 115.653 -174.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 43' ' ' ILE . . . . . . . . . . . . . 31.7 mm -74.92 -33.23 29.31 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 119.117 0.871 . . . . 0.0 109.066 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 44' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -63.68 -40.36 96.62 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.49 -1.232 . . . . 0.0 111.554 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 45' ' ' ARG . . . . . . . . . . . . . 4.3 ttp180 -64.82 -44.02 91.22 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 115.742 1.756 . . . . 0.0 115.742 -177.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 46' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.98 -55.67 5.52 Favored 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 115.911 1.819 . . . . 0.0 115.911 -175.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 47' ' ' ALA . . . . . . . . . . . . . . . -63.61 -36.36 83.57 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.279 -0.568 . . . . 0.0 112.012 -176.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 48' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -108.41 113.53 26.66 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 49' ' ' GLY . . . . . . . . . . . . . . . -138.65 -9.46 1.0 Allowed Glycine 0 N--CA 1.48 1.577 0 N-CA-C 111.654 -0.578 . . . . 0.0 111.654 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 50' ' ' SER . . . . . . . . . . . . . 58.4 m -110.87 102.8 11.28 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 117.279 0.54 . . . . 0.0 111.599 -179.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 51' ' ' MET . . . . . . . . . . . . . 67.1 mtm -73.64 -36.44 65.42 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.583 0.706 . . . . 0.0 110.111 177.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 52' ' ' GLY . . . . . . . . . . . . . . . -51.35 108.84 0.65 Allowed Glycine 0 CA--C 1.52 0.406 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.044 -178.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.29 -34.71 90.69 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.97 -174.24 51.06 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 55' ' ' SER . . . . . . . . . . . . . 87.3 p -74.73 161.95 29.15 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.017 0.437 . . . . 0.0 110.386 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 56' ' ' LEU . . . . . . . . . . . . . 57.8 tp -88.75 129.22 35.6 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.816 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 57' ' ' ARG . . . . . 0.403 HH21 ' HG3' ' N' ' 57' ' ' ARG . 11.6 ttm-85 -62.05 137.9 58.31 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.065 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 58' ' ' GLY . . . . . . . . . . . . . . . 81.49 16.03 74.64 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.68 -0.568 . . . . 0.0 111.68 179.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 59' ' ' SER . . . . . . . . . . . . . 89.2 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.628 179.924 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' BCL . . . . . 0.788 HBB2 HMB1 ' A' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 101' ' ' BCL . . . . . 0.771 HBB2 HMB1 ' B' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 101' ' ' BCL . . . . . 0.875 HBB2 HMB1 ' C' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 101' ' ' BCL . . . . . 0.863 HBB2 HMB1 ' D' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 101' ' ' BCL . . . . . 0.878 HBB2 HMB1 ' E' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 101' ' ' BCL . . . . . 0.898 HBB2 HMB1 ' F' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 101' ' ' BCL . . . . . 0.891 HBB2 HMB1 ' G' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 101' ' ' BCL . . . . . 0.917 HBB2 HMB1 ' H' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 101' ' ' BCL . . . . . 0.844 HBB2 HMB1 ' I' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 101' ' ' BCL . . . . . 0.622 HBB2 HMB1 ' J' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 101' ' ' BCL . . . . . 0.861 HBB2 HMB1 ' K' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 101' ' ' BCL . . . . . 0.869 HBB2 HMB1 ' L' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 101' ' ' BCL . . . . . 0.83 HBB2 HMB1 ' M' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 101' ' ' BCL . . . . . 0.854 HBB2 HMB1 ' N' ' 101' ' ' BCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_